ý
|
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
¨
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
Delaware
|
|
13-5315170
|
(State or other jurisdiction of
incorporation or organization)
|
|
(I.R.S. Employer
Identification Number)
|
|
|
|
235 East 42nd Street
|
|
10017-5755
|
New York, New York
(Address of principal executive offices)
|
|
(Zip Code)
|
Title of each class
|
|
Name of each exchange
on which registered
|
Common Stock, $.05 par value
|
|
New York Stock Exchange
|
Large accelerated filer
ý
|
|
Accelerated filer
¨
|
|
Non-accelerated filer
¨
|
|
Smaller reporting company
¨
|
Portions of the 2012 Annual Report to Shareholders
|
|
Parts I, II and IV
|
Portions of the Proxy Statement for the 2013 Annual Meeting of Shareholders
|
|
Part III
|
|
Page
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
ITEM 1.
|
BUSINESS
|
•
|
Primary Care operating segment
—
includes revenues from human prescription pharmaceutical products primarily prescribed by primary-care physicians, and may include products in the following therapeutic and disease areas: Alzheimer’s disease, cardiovascular (excluding pulmonary arterial hypertension), erectile dysfunction,
|
•
|
Specialty Care and Oncology operating segment
—
comprises the Specialty Care business unit and the Oncology business unit.
|
·
|
Specialty Care
—
includes revenues from human prescription pharmaceutical products primarily prescribed by physicians who are specialists, and may include products in the following therapeutic and disease areas: anti-infectives, endocrine disorders, hemophilia, inflammation, ophthalmology, pulmonary arterial hypertension, specialty neuroscience and vaccines. Examples of products in this business unit in 2012 include
BeneFIX
,
Enbrel
,
Genotropin
,
Geodon
(outside the U.S.), the
Prevnar/Prevenar
family,
ReFacto AF
,
Revatio
(outside the U.S.),
Tygacil
,
Vfend
(outside the U.S. and South Korea),
Vyndaqel
(outside the U.S.),
Xalatan
(outside the U.S., Canada and South Korea),
Xeljanz
(in the U.S.),
Xyntha
and
Zyvox
. All revenues for these products are allocated to the Specialty Care business unit, except those generated in emerging markets and those that are managed by the Established Products business unit.
|
·
|
Oncology
—
includes revenues from human prescription pharmaceutical products addressing oncology and oncology-related illnesses. The products in this business unit in 2012 include
Inlyta
,
Sutent
,
Torisel
,
Xalkori
,
Mylotarg
(in Japan) and
Bosulif
(in the U.S.). All revenues for these products are allocated to the Oncology business unit, except those generated in emerging markets and those that are managed by the Established Products business unit.
|
•
|
Established Products and Emerging Markets operating segment
—
comprises the Established Products business unit and the Emerging Markets business unit.
|
·
|
Established Products
—
includes revenues from human prescription pharmaceutical products that have lost patent protection or marketing exclusivity in certain countries and/or regions. Typically, products are transferred to this business unit in the beginning of the fiscal year following loss of patent protection or marketing exclusivity. However, in certain situations, products may be transferred to this business unit at a different point than the beginning of the fiscal year following loss of patent protection or marketing exclusivity in order to maximize their value. This business unit also excludes revenues generated in emerging markets. Examples of products in this business unit in 2012 include
Arthrotec
,
Effexor
,
Lipitor
(in the U.S., Canada, South Korea and Japan),
Medrol
,
Norvasc
,
Protonix
,
Relpax
,
Vfend
(in the U.S. and South Korea),
Xalatan
(in the U.S., Canada and South Korea)
and
Zosyn/Tazocin
.
|
·
|
Emerging Markets
—
includes revenues from all human prescription pharmaceutical products sold in emerging markets, including Asia (excluding Japan and South Korea), Latin America, the Middle East, Eastern Europe, Africa, Turkey and Central Europe.
|
•
|
Animal Health operating segment
—
includes worldwide revenues from products and services to prevent and treat disease in livestock and companion animals, including anti-infectives, vaccines, parasiticides, medicinal feed additives, other pharmaceutical products and other non-pharmaceutical products.
|
•
|
Consumer Healthcare operating segment
—
includes worldwide revenues from non-prescription products in the following therapeutic categories: dietary supplements, pain management, respiratory and personal care. Products marketed by Consumer Healthcare include
Advil
,
Caltrate
,
Centrum
,
ChapStick
,
Emergen-C
,
Preparation H
and
Robitussin
.
|
•
|
Anti-infectives: products that prevent, kill or slow the growth of bacteria, fungi or protozoa. Examples of products in this category include
Draxxin
,
Terramycin
,
Clavamox
/
Synulox
, and the
Ceftiofur
line;
|
•
|
Vaccines: biological preparations that prevent diseases of the respiratory, gastrointestinal and reproductive tracts or induce a specific immune response. Examples of products in this category include the
Bovishield
line,
Improvac
, and
Vanguard
;
|
•
|
Parasiticides: products that prevent or eliminate external and internal parasites, such as fleas, ticks and worms. Examples of products in this category include
Cydectin
,
Dectomax
, and
Revolution
;
|
•
|
Medicinal feed additives: products that provide medicines, nutrients and probiotics to livestock; and
|
•
|
Other pharmaceutical products and other non-pharmaceutical products: complementary products, such as pain and sedation, oncology and antiemetic products. Examples of products in this category include
Palladia
and
Rimadyl
.
|
•
|
Dietary supplements:
Centrum
brands (including
Centrum
,
Centrum Silver
,
Centrum Men’s
and
Women’s
,
Centrum Specialist
,
Centrum Flavor Burst
, and
Centrum Kids
),
Caltrate
, and
Emergen-C
;
|
•
|
Pain management:
Advil
brands (including
Advil
,
Advil PM
,
Advil Liqui-Gels
,
Children’s Advil
,
Infants’ Advil
,
and Advil Migraine)
, and
ThermaCare
;
|
•
|
Respiratory:
Robitussin
,
Advil Cold & Sinus
,
Advil Congestion Relief
, and
Dimetapp
; and
|
•
|
Personal care:
ChapStick
and
Preparation H.
|
•
|
McKesson, Inc.
—
12% of our total revenues (and 28% of our total U.S. revenues);
|
•
|
Cardinal Health, Inc.
—
9% of our total revenues (and 23% of our total U.S. revenues); and
|
•
|
AmerisourceBergen Corporation
—
7% of our total revenues (and 17% of our total U.S. revenues).
|
Drug
|
|
U.S. Basic Product Patent Expiration Year
(1)(2)(3)
|
Detrol
|
|
2012
(2)
|
Viagra
|
|
2012
(3)
|
Celebrex
|
|
2014
|
Zyvox
|
|
2015
|
Lyrica
|
|
2018
|
Bosulif
|
|
2019
|
Chantix
|
|
2020
|
Inlyta
|
|
2020
|
Xeljanz
|
|
2020
|
Sutent
|
|
2021
|
Eliquis
|
|
2023
|
Xalkori
|
|
2029
|
•
|
With respect to Japan, the patent expiration year for
Celebrex
is 2019, for
Zyvox
is 2019, for
Lyrica
is 2022, for
Champix
is 2022, and for
Sutent
is 2024. For
Detrol
, post-marketing surveillance in Japan extends until 2014.
|
•
|
With respect to major European markets, the patent expiration year for
Xalkori
is 2025. For
Lyrica
, regulatory exclusivity in Europe extends until 2014.
|
•
|
an increase, from 15.1% to 23.1%, in the minimum rebate on branded prescription drugs sold to Medicaid beneficiaries (effective January 1, 2010);
|
•
|
extension of Medicaid prescription drug rebates to drugs dispensed to enrollees in certain Medicaid managed care organizations (effective March 23, 2010);
|
•
|
expansion of the types of institutions eligible for the “Section 340B discounts” for outpatient drugs provided to hospitals serving a disproportionate share of low-income individuals and meeting the qualification criteria under Section 340B of the Public Health Service Act of 1944 (effective January 1, 2010);
|
•
|
discounts on branded prescription drug sales to Medicare Part D participants who are in the Medicare “coverage gap,” also known as the “doughnut hole” (effective January 1, 2011); and
|
•
|
a fee payable to the federal government (which is not deductible for U.S. income tax purposes) based on our prior-calendar-year share relative to other companies of branded prescription drug sales to specified government programs (effective January 1, 2011, with the total fee to be paid each year by the pharmaceutical industry increasing annually through 2018).
|
•
|
environment-related capital expenditures
—
$27 million; and
|
•
|
other environment-related expenses
—
$157 million.
|
(1)
|
Pursuant to U.S. government authorizations, during 2012, our Animal Health business unit, through a non-U.S. affiliate, shipped Pfizer products to authorized customers in Iran. These shipments were backed by letters of credit issued by Bank Tejarat to a non-U.S. company acquired by Pfizer in 2011. The letters of credit were issued by Bank Tejarat and the Pfizer products were shipped to customers in Iran prior to the Bank’s designation as a Specially Designated National (SDN) under Executive Order 13382. After Bank Tejarat’s designation, Pfizer’s non-U.S. affiliate sought payment from Bank Tejarat by presenting shipping documentation to the non-U.S. affiliate’s bank in Europe
|
(2)
|
Pursuant to U.S. government authorizations, during 2012, our Emerging Markets business unit, through a non-U.S. affiliate, shipped Pfizer products to authorized customers in Iran. The shipments were backed by letters of credit issued by Bank Tejarat prior to its designation as an SDN under Executive Order 13382. As a result of the shipments, which also occurred prior to Bank Tejarat’s designation, Pfizer’s non-U.S. affiliate sought payment from Bank Tejarat by presenting shipping documentation to the non-U.S. affiliate’s bank in Europe. In some cases, the presentation of documents occurred before Bank Tejarat’s designation, and in other cases after such designation. Not all funds related to these transactions have been received from Bank Tejarat. We have received U.S. government authorization for several of the foregoing transactions with Bank Tejarat and, where required, have requested U.S. government authorization for the other transactions with Bank Tejarat. For funds received in 2012, our estimated gross revenues associated with these transactions were euro 397,071. As noted above, we do not allocate net profits on a country-by-country or activity-by-activity basis and, thus, cannot provide specific net profits ascribable to this activity. Pfizer’s net profits attributable to these transactions in 2012 were a fraction of the gross revenues.
|
(3)
|
Pursuant to U.S. government authorizations, during 2012, our Emerging Markets business unit, through a non-U.S. affiliate, shipped Pfizer products to an authorized customer in Syria. These shipments were backed by a letter of credit issued by Syria International Islamic Bank (SIIB) prior to SIIB’s designation as an SDN under Executive Order 13382. As a result of the shipment, which occurred prior to SIIB’s designation as an SDN, Pfizer’s non-U.S. affiliate sought payment from SIIB by presenting shipping documentation to the non-U.S. affiliate’s bank in Europe. Both the presentation of documents and the resulting payment occurred after SIIB was designated as an SDN. Where required, we have requested U.S. government authorization to process the funds received. Our estimated gross revenues in 2012 associated with this transaction were euro 315,960. As noted above, we do not allocate net profits on a country-by-country or activity-by-activity basis and, thus, cannot provide specific net profits ascribable to this activity. Pfizer’s net profits attributable to this transaction in 2012 were a fraction of the gross revenues.
|
ITEM 1A.
|
RISK FACTORS
|
ITEM 1B.
|
UNRESOLVED STAFF COMMENTS
|
ITEM 2.
|
PROPERTIES
|
ITEM 3.
|
LEGAL PROCEEDINGS
|
ITEM 4.
|
MINE SAFETY DISCLOSURES
|
Name
|
|
Age
|
|
Position
|
|
Ian C. Read
|
|
59
|
|
|
Chairman and Chief Executive Officer since December 2011. President and Chief Executive Officer from December 2010 until December 2011. Senior Vice President, Group President of the Worldwide Biopharmaceutical Businesses (Primary Care, Specialty Care, Oncology, Established Products and Emerging Markets), from 2006 through December 2010. Since joining Pfizer in 1978 as an operational auditor, Mr. Read has held various positions of increasing responsibility in pharmaceutical operations. He worked in Latin America through 1995, holding positions including Chief Financial Officer, Pfizer Mexico, and Country Manager, Pfizer Brazil. In 1996, Mr. Read was appointed President of Pfizer’s International Pharmaceuticals Group, with responsibility for Latin America and Canada. He became Executive Vice President, Europe in 2000, was named a Corporate Vice President in 2001, and assumed responsibility for Canada, in addition to Europe, in 2002. Mr. Read later became accountable for operations in both the Africa/Middle East region and Latin America as well. Currently a Director of Kimberly-Clark Corporation. Serves on the Boards of Pharmaceutical Research and Manufacturers of America (PhRMA), and the Partnership for New York City. Our Director since December 2010.
|
|
|
|
|
|
|
Olivier Brandicourt
|
|
57
|
|
|
President and General Manager, Pfizer Emerging Markets and Established Products since June 2012. President and General Manager of Pfizer Primary Care from 2009 until June 2012. In early 2009, served as President and General Manager of Pfizer Specialty Care. Senior Vice President and General Manager of U.S. Pratt Business Unit from 2007 until 2008. Managing Director of the United Kingdom/Ireland Pfizer subsidiary from 2004 to 2007.
|
|
|
|
|
|
|
Frank A. D’Amelio
|
|
55
|
|
|
Executive Vice President, Business Operations and Chief Financial Officer since December 2010. Senior Vice President and Chief Financial Officer from September 2007 until December 2010. Prior to joining Pfizer he was Senior Executive Vice President of Integration and Chief Administrative Officer of Alcatel-Lucent from November 2006 until August 2007. Chief Operating Officer of Lucent Technologies from January 2006 until November 2006. Chairman and Director of Zoetis. Director of Humana, Inc. and Chair of the Humana Audit Committee. He is a Director of the Independent College Fund of New Jersey.
|
|
|
|
|
|
|
Mikael Dolsten
|
|
54
|
|
|
President of Worldwide Research and Development since December 2010. Senior Vice President; President of Worldwide Research and Development from May 2010 until December 2010. Senior Vice President; President of Pfizer BioTherapeutics Research & Development Group from October 2009 until May 2010. He was Senior Vice President of Wyeth and President, Wyeth Research from June 2008 until October 2009. He was a Private Equity Partner at Orbimed Advisors, LLC from January 2008 until June 2008. Dr. Dolsten was Global Head, Corporate Division Pharma Research and Discovery, of Boehringer Ingelheim Corporation from 2003 to 2007.
|
Name
|
|
Age
|
|
Position
|
|
|
|
|
|
|
|
Geno J. Germano
|
|
52
|
|
|
President and General Manager, Pfizer Specialty Care and Oncology since December 2010. President and General Manager, Specialty Care from October 2009 until December 2010. President, U.S. Pharmaceuticals and Women’s Health Care Unit, Wyeth Pharmaceuticals from 2008 through October 2009. President and General Manager, U.S. Pharmaceutical Business Unit, Wyeth Pharmaceuticals from 2007 through 2008. Executive Vice President and General Manager, Pharmaceutical Business Unit, Wyeth Pharmaceuticals from 2004 through 2007. Currently a Director of Zoetis, Member of the Board of Trustees for Albany College of Pharmacy and Health Sciences and Member of the Board of Directors of BIO – Biotechnology Industry Organization.
|
|
|
|
|
|
|
Charles H. Hill III
|
|
57
|
|
|
Executive Vice President, Worldwide Human Resources since December 2010. Senior Vice President, Human Resources for Worldwide Biopharmaceuticals Businesses from 2008 through December 2010. Vice President, Human Resources, Worldwide Pharmaceutical Operations from 2004 through 2008. Currently a Director of Zoetis and Chair of the Zoetis Compensation Committee.
|
|
|
|
|
|
|
Douglas M. Lankler
|
|
47
|
|
|
Executive Vice President, Chief Compliance and Risk Officer since February 2011. Executive Vice President, Chief Compliance Officer from December 2010 until February 2011. Senior Vice President and Chief Compliance Officer from January 2010 until December 2010. Senior Vice President, Deputy General Counsel and Chief Compliance Officer from August 2009 until January 2010. Senior Vice President, Associate General Counsel and Chief Compliance Officer from October 2006 until August 2009. Prior to October 2006, Mr. Lankler held various positions of increasing responsibility within the Pfizer Legal Division.
|
|
|
|
|
|
|
Freda C. Lewis-Hall
|
|
58
|
|
|
Executive Vice President, Chief Medical Officer since December 2010. Senior Vice President, Chief Medical Officer from May 2009 until December 2010. Previously, she was Chief Medical Officer and Executive Vice President, Medicines Development at Vertex Pharmaceuticals from June 2008 until May 2009. Dr. Lewis-Hall was Senior Vice President, U.S. Pharmaceuticals, Medical Affairs for Bristol-Myers Squibb Company from 2003 until May 2008.
|
|
|
|
|
|
|
Anthony J. Maddaluna
|
|
60
|
|
|
Executive Vice President; President, Pfizer Global Supply since January 2013. President, Pfizer Global Supply from 2011 until December 2012. Senior Vice President, Strategy & Supply Network Transformation from 2009 until December 2010. Vice President, Strategy & Supply Network Transformation from 2008 until 2009. Vice President and Team Leader, Europe from 1998 until 2008 including responsibility for global logistics and strategic planning from 2005 through 2008. Mr. Maddaluna held a number of positions of increasing responsibility in manufacturing before being named General Manager of Pfizer Pharmaceuticals Inc. in Puerto Rico from 1994 until 1998. Mr. Maddaluna represents Pfizer on the National Association of Manufacturers (NAM) and is a member of the NAM Executive Committee. Mr. Maddaluna joined Pfizer in 1975.
|
|
|
|
|
|
|
Laurie J. Olson
|
|
49
|
|
|
Executive Vice President, Strategy, Portfolio and Commercial Operations since July 2012. Senior Vice President - Strategy and Portfolio Management from 2011 until July 2012. Senior Vice President - Portfolio Management and Analytics from 2008 until 2010. Since joining Pfizer in 1987 as an Analyst in the Company's marketing research organization, Ms. Olson has served in a variety of marketing leadership positions with increasing responsibility in both the Company’s U.S. and global commercial organizations.
|
Name
|
|
Age
|
|
Position
|
|
|
|
|
|
|
|
Amy W. Schulman
|
|
52
|
|
|
Executive Vice President and General Counsel since December 2010 and Business Unit Lead, Consumer Healthcare for Pfizer since August 2012.
Executive Vice President and General Counsel; President and General Manager, Nutrition from December 2010 until November 2012. Senior Vice President and General Counsel from June 2008 until December 2010. Ms. Schulman was a partner at the law firm of DLA Piper from 1997 until joining Pfizer in June 2008. Currently a Director of Zoetis and Chair of the Zoetis Corporate Governance Committee, Member of the Board of Directors of Wesleyan University and the Brooklyn Academy of Music.
|
|
|
|
|
|
|
Sally Susman
|
|
51
|
|
|
Executive Vice President, Policy, External Affairs and Communications of Pfizer since December 2010. Senior Vice President, Policy, External Affairs and Communications from December 2009 until December 2010. Senior Vice President and Chief Communications Officer from February 2008 until December 2009. Prior to joining Pfizer, Ms. Susman held senior level positions at The Estee Lauder Companies, including Executive Vice President from 2004 to January 2008.
|
|
|
|
|
|
|
John D. Young
|
|
48
|
|
|
President and General Manager, Pfizer Primary Care since June 2012. Primary Care Business Unit’s Regional President for Europe and Canada from 2009 until June 2012. UK Country Manager from 2007 until 2009. Since joining Pfizer in 1987, Mr. Young has held a number of positions of increasing responsibility in sales and marketing management before being appointed Country Manager for Australia/New Zealand in 2004.
|
ITEM 5.
|
MARKET FOR THE COMPANY’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES
|
Period
|
Total Number of
Shares Purchased
(b)
|
|
Average
Price
Paid per
Share
(b)
|
|
Total Number of
Shares Purchased as
Part of Publicly
Announced Plan
(a)
|
|
Approximate
Dollar Value of
Shares that May
Yet Be Purchased
Under the Plan
(a)
|
||||||
October 1, 2012
Through
October 28, 2012
|
36,961,538
|
|
|
$
|
25.33
|
|
|
36,902,797
|
|
|
$
|
14,264,821,207
|
|
October 29, 2012
Through
November 30, 2012
|
52,404,279
|
|
|
$
|
24.39
|
|
|
51,587,525
|
|
|
$
|
13,007,534,929
|
|
December 1, 2012
Through
December 31, 2012
|
47,745,688
|
|
|
$
|
25.30
|
|
|
47,491,654
|
|
|
$
|
11,805,897,162
|
|
Total
|
137,111,505
|
|
|
$
|
24.96
|
|
|
135,981,976
|
|
|
|
(a)
|
On December 12, 2011, we announced that the Board of Directors had authorized a $10 billion share-purchase plan (the December 2011 Stock Purchase Plan). On November 1, 2012, we announced that the Board of Directors had authorized an additional $10 billion share-purchase plan, which became effective on November 30, 2012.
|
(b)
|
In addition to amounts purchased under the December 2011 Stock Purchase Plan, these columns reflect the following transactions during the fourth fiscal quarter of 2012: (i) the surrender to Pfizer of 1,078,047 shares of common stock to satisfy tax withholding obligations in connection with the vesting of restricted stock and restricted stock units issued to employees; (ii) the open market purchase by the trustee of 32,674 shares of common stock in connection with the reinvestment of dividends paid on common stock held in trust for employees who were granted performance share awards and who deferred receipt of such awards; and (iii) the surrender to Pfizer of 18,808 shares of common stock to satisfy tax withholding obligations in connection with the vesting of performance share awards issued to employees.
|
ITEM 6.
|
SELECTED FINANCIAL DATA
|
ITEM 7.
|
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
|
ITEM 7A.
|
QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
|
ITEM 8.
|
FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
|
ITEM 9.
|
CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE
|
ITEM 9A.
|
CONTROLS AND PROCEDURES
|
ITEM 9B.
|
OTHER INFORMATION
|
ITEM 10.
|
DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE
|
ITEM 11.
|
EXECUTIVE COMPENSATION
|
ITEM 12.
|
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS
|
ITEM 13.
|
CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE
|
ITEM 14.
|
PRINCIPAL ACCOUNTING FEES AND SERVICES
|
ITEM 15.
|
EXHIBITS, FINANCIAL STATEMENT SCHEDULES
|
•
|
Report of Independent Registered Public Accounting Firm on the Consolidated Financial Statements
|
•
|
Consolidated Statements of Income
|
•
|
Consolidated Statements of Comprehensive Income
|
•
|
Consolidated Balance Sheets
|
•
|
Consolidated Statements of Equity
|
•
|
Consolidated Statements of Cash Flows
|
•
|
Notes to Consolidated Financial Statements
|
•
|
Quarterly Consolidated Financial Data (Unaudited)
|
3.1
|
|
Our Restated Certificate of Incorporation dated April 12, 2004, is incorporated by reference from our 10-Q report for the period ended March 28, 2004 (File No. 001-03619).
|
|
|
|
3.2
|
|
Amendment dated May 1, 2006 to Restated Certificate of Incorporation dated April 12, 2004, is incorporated by reference from our 10-Q report for the period ended July 2, 2006 (File No. 001-03619).
|
|
|
|
3.3
|
|
Our By-laws, as amended April 22, 2010, are incorporated by reference from our 10-Q report for the period ended April 4, 2010 (File No. 001-03619).
|
|
|
|
4.1
|
|
Indenture, dated as of January 30, 2001, between us and The Chase Manhattan Bank, is incorporated by reference from our 8-K report filed on January 30, 2001 (File No. 001-03619).
|
|
|
|
4.2
|
|
First Supplemental Indenture, dated as of March 24, 2009, between us and The Bank of New York Mellon (successor to JPMorgan Chase Bank, N.A. (formerly JPMorgan Chase Bank, formerly The Chase Manhattan Bank)), as Trustee, to Indenture dated as of January 30, 2001, is incorporated by reference from our 10-Q report for the period ended June 28, 2009 (File No. 001-03619).
|
|
|
|
4.3
|
|
Second Supplemental Indenture, dated as of June 2, 2009, between us and The Bank of New York Mellon (successor to JPMorgan Chase Bank, N.A. (formerly JPMorgan Chase Bank, formerly The Chase Manhattan Bank)), as Trustee, to Indenture dated as of January 30, 2001, is incorporated by reference from our 8-K report filed on June 3, 2009 (File No. 001-03619).
|
|
|
|
4.4
|
|
Indenture, dated as of April 10, 1992, between Wyeth and The Bank of New York Mellon (as successor to JPMorgan Chase Bank, N.A.), as Trustee, is incorporated by reference from Wyeth’s Registration Statement on Form S-3 (File No. 33-57339), filed on January 18, 1995.
|
|
|
|
4.5
|
|
Supplemental Indenture, dated as of October 13, 1992, between Wyeth and The Bank of New York Mellon (as successor to JPMorgan Chase Bank, N.A.), as Trustee, is incorporated by reference from Wyeth’s Registration Statement on Form S-3 (File No. 33-57339), filed on January 18, 1995.
|
|
|
|
4.6
|
|
Fifth Supplemental Indenture, dated as of December 16, 2003, between Wyeth and The Bank of New York Mellon (as successor to JPMorgan Chase Bank, N.A.), as Trustee, is incorporated by reference from Wyeth’s 2003 10-K report (File No. 001-01225).
|
4.7
|
|
Sixth Supplemental Indenture, dated as of November 14, 2005, between Wyeth and The Bank of New York Mellon (as successor to JPMorgan Chase Bank, N.A.), as Trustee, is incorporated by reference from Wyeth’s 8-K report filed on November 15, 2005 (File No. 001-01225).
|
|
|
|
4.8
|
|
Seventh Supplemental Indenture, dated as of March 27, 2007, between Wyeth and The Bank of New York Mellon (as successor to JPMorgan Chase Bank, N.A.), as Trustee, is incorporated by reference from Wyeth’s 8-K report filed on March 28, 2007 (File No. 001-01225).
|
|
|
|
4.9
|
|
Eighth Supplemental Indenture, dated as of October 30, 2009, between Wyeth, us and The Bank of New York Mellon (as successor to JPMorgan Chase Bank, formerly The Chase Manhattan Bank), as Trustee, to Indenture dated as of April 10, 1992 (as amended on October 13, 1992), is incorporated by reference from our 8-K report filed on November 3, 2009 (File No. 001-03619).
|
|
|
|
4.10
|
|
Except as set forth in Exhibits 4.1-9 above, the instruments defining the rights of holders of long-term debt securities of the Company and its subsidiaries have been omitted.
1
|
|
|
|
10.1
|
|
2001 Stock and Incentive Plan is incorporated by reference from our Proxy Statement for the 2001 Annual Meeting of Shareholders (File No. 001-03619).
|
|
|
|
10.2
|
|
Pfizer Inc. 2004 Stock Plan, as Amended and Restated is incorporated by reference from our 2011 10-K Report (File No. 001-03619).
|
|
|
|
10.3
|
|
Form of Stock Option Grant Notice and Summary of Key Terms is incorporated by reference from our 10-Q report for the period ended September 26, 2004 (File No. 001-03619).
|
|
|
|
10.4
|
|
Form of Performance-Contingent Share Award Grant Notice is incorporated by reference from our 10-Q report for the period ended September 26, 2004 (File No. 001-03619).
|
|
|
|
*10.5
|
|
Form of Executive Grant Letter.
|
|
|
|
10.6
|
|
Amended and Restated Nonfunded Supplemental Retirement Plan, together with all material Amendments is incorporated by reference from our 2011 10-K Report (File No. 001-03619).
|
|
|
|
*10.7
|
|
Amended and Restated Nonfunded Deferred Compensation and Supplemental Savings Plan.
|
|
|
|
*10.8
|
|
Executive Annual Incentive Plan.
|
|
|
|
*10.9
|
|
Amended and Restated Deferred Compensation Plan.
|
|
|
|
10.10
|
|
Non-Employee Directors’ Retirement Plan (frozen as of October 1996) is incorporated by reference from our 1996 10-K report (File No. 001-03619).
|
|
|
|
10.11
|
|
Restricted Stock Plan for Non-Employee Directors is incorporated by reference from our 1996 10-K report (File No. 001-03619).
|
|
|
|
10.12
|
|
Amended and Restated Wyeth Supplemental Employee Savings Plan (effective as of January 1, 2005), together with all material Amendments is incorporated by reference from our 2011 10-K Report (File No. 001-03619).
|
|
|
|
10.13
|
|
Amended and Restated Wyeth Supplemental Executive Retirement Plan (effective as of January 1, 2005), together with all material Amendments is incorporated by reference from our 2011 10-K Report (File No. 001-03619).
|
|
|
|
10.14
|
|
Wyeth Directors’ Deferral Plan (as amended through December 15, 2007) is incorporated by reference from Wyeth’s 2007 10-K report (File No. 001-01225).
|
|
|
|
10.15
|
|
The form of Indemnification Agreement with each of our non-employee Directors is incorporated by reference from our 1996 10-K report (File No. 001-03619).
|
|
|
|
10.16
|
|
The form of Indemnification Agreement with each of the Named Executive Officers identified in our 2013 Proxy Statement is incorporated by reference from our 1997 10-K report (File No. 001-03619).
|
|
|
|
10.17
|
|
Letter to Frank A. D’Amelio regarding replacement pension benefit dated August 22, 2007 is incorporated by reference from our 8-K report filed on August 22, 2007 (File No. 001-03619).
|
|
|
|
10.18
|
|
Executive Severance Plan is incorporated by referenced from our 8-K report filed on February 20, 2009 (File No. 001-03619).
|
|
|
|
10.19
|
|
Annual Retainer Unit Award Plan (for Non-Employee Directors) (frozen as of March 1, 2006) as amended, is incorporated by reference from our 2008 10-K report (File No. 001-03619).
|
|
|
|
10.20
|
|
Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors, as amended, is incorporated by reference from our 10-Q report for the period ended July 3, 2011 (File No. 001-03619).
|
|
|
|
10.21
|
|
Form of Special Award Letter Agreement is incorporated by reference from our 8-K report filed on October 28, 2009 (File No. 001-03619).
|
|
|
|
10.22
|
|
Offer Letter to G. Mikael Dolsten, dated April 6, 2009, is incorporated by reference from our 10-Q report for the period ended April 3, 2011 (File No. 001-03619).
|
|
|
|
10.23
|
|
Offer Letter to Geno J. Germano, dated April 6, 2009, is incorporated by reference from our 10-Q report for the period ended April 3, 2011 (File No. 001-03619).
|
|
|
|
10.24
|
|
Warner-Lambert Company 1996 Stock Plan, as amended, is incorporated by reference from Warner-Lambert's 1999 10-K report (File No. 001-03608).
|
|
|
|
*12
|
|
Computation of Ratio of Earnings to Fixed Charges.
|
|
|
|
*13
|
|
Portions of the 2012 Financial Report, which, except for those sections incorporated by reference, are furnished solely for the information of the SEC and are not to be deemed “filed.”
|
|
|
|
*21
|
|
Subsidiaries of the Company.
|
|
|
|
*23
|
|
Consent of KPMG LLP, Independent Registered Public Accounting Firm.
|
|
|
|
*24
|
|
Power of Attorney (included as part of signature page).
|
|
|
|
*31.1
|
|
Certification by the Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
|
|
|
|
*31.2
|
|
Certification by the Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
|
|
|
|
*32.1
|
|
Certification by the Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
|
|
|
|
*32.2
|
|
Certification by the Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
|
|
|
|
*101.INS
|
|
XBRL Instance Document
|
|
|
|
*101.SCH
|
|
XBRL Taxonomy Extension Schema
|
|
|
|
*101.CAL
|
|
XBRL Taxonomy Extension Calculation Linkbase
|
|
|
|
*101.LAB
|
|
XBRL Taxonomy Extension Label Linkbase
|
|
|
|
*101.PRE
|
|
XBRL Taxonomy Extension Presentation Linkbase
|
|
|
|
*101.DEF
|
|
XBRL Taxonomy Extension Definition Document
|
|
Pfizer Inc.
|
||
|
|
|
|
Dated: February 28, 2013
|
By:
|
|
/s/ M
ATTHEW
L
EPORE
|
|
|
|
Matthew Lepore
Vice President and Corporate Secretary,
Chief Counsel – Corporate Governance
|
Signature
|
|
Title
|
|
Date
|
|
|
|
|
|
/
S
/ I
AN
C. R
EAD
Ian C. Read
|
|
Chairman, Chief Executive Officer and Director
(Principal Executive Officer)
|
|
February 28, 2013
|
|
|
|
|
|
/
S
/ F
RANK
A. D’A
MELIO
Frank A. D’Amelio
|
|
Executive Vice President, Business Operations and
Chief Financial Officer (Principal Financial Officer)
|
|
February 28, 2013
|
|
|
|
|
|
/
S
/ L
ORETTA
V. C
ANGIALOSI
Loretta V. Cangialosi
|
|
Senior Vice President—Controller
(Principal Accounting Officer)
|
|
February 28, 2013
|
|
|
|
|
|
/
S
/ D
ENNIS
A. A
USIELLO
Dennis A. Ausiello
|
|
Director
|
|
February 28, 2013
|
|
|
|
|
|
/
S
/ M. A
NTHONY
B
URNS
M. Anthony Burns
|
|
Director
|
|
February 28, 2013
|
|
|
|
|
|
/
S
/ W. D
ON
C
ORNWELL
W. Don Cornwell
|
|
Director
|
|
February 28, 2013
|
|
|
|
|
|
/
S
/ F
RANCES
D. F
ERGUSSON
Frances D. Fergusson
|
|
Director
|
|
February 28, 2013
|
|
|
|
|
|
/
S
/ W
ILLIAM
H. G
RAY,
III
William H. Gray, III
|
|
Director
|
|
February 28, 2013
|
|
|
|
|
|
/
S
/ H
ELEN
H. H
OBBS
Helen H. Hobbs
|
|
Director
|
|
February 28, 2013
|
Signature
|
|
Title
|
|
Date
|
|
|
|
|
|
/
S
/ C
ONSTANCE
J. H
ORNER
Constance J. Horner
|
|
Director
|
|
February 28, 2013
|
|
|
|
|
|
/
S
/ S
UZANNE
N
ORA
J
OHNSON
Suzanne Nora Johnson
|
|
Director
|
|
February 28, 2013
|
|
|
|
|
|
/
S
/ J
AMES
M. K
ILTS
James M. Kilts
|
|
Director
|
|
February 28, 2013
|
|
|
|
|
|
/
S
/ G
EORGE
A. L
ORCH
George A. Lorch
|
|
Director
|
|
February 28, 2013
|
|
|
|
|
|
/
S
/ J
OHN
P. M
ASCOTTE
John P. Mascotte
|
|
Director
|
|
February 28, 2013
|
|
|
|
|
|
/
S
/ S
TEPHEN
W. S
ANGER
Stephen W. Sanger
|
|
Director
|
|
February 28, 2013
|
|
|
|
|
|
/
S
/ M
ARC
T
ESSIER
-L
AVIGNE
Marc Tessier-Lavigne
|
|
Director
|
|
February 28, 2013
|
Award Type
|
Grant Price
|
Shares (#)
|
Dates
|
5-Year Total Shareholder Return Units (“5-YR TSRUs”)
|
$21.03
|
«M_5Yr_TSRU»
|
Grant Date – February 23, 2012
Vesting Date* – February 23, 2015
Settlement Date – February 23, 2017
|
7-Year Total Shareholder Return Units (“7-YR TSRUs”)
|
$21.03
|
«M_7Yr_TSRU»
|
Grant Date – February 23, 2012
Vesting Date* – February 23, 2015
Settlement Date – February 23, 2019
|
Performance Share Awards (“PSAs”)
|
N/A
|
«PFE_PS»
|
Grant Date – February 23, 2012
Vesting Date* – February 23, 2015
Performance Period: January 1, 2012 through December 31, 2014
|
Restricted Stock Units (“RSUs”)
|
N/A
|
«RSU»
|
Grant Date – February 23, 2012
Vesting Date* – February 23, 2015
|
(a)
|
The election may not take effect for at least twelve (12) months;
|
(i)
|
to determine who are Eligible Employees for purposes of participation in the Plan;
|
(ii)
|
to interpret the terms and provisions of the Plan and to determine any and all questions arising under the Plan, including without limitation, the right to remedy possible ambiguities, inconsistencies, or omissions by a general rule or particular decision; and
|
(iii)
|
to adopt rules consistent with the Plan.
|
i
|
at any time during a two-year period, at least a majority of the Company’s Board of Directors shall cease to consist of “Continuing Directors” (meaning directors of the Company who either were directors at the beginning of such two-year period or who subsequently became directors and whose election, or nomination for election by the Company’s stockholders, was approved by a majority of the then Continuing Directors); or
|
ii
|
any “person” or “group” (as determined for purposes of Section 13(d)(3) of the Securities Exchange Act of 1934), except any majority-owned subsidiary of the Company or any employee benefit plan of the Company or any trust or investment manager thereunder, shall have acquired “beneficial ownership” (as determined for purposes of Securities and Exchange Commission (“SEC”) Regulation 13d-3) of shares of Common Stock of the Company having 15% or more of the voting power of all outstanding shares of capital stock of the Company, unless such acquisition
|
iii
|
a merger or consolidation occurs to which the Company is a party, whether or not the Company is the surviving corporation, in which outstanding shares of Common Stock of the Company are converted into shares of another company (other than a conversion into shares of voting common stock of the successor corporation or a holding company thereof representing 80% of the voting power or all capital stock thereof outstanding immediately after the merger or consolidation) or other securities (of either the Company or another company) or cash or other property; or (iv) the sale of all, or substantially all, of the Company’s assets occurs; or (v) the stockholders of the Company approve a plan of complete liquidation of the Company.
|
(b)
|
The length of the deferral period with respect to each eligible component of Compensation or the date or event upon which the Compensation is to be paid in the future, pursuant to the terms of Section 5.3 and 5.4 herein;
|
(d)
|
The form or method for payment of the Compensation to a beneficiary in the event of the death of the Participant as designated in Section 6.4.
|
(a)
|
The election may not take effect until at least twelve (12) months after the date on which the election is made;
|
(b)
|
In the case of an election to change the time or form of a distribution under Sections 5.6, a distribution may not be made earlier than at least five (5) years from the date the distribution would have otherwise been made; and
|
(c)
|
In the case of an election to change the time or form of a distribution under Section 5.6, the election must be made at least twelve (12) months before the date the distribution is scheduled to be paid.
|
(a)
|
The Company's deduction with respect to such payment would be eliminated by application of Code section 162(m); or
|
(b)
|
The making of the payment would violate Federal securities laws or other applicable law;
|
a
|
“Award” means the Annual Incentive Award based on an assessment of performance, payable by the Company to a Participant for the Participant’s services during a given calendar year of the Company. Awards shall be deemed earned only upon formal announcement thereof by the Company.
|
b
|
“Board” or “Board of Directors” means the Board of Directors of the Company
|
c
|
“Change in Control” shall mean the occurance of any of the following events:
|
i
|
at any time during a two-year period, at least a majority of the Company’s Board of Directors shall cease to consist of “Continuing Directors” (meaning directors of the Company who either were directors at the beginning of such two-year period or who subsequently became directors and whose election, or nomination for election by the Company’s stockholders, was approved by a majority of the then Continuing Directors); or
|
ii
|
any “person” or “group” (as determined for purposes of Section 13(d)(3) of the Securities Exchange Act of 1934), except any majority-owned subsidiary of the Company or any employee benefit plan of the Company or any trust or investment manager thereunder, shall have acquired “beneficial ownership” (as determined for purposes of Securities and Exchange Commission (“SEC”) Regulation 13d-3) of shares of Common Stock of the Company having 15% or more of the voting power of all outstanding shares of capital stock of the Company, unless such acquisition is approved by a majority of the directors of the Company in office immediately preceding such acquisition; or
|
iii
|
a merger or consolidation occurs to which the Company is a party, whether or not the Company is the surviving corporation, in which outstanding shares of Common Stock of the Company are converted into shares of another company (other than a conversion into shares of voting common stock of the successor corporation or a holding company thereof representing 80% of the voting power or all capital stock thereof outstanding immediately after the merger or consolidation) or other securities (of either the Company or another company) or cash or other property; or (iv) the
|
d
|
“Code” means the Internal Revenue Code of 1986, as amended.
|
e
|
“Committee” means the Executive Compensation Committee of the Board or the Employee Compensation and Management Development Committee, as appropriate, and any successor thereto.
|
f
|
“Company” means Pfizer Inc, a Delaware corporation (including any and all subsidiaries), and any successor thereto.
|
g
|
“Compensation” means the gross Salary, Award, Long-Term Incentive Awards, and other payments which may be eligible for deferral under the Plan, which are payable to a Participant with respect to services performed during a specified period.
|
h
|
“Disability” means a disability which would qualify the Participant for Long-Term Disability benefits under the Pfizer Long Term Disability Plan and, as such plan may be amended from time to time.
|
i
|
“Employee” means a salaried employee of the Company.
|
j
|
“ERISA” means the Employee Retirement Income Security Act of 1974.
|
k
|
“Federal Long-term Rate” means the 30-year constant maturity U.S. Treasury Rate from the Federal Reserve Bank for the previous month.
|
l
|
“Long-Term Incentive Awards” means Performance-Contingent Share Awards or earnings from stock option exercises.
|
m
|
“Participant” means an Employee who has elected to participate in the Plan.
|
n
|
“Salary” means all regular, basic wages, before reduction for amounts deferred pursuant to the Plan or any other plan of the Company, payable in cash to a Participant for services to be rendered during the calendar year, exclusive of any Bonus, Long-Term Awards, other special fees, awards, or incentive compensation, allowance, or amounts designated by the Company as payment toward or reimbursement of expenses.
|
|
Year Ended December 31,
|
||||||||||||||
(IN MILLIONS, EXCEPT RATIOS)
|
2012
|
|
2011
|
|
2010
|
|
2009
|
|
2008
|
|
|||||
|
|
|
|
|
|
||||||||||
Determination of earnings:
|
|
|
|
|
|
||||||||||
Income from continuing operations before provision for taxes on income, noncontrolling interests and cumulative effect of a change in accounting principles
|
$
|
12,080
|
|
$
|
12,304
|
|
$
|
9,471
|
|
$
|
10,723
|
|
$
|
9,520
|
|
Less:
|
|
|
|
|
|
||||||||||
Net income attributable to noncontrolling interests
|
28
|
|
40
|
|
31
|
|
9
|
|
22
|
|
|||||
Income attributable to Pfizer Inc.
|
12,052
|
|
12,264
|
|
9,440
|
|
10,714
|
|
9,498
|
|
|||||
Add:
|
|
|
|
|
|
||||||||||
Fixed charges
|
1,640
|
|
1,813
|
|
1,930
|
|
1,358
|
|
647
|
|
|||||
Total earnings as defined
|
$
|
13,692
|
|
$
|
14,077
|
|
$
|
11,370
|
|
$
|
12,072
|
|
$
|
10,145
|
|
|
|
|
|
|
|
||||||||||
Fixed charges:
|
|
|
|
|
|
||||||||||
Interest expense
(a)
|
$
|
1,524
|
|
$
|
1,681
|
|
$
|
1,797
|
|
$
|
1,232
|
|
$
|
516
|
|
Preferred stock dividends
(b)
|
4
|
|
5
|
|
6
|
|
7
|
|
8
|
|
|||||
Rents
(c)
|
112
|
|
127
|
|
127
|
|
119
|
|
123
|
|
|||||
Fixed charges
|
1,640
|
|
1,813
|
|
1,930
|
|
1,358
|
|
647
|
|
|||||
Capitalized interest
|
41
|
|
50
|
|
36
|
|
34
|
|
46
|
|
|||||
|
|
|
|
|
|
||||||||||
Total fixed charges
|
$
|
1,681
|
|
$
|
1,863
|
|
$
|
1,966
|
|
$
|
1,392
|
|
$
|
693
|
|
|
|
|
|
|
|
||||||||||
Ratio of earnings to fixed charges
|
8.1
|
|
7.6
|
|
5.8
|
|
8.7
|
|
14.6
|
|
(a)
|
Interest expense includes amortization of debt premium, discount and expenses. Interest expense does not include interest related to uncertain tax positions of $268 million for 2012; $343 million for 2011; $389 million for 2010; $337 million for 2009; and $333 million for 2008.
|
(b)
|
Preferred stock dividends related to our Series A convertible perpetual preferred stock held by an Employee Stock Ownership Plan Trust.
|
(c)
|
Rents included in the computation consist of one-third of rental expense, which we believe to be a conservative estimate of an interest factor in our leases, which are not material.
|
|
|
|
|
Pfizer Inc. 2012 Financial Report
|
|
|
|
|
|
|
|
•
|
Overview of Our Performance, Operating Environment, Strategy and Outlook
. This section, beginning on page 2, provides information about the following: our business; our 2012 performance; our operating environment; our strategy; our business development initiatives, such as acquisitions, dispositions, licensing and collaborations; and our financial guidance for 2013.
|
•
|
Significant Accounting Policies and Application of Critical Accounting Estimates
. This section, beginning on page 10, discusses those accounting policies and estimates that we consider important in understanding Pfizer’s consolidated financial statements. For additional discussion of our accounting policies, see Notes to Consolidated Financial Statements—
Note 1. Basis of Presentation and Significant Accounting Policies
.
|
•
|
Analysis of the Consolidated Statements of Income.
This section begins on page 15, and consists of the following sections:
|
◦
|
Revenues.
This sub-section, beginning on page 15, provides an analysis of our revenues and products for the three years ended December 31, 2012, including an overview of research and development expenses and important biopharmaceutical product developments.
|
◦
|
Costs and Expenses
. This sub-section, beginning on page 28, provides a discussion about our costs and expenses.
|
◦
|
Provision for Taxes on Income.
This sub-section, beginning on page 33, provides a discussion of items impacting our tax provisions.
|
◦
|
Discontinued Operations.
This sub-section, on page 34, provides an analysis of the financial statement impact of our discontinued operations.
|
◦
|
Adjusted Income
. This sub-section, beginning on page 34, provides a discussion of an alternative view of performance used by management.
|
•
|
Analysis of the Consolidated Statements of Comprehensive Income.
This section, on page 38, provides a discussion of changes in certain components of other comprehensive income.
|
•
|
Analysis of the Consolidated Balance Sheets.
This section, beginning on page 38, provides a discussion of changes in certain balance sheet accounts.
|
•
|
Analysis of the Consolidated Statements of Cash Flows.
This section, beginning on page 39, provides an analysis of our consolidated cash flows for the three years ended December 31, 2012.
|
•
|
Analysis of Financial Condition, Liquidity and Capital Resources
. This section, beginning on page 40, provides an analysis of selected measures of our liquidity and of our capital resources as of December 31, 2012 and December 31, 2011, as well as a discussion of our outstanding debt and other commitments that existed as of December 31, 2012. Included in the discussion of outstanding debt is a discussion of the amount of financial capacity available to help fund Pfizer’s future activities.
|
•
|
New Accounting Standards
. This section, on page 44, discusses accounting standards that we have recently adopted, as well as those that recently have been issued, but not yet adopted.
|
•
|
Forward-Looking Information and Factors That May Affect Future Results
. This section, beginning on page 44, provides a description of the risks and uncertainties that could cause actual results to differ materially from those discussed in forward-looking statements presented in this Financial Review relating to, among other things, our anticipated financial and operating performance, business plans and prospects, in-line products and product candidates, strategic reviews, capital allocation, business-development plans, and plans relating to share repurchases and dividends. Such forward-looking statements are based on management’s current expectations about future events, which are inherently susceptible to uncertainty and changes in circumstances. Also included in this section are discussions of Financial Risk Management and Legal Proceedings and Contingencies.
|
2012 Financial Report
|
|
1
|
|
|
|
|
2
|
|
2012 Financial Report
|
|
|
|
|
|
|
2012 v. 2011
|
|||||
(MILLIONS OF DOLLARS)
|
|
Increase/
(Decrease)
|
|
|
%
Change
|
|
|
Lipitor
(a)
|
|
$
|
(5,629
|
)
|
|
(59
|
)
|
Geodon/Zeldox
(a)
|
|
(669
|
)
|
|
(65
|
)
|
|
Xalatan/Xalacom
(a)
|
|
(444
|
)
|
|
(36
|
)
|
|
Caduet
(a)
|
|
(280
|
)
|
|
(52
|
)
|
|
Effexor
|
|
(253
|
)
|
|
(37
|
)
|
|
Zosyn/Tazocin
|
|
(152
|
)
|
|
(24
|
)
|
|
Aromasin
(a)
|
|
(151
|
)
|
|
(42
|
)
|
|
Aricept
(b)
|
|
(124
|
)
|
|
(28
|
)
|
|
Detrol/Detrol LA
(a)
|
|
(122
|
)
|
|
(14
|
)
|
|
Celebrex
|
|
196
|
|
|
8
|
|
|
Lyrica
|
|
465
|
|
|
13
|
|
|
Alliance revenues
(a)
|
|
(138
|
)
|
|
(4
|
)
|
|
All other biopharmaceutical products
(c)
|
|
525
|
|
|
7
|
|
|
Animal Health products
|
|
115
|
|
|
3
|
|
|
Consumer Healthcare products
|
|
184
|
|
|
6
|
|
(a)
|
Lipitor and Caduet lost exclusivity in the U.S. in November 2011 and various other major markets in 2011 and 2012. Xalatan lost exclusivity in the U.S. in March 2011 and in the majority of European markets in January 2012. Aromasin lost exclusivity in the U.S. in April 2011, in the majority of European markets in July 2011 and in Japan in November 2011. Geodon lost exclusivity in the U.S. in March 2012. Detrol immediate release (Detrol IR) lost exclusivity in the U.S. in June 2012. Detrol lost exclusivity in most European markets in September 2012. We lost exclusivity for Aricept 5mg and 10mg tablets, which are included in Alliance revenues, in the U.S. in November 2010 and in the majority of European markets in February 2012 and April 2012. Lower revenues for Spiriva in certain European countries, Canada and Australia reflect final-year terms of our collaboration agreements in those markets.
|
(b)
|
Represents direct sales under license agreement with Eisai Co., Ltd.
|
(c)
|
Includes the “All other” category included in the
Revenues
—
Major Biopharmaceutical Products
table presented in this Financial Review, which includes sales of generic atorvastatin.
|
•
|
a settlement with the U.S. Internal Revenue Service and the resolution of certain foreign tax audits in 2012, all of which related to multiple tax years, which resulted in a tax benefit of approximately $1.1 billion and $310 million, respectively, representing tax and interest (see further discussion in Notes to Consolidated Financial Statements––
Note 5A. Tax Matters: Taxes on Income from Continuing Operations
);
|
•
|
purchase accounting charges that were approximately $1.8 billion (pre-tax) lower in 2012 than 2011;
|
•
|
acquisition-related costs that were approximately $1.0 billion (pre-tax) lower in 2012 than 2011; and
|
•
|
charges related to our non-acquisition related cost-reduction and productivity initiatives that were approximately $645 million (pre-tax) lower in 2012 than 2011,
|
•
|
the loss of exclusivity of Lipitor, as well as certain other products, resulting in lower revenues and associated expenses (see also "The Loss or Expiration of Intellectual Property Rights" section of this Financial Review);
|
•
|
charges for certain legal matters that were approximately $1.4 billion (pre-tax) higher in 2012 than 2011 (see further discussion in the “Costs and Expenses––Other Deductions––Net” section of this Financial Review and Notes to Consolidated Financial Statements––
Note 4. Other Deductions––Net
); and
|
•
|
charges in 2012 associated with the separation of Zoetis of $325 million (pre-tax) (see further discussion in the “Costs and Expenses––Selling, Informational and Administrative (SI&A) Expenses" and "Other Deductions––Net” sections of this Financial Review and Notes to Consolidated Financial Statements––
Note 4. Other Deductions––Net
).
|
2012 Financial Report
|
|
3
|
|
|
|
|
•
|
an increase, from 15.1% to 23.1%, in the minimum rebate on branded prescription drugs sold to Medicaid beneficiaries (effective January 1, 2010);
|
•
|
extension of Medicaid prescription drug rebates to drugs dispensed to enrollees in certain Medicaid managed care organizations (effective March 23, 2010);
|
•
|
expansion of the types of institutions eligible for the “Section 340B discounts” for outpatient drugs provided to hospitals serving a disproportionate share of low-income individuals and meeting the qualification criteria under Section 340B of the Public Health Service Act of 1944 (effective January 1, 2010);
|
•
|
discounts on branded prescription drug sales to Medicare Part D participants who are in the Medicare “coverage gap,” also known as the “doughnut hole” (effective January 1, 2011); and
|
•
|
a fee payable to the federal government (which is not deductible for U.S. income tax purposes) based on our prior-calendar-year share relative to other companies of branded prescription drug sales to specified government programs (effective January 1, 2011, with the total fee to be paid each year by the pharmaceutical industry increasing annually through 2018).
|
•
|
$593 million recorded as a reduction to
Revenues,
related to the higher, extended and expanded rebate provisions and the Medicare “coverage gap” discount provision; and
|
•
|
$336 million recorded in
Selling, informational and administrative expenses
, related to the fee payable to the federal government referred to above.
|
•
|
$648 million recorded as a reduction to
Revenues,
related to the higher, extended and expanded rebate provisions and the Medicare “coverage gap” discount provision; and
|
•
|
$248 million recorded in
Selling, informational and administrative expenses
, related to the fee payable to the federal government referred to above.
|
•
|
Individual Mandate
—The financial impact of U.S. healthcare reform may be affected by certain additional developments over the next few years, including pending implementation guidance relating to the U.S. Healthcare Legislation and certain healthcare reform proposals. In addition, the U.S. Healthcare Legislation requires that, except in certain circumstances, individuals obtain health insurance beginning in 2014, and it also provides for an expansion of Medicaid coverage in 2014. It is expected that, as a result of these provisions, there will be a substantial increase in the number of Americans with health insurance beginning in 2014, a significant portion of whom will be eligible for Medicaid. We anticipate that this will increase demand for pharmaceutical products overall. However, because of the substantial mandatory rebates we pay under the Medicaid program and because a significant percentage of the Americans who will be included in the coverage expansion are expected to be young, we do not anticipate that implementation of the coverage expansion will generate significant additional revenues for Pfizer. In June 2012, the U.S. Supreme Court upheld the constitutionality of all provisions of the U.S. Healthcare Legislation, with the exception of the provisions concerning Medicaid expansion; as a result of the Court's ruling regarding Medicaid, states can choose not to expand their Medicaid populations without losing federal funding for their existing Medicaid populations. The Congressional Budget Office estimates that the new state flexibility is likely to result in six million fewer new Medicaid enrollees than were initially expected to enroll as a result of the eligibility expansion and that half of these people are expected to gain coverage through Health Insurance Exchanges, and the remaining three million are likely to remain uninsured.
|
•
|
Biotechnology Products—
The U.S. Healthcare Legislation also created a framework for the approval of biosimilars (also known as follow-on biologics) following the expiration of 12 years of exclusivity for the innovator biologic, with a potential six-month pediatric extension. Under the U.S. Healthcare Legislation, biosimilars applications may not be submitted until four years after the approval of the reference,
|
4
|
|
2012 Financial Report
|
|
|
|
|
•
|
Lipitor in the U.S.
––
We lost exclusivity for Lipitor in the U.S. in November 2011. The entry of multi-source generic competition in the U.S. began in May 2012, with attendant increased competitive pressures. Through the end of 2011, sales of Lipitor in the U.S. were reported in our Primary Care business unit. Beginning in 2012, sales of Lipitor in the U.S. were reported in our Established Products business unit.
|
•
|
Other recent loss of exclusivity impacts—In the U.S., we lost exclusivity for Vfend tablets in February 2011, for Xalatan in March 2011 and for Geodon in March 2012. The basic U.S. patent (including the six-month pediatric exclusivity period) for Protonix expired in January 2011. The basic patent for Vfend tablets in Brazil expired in January 2011. We lost exclusivity for Aromasin in the U.S. in April 2011, in the majority of European markets in July 2011 and in Japan in November 2011. We lost exclusivity for Xalatan and Xalacom in the majority of European markets in January 2012. We lost exclusivity for Aricept in the majority of European markets in February 2012 and April 2012. Caduet lost exclusivity in the U.S. in November 2011 and in the majority of European markets in March and May 2012. We lost exclusivity in the U.S. in September 2012 for Revatio tablet, and in June 2012 for Detrol IR. Detrol lost exclusivity in most European markets in September 2012.
|
•
|
Aricept—Our rights to Aricept in Japan returned to Eisai Co., Ltd. in December 2012. We expect to lose exclusivity for the Aricept 23mg tablet in the U.S. in July 2013.
|
•
|
Spiriva—Our collaboration with Boehringer Ingelheim (BI) for Spiriva expires on a country-by-country basis between 2012 and 2016, including the expiration in certain EU markets and Canada and Australia in 2012, which adversely impacted our 2012 results. We expect to experience a graduated decline in revenues from Spiriva through 2016.
|
•
|
Enbrel—Our U.S. and Canada collaboration agreement with Amgen Inc. for Enbrel will expire in October 2013. While we are entitled to royalties for 36 months thereafter, we expect that those royalties will be significantly less than our current share of Enbrel profits from U.S. and Canada sales. Outside the U.S. and Canada, our exclusive rights to Enbrel continue in perpetuity.
|
2012 Financial Report
|
|
5
|
|
|
|
|
•
|
Rebif—Our collaboration agreement with EMD Serono Inc. (Serono) to co-promote Rebif in the U.S. will expire either at the end of 2013 or the end of 2015, depending on the outcome of pending litigation between Pfizer and Serono concerning the interpretation of the agreement. We believe that we are entitled to a 24-month extension of the agreement to the end of 2015. Serono believes that we are not entitled to the extension and that the agreement will expire at the end of 2013. In October 2011, the Philadelphia Court of Common Pleas sustained our preliminary objections and dismissed Serono’s complaint, and Serono has appealed the decision to the Superior Court of Pennsylvania. For additional information, see Notes to Consolidated Financial Statements––
Note 17. Commitments and Contingencies
.
|
6
|
|
2012 Financial Report
|
|
|
|
|
2012 Financial Report
|
|
7
|
|
|
|
|
•
|
On February 6, 2013, an initial public offering of Zoetis was completed, pursuant to which we sold 99.015 million shares of Zoetis in exchange for the retirement of approximately $2.5 billion of Pfizer commercial paper issued on January 10, 2013. The IPO represented approximately 19.8% of the total outstanding Zoetis shares. For additional information, see Notes to Consolidated Financial Statements––
Note 19A. Subsequent Events: Zoetis Debt Offering and Initial Public Offering.
|
•
|
On November 30, 2012, we completed the sale of our Nutrition business to Nestlé for $11.85 billion in cash. For additional information, see Notes to Consolidated Financial Statements—
Note 2B. Acquisitions, Divestitures, Collaborative Arrangements and Equity-Method Investments: Divestitures
.
|
•
|
On November 27, 2012, we completed our acquisition of NextWave Pharmaceuticals Incorporated (NextWave), a privately held, specialty pharmaceutical company. As a result of the acquisition, Pfizer now holds exclusive North American rights to Quillivant XR™ (methylphenidate hydrochloride), the first once-daily liquid medication approved in the U.S. for the treatment of ADHD. The total consideration for the acquisition was approximately $442 million. For additional information, see Notes to Consolidated Financial Statements—
Note 2A. Acquisitions, Divestitures, Collaborative Arrangements and Equity-Method Investments: Acquisitions
.
|
•
|
On October 31, 2012, our equity-method investee, ViiV Healthcare Limited (ViiV), acquired the remaining 50% of Shionogi-ViiV Healthcare LLC, its equity-method investee, from Shionogi & Co., Ltd. (Shionogi) in consideration for a 10% interest in ViiV (newly issued shares) and contingent consideration in the form of future royalties. For additional information, see Notes to Consolidated Financial Statements—
Note 2D. Acquisitions, Divestitures, Collaborative Arrangements and Equity-Method Investments: Equity-Method Investments
.
|
8
|
|
2012 Financial Report
|
|
|
|
|
•
|
On September 6, 2012, Pfizer and Zhejiang Hisun Pharmaceuticals Co., Ltd., a leading Chinese pharmaceutical company, created a new company, Hisun Pfizer Pharmaceuticals Company Limited (HPP), to develop, manufacture and commercialize off-patent pharmaceutical products in China and global markets. HPP was established with registered capital of $250 million. For additional information, see Notes to Consolidated Financial Statements—
Note 2D. Acquisitions, Divestitures, Collaborative Arrangements and Equity-Method Investments: Equity-Method Investments.
|
•
|
On August 13, 2012, we announced that we entered into an agreement with AstraZeneca for the global over-the-counter (OTC) rights for Nexium, a leading prescription drug currently approved to treat the symptoms of gastroesophageal reflux disease. We made an upfront payment of $250 million to AstraZeneca, and AstraZeneca is eligible to receive milestone payments of up to $550 million based on product launches and level of sales as well as royalty payments based on sales. A marketing authorization application for OTC Nexium in a 20mg tablet form was filed with the European Medicines Agency in June 2012. A new drug application filing for OTC Nexium in the U.S. in a 20mg delayed-release capsule is targeted for the first half of 2013. For additional information, see Notes to Consolidated Financial Statements—
Note 2A. Acquisitions, Divestitures, Collaborative Arrangements and Equity-Method Investments: Acquisitions
.
|
•
|
On March 12, 2012, Biocon and Pfizer announced the conclusion of their October 18, 2010 alliance to commercialize Biocon’s biosimilar versions of insulin and insulin analog products. The companies agreed that, due to the individual priorities for their respective biosimilars businesses, each company would move forward independently.
|
•
|
On February 26, 2012, we completed our acquisition of Alacer Corp. (Alacer), a company that manufactures, markets and distributes Emergen-C, a line of effervescent, powdered drink mix vitamin supplements that is the largest-selling branded vitamin C line in the U.S. For additional information, see Notes to Consolidated Financial Statements—
Note 2A. Acquisitions, Divestitures, Collaborative Arrangements and Equity-Method Investments: Acquisitions.
|
•
|
On December 1, 2011, we completed our acquisition of the consumer healthcare business of Ferrosan Holding A/S (Ferrosan), a Danish company engaged in the sale of science-based consumer healthcare products, including dietary supplements and lifestyle products, primarily in the Nordic region and the emerging markets of Russia and Central and Eastern Europe. Our acquisition of Ferrosan’s consumer healthcare business strengthens our presence in dietary supplements with a new set of brands and pipeline products. For additional information, see Notes to Consolidated Financial Statements—
Note 2A. Acquisitions, Divestitures, Collaborative Arrangements and Equity-Method Investments: Acquisitions.
|
•
|
On November 30, 2011, we completed our acquisition of Excaliard Pharmaceuticals, Inc. (Excaliard), a privately owned biopharmaceutical company. Excaliard‘s lead compound, EXC-001, a Phase 2 compound, is an antisense oligonucleotide designed to interrupt the process of skin fibrosis by inhibiting expression of connective tissue growth factor (CTGF). The total consideration for the acquisition was approximately $174 million. For additional information, see Notes to Consolidated Financial Statements—
Note 2A. Acquisitions, Divestitures, Collaborative Arrangements and Equity-Method Investments: Acquisitions
.
|
•
|
In October 2011, we entered into an agreement with GlycoMimetics, Inc. for their investigational compound GMI-1070. GMI-1070 is a pan-selectin antagonist currently in Phase 2 development for the treatment of vaso-occlusive crisis associated with sickle cell disease. GMI-1070 has received Orphan Drug and Fast Track status from the FDA. Under the terms of the agreement, Pfizer received an exclusive worldwide license to GMI-1070 for vaso-occlusive crisis associated with sickle cell disease and for other diseases for which the drug candidate may be developed. GlycoMimetics is responsible for completion of the ongoing Phase 2 trial under Pfizer’s oversight, and Pfizer is responsible for all further development and commercialization. GlycoMimetics is entitled to payments up to approximately $340 million, including an upfront payment as well as development, regulatory and commercial milestones. GlycoMimetics is also eligible for royalties on any sales.
|
•
|
On September 20, 2011, we completed our cash tender offer for the outstanding shares of Icagen, Inc. (Icagen), resulting in an approximate 70% ownership of the outstanding shares of Icagen, a biopharmaceutical company focused on discovery, development and commercialization of novel, orally-administered small molecule drugs that modulate ion channel targets. On October 27, 2011, we acquired all of the remaining shares of Icagen. For additional information, see Notes to Consolidated Financial Statements—
Note 2A. Acquisitions, Divestitures, Collaborative Arrangements and Equity-Method Investments: Acquisitions
.
|
•
|
On August 1, 2011, we sold our Capsugel business for approximately $2.4 billion in cash. For additional information, see Notes to Consolidated Financial Statements—
Note 2B. Acquisitions, Divestitures, Collaborative Arrangements and Equity-Method Investments: Divestitures
.
|
•
|
On January 31, 2011 (the acquisition date), we completed a tender offer for the outstanding shares of common stock of King and acquired approximately 92.5% of the outstanding shares for approximately $3.3 billion in cash. On February 28, 2011, we acquired the remaining shares of King for approximately $300 million in cash. As a result, the total fair value of consideration transferred for King was approximately $3.6 billion in cash ($3.2 billion, net of cash acquired). For additional information, see Notes to Consolidated Financial Statements—
Note 2A. Acquisitions, Divestitures, Collaborative Arrangements and Equity-Method Investments: Acquisitions.
|
•
|
On November 8, 2010, we consummated our partnership to develop and commercialize generic medicines with Laboratório Teuto Brasileiro S.A. (Teuto) a leading generics company in Brazil. As part of the transaction, we acquired a 40% equity stake in Teuto, and entered into a series of commercial agreements. The partnership is enhancing our position in Brazil, a key emerging market, by providing access to Teuto’s portfolio of products. Through this partnership, we have access to significant distribution networks in rural and suburban areas in Brazil and the opportunity to register and commercialize Teuto’s products in various markets outside Brazil. For additional information, see also Notes to Consolidated Financial Statements—
Note 2D. Acquisitions, Divestitures, Collaborative Arrangements and Equity-Method Investments: Equity-Method Investments
.
|
•
|
On October 6, 2010, we completed our acquisition of FoldRx Pharmaceuticals, Inc. (FoldRx), a privately held drug discovery and clinical development company. FoldRx’s lead product candidate, Vyndaqel (tafamidis meglumine), was approved in the EU in November 2011 and our new drug application was accepted for review in the U.S. in February 2012. This product is a first-in-class oral therapy for the treatment of transthyretin familial amyloid polyneuropathy (TTR-FAP), a progressively fatal genetic neurodegenerative disease, for which
|
2012 Financial Report
|
|
9
|
|
|
|
|
|
|
Full-Year 2013 Guidance
|
||
(BILLIONS OF DOLLARS, EXCEPT PER SHARE AMOUNTS)
|
|
Net Income
(a)
|
|
Diluted EPS
(a)
|
Adjusted income/adjusted diluted EPS
(b)
guidance
|
|
~$15.4 - $16.1
|
|
~$2.20 - $2.30
|
Purchase accounting impacts of transactions completed as of December 31, 2012
|
|
(3.4)
|
|
(0.49)
|
Acquisition-related costs
|
|
(0.4 - 0.5)
|
|
(0.06 - 0.07)
|
Non-acquisition-related restructuring costs
(c)
|
|
(0.5 - 0.8)
|
|
(0.8 - 0.12)
|
Costs associated with the separation of Zoetis
(d)
|
|
(0.2)
|
|
(0.2)
|
Reported net income attributable to Pfizer Inc./diluted EPS guidance
(d)
|
|
~$10.5 - $11.6
|
|
~$1.50 - $1.65
|
(a)
|
Does not assume the completion of any business development transactions not completed as of December 31, 2012, including any one-time upfront payments associated with such transactions, and excludes the potential effects of the resolution of litigation-related matters not substantially resolved as of December 31, 2012
.
|
(b)
|
For an understanding of Adjusted income and Adjusted diluted EPS, see the “Adjusted Income” section of this Financial Review.
|
(c)
|
Includes amounts related to our initiatives to reduce R&D spending, including our realigned R&D footprint, and amounts related to other cost-reduction and productivity initiatives. In our reconciliation between
Net income attributable to Pfizer Inc.
, as reported under principles generally accepted in the United States of America (U.S. GAAP), and Adjusted income, and in our reconciliation between diluted EPS, as reported under U.S. GAAP, and Adjusted diluted EPS, these amounts are categorized as Certain Significant Items (see the “Adjusted Income––Reconciliation” section of this Financial Review).
|
(d)
|
Reported Diluted EPS guidance includes a $0.02 unfavorable impact for certain non-recurring costs that we expect to incur related to the separation of Zoetis, including new branding, the creation of a standalone infrastructure, site separation and certain legal registration and patent assignment costs.
|
10
|
|
2012 Financial Report
|
|
|
|
|
•
|
For Medicaid, Medicare and performance-based contract rebates, we use experience ratios, which may be adjusted to better match our current experience or our expected future experience.
|
•
|
For contractual or legislatively mandated deductions outside the U.S., we use estimated allocation factors, based on historical payments and some third-party reports, to project the expected level of reimbursement.
|
•
|
For chargebacks, we closely approximate actual as we settle these deductions generally within two to five weeks after incurring the liability.
|
•
|
For sales returns, we perform calculations in each market that incorporate the following, as appropriate: local returns policies and practices; returns as a percentage of sales; an understanding of the reasons for past returns; estimated shelf life by product; an estimate of the amount of time between shipment and return or lag time; and any other factors that could impact the estimate of future returns, such as loss of exclusivity, product recalls or a changing competitive environment.
|
•
|
For sales incentives, we use our historical experience with similar incentives programs to predict customer behavior.
|
•
|
A significant adverse change in legal factors or in the business climate that could affect the value of the asset. For example, a successful challenge of our patent rights would likely result in generic competition earlier than expected.
|
•
|
A significant adverse change in the extent or manner in which an asset is used. For example, restrictions imposed by the FDA or other regulatory authorities could affect our ability to manufacture or sell a product.
|
•
|
A projection or forecast that demonstrates losses or reduced profits associated with an asset. This could result, for example, from a change in a government reimbursement program that results in an inability to sustain projected product revenues and profitability. This also could result from the introduction of a competitor’s product that results in a significant loss of market share or the inability to achieve the previously projected revenue growth, as well as the lack of acceptance of a product by patients, physicians and payers. For in-process research and development (IPR&D) projects, this could result from, among other things, a change in outlook based on clinical trial data, a delay in the projected launch date or additional expenditures to commercialize the product.
|
•
|
In
2012
,
$872 million
, reflecting (i)
$393 million
of IPR&D assets, primarily related to compounds that targeted autoimmune and inflammatory diseases (full write-off) and, to a lesser extent, compounds related to pain treatment; (ii)
$175 million
related to our Consumer Healthcare indefinite-lived brand assets, primarily Robitussin, a cough suppressant; (iii)
$279 million
related to Developed Technology Rights, a charge comprised of impairments of various products, none of which individually exceeded
$45 million
; and (iv)
$25 million
of finite-lived brands. The intangible asset impairment charges for
2012
reflect, among other things, the impact of new scientific
|
2012 Financial Report
|
|
11
|
|
|
|
|
•
|
In
2011
,
$851 million
, the majority of which relates to intangible assets that were acquired as part of our acquisition of Wyeth. These impairment charges reflect (i)
$475 million
of IPR&D assets, primarily related to two compounds for the treatment of certain autoimmune and inflammatory diseases; (ii)
$193 million
related to our biopharmaceutical indefinite-lived brand, Xanax; and (iii)
$183 million
related to Developed Technology Rights comprising the impairment of five assets. The intangible asset impairment charges for
2011
reflect, among other things, the impact of new scientific findings and an increased competitive environment. The impairment charges in
2011
are associated with the following: Worldwide Research and Development (
$394 million
); Established Products (
$193 million
); Specialty Care (
$135 million
); Primary Care (
$56 million
); Oncology (
$56 million
) and Animal Health (
$17 million
).
|
•
|
In 2010, $1.8 billion, the majority of which relates to intangible assets that were acquired as part of our acquisition of Wyeth. These impairment charges reflect (i) $945 million of IPR&D assets, primarily Prevnar 13/Prevenar 13 Adult, a compound for the prevention of pneumococcal disease in adults age 50 and older, and Neratinib, a compound for the treatment of breast cancer; (ii) $292 million of indefinite-lived Brands, primarily related to Robitussin, a cough suppressant; and (iii) $540 million of Developed Technology Rights, primarily Thelin, a product that treated pulmonary hypertension, and Protonix, a product that treats erosive gastroesophageal reflux disease. These impairment charges, most of which occurred in the third quarter of 2010, reflect, among other things, the following: for IPR&D assets, the impact of changes to the development programs, the projected development and regulatory time-frames and the risk associated with these assets; for Brand assets, the current competitive environment and planned investment support; and, for Developed Technology Rights, in the case of Thelin, we voluntarily withdrew the product in regions where it was approved and discontinued all clinical studies worldwide, and for the others, an increased competitive environment. The impairment charges in 2010 are generally associated with the following: Specialty Care ($708 million); Oncology ($396 million); Consumer Healthcare ($292 million); Established Products ($182 million); Primary Care ($145 million); and Worldwide Research and Development ($54 million).
|
•
|
Some of our indefinite-lived Consumer Healthcare brands, mainly Robitussin and Chapstick, have fair values that approximate their combined carrying value of about $900 million, which reflects impairment charges that were taken in the fourth quarter and first quarter of 2012. These assets continue to be at risk for future impairment. Any negative change in the undiscounted cash flows, discount rate and/or tax rate could result in an impairment charge. We re-considered and confirmed the classification of these assets as indefinite-lived. We will continue to closely monitor these assets.
|
•
|
One of our indefinite-lived biopharmaceutical brands, Xanax, was written down to its fair value of $1.2 billion at the end of 2011. This asset continues to be at risk for future impairment. Any negative change in the undiscounted cash flows, discount rate and/or tax rate could result in an impairment charge. Xanax, which was launched in the mid-1980’s and acquired in 2003, must continue to remain competitive against its generic challengers or the associated asset may become impaired again. We re-considered and confirmed the classification of this asset as indefinite-lived. We will continue to closely monitor this asset.
|
12
|
|
2012 Financial Report
|
|
|
|
|
•
|
The market approach is a historical approach to estimating fair value and relies primarily on external information. Within the market approach are two methods that we may use:
|
◦
|
Guideline public company method—this method employs market multiples derived from market prices of stocks of companies that are engaged in the same or similar lines of business and that are actively traded on a free and open market and the application of the identified multiples to the corresponding measure of our reporting unit’s financial performance.
|
◦
|
Guideline transaction method—this method relies on pricing multiples derived from transactions of significant interests in companies engaged in the same or similar lines of business and the application of the identified multiples to the corresponding measure of our reporting unit’s financial performance.
|
•
|
The income approach is a forward-looking approach to estimating fair value and relies primarily on internal forecasts. Within the income approach, the method that we use is the discounted cash flow method. We start with a forecast of all the expected net cash flows associated with the reporting unit, which includes the application of a terminal value, and then we apply a reporting unit-specific discount rate to arrive at a net present value amount. Some of the more significant estimates and assumptions inherent in this approach include: the amount and timing of the projected net cash flows, which includes the expected impact of technological risk and competitive, legal and/or regulatory forces on the projections, as well as the selection of a long-term growth rate; the discount rate, which seeks to reflect the various risks inherent in the projected cash flows; and the tax rate, which seeks to incorporate the geographic diversity of the projected cash flows.
|
•
|
When we estimate the fair value of our five biopharmaceutical reporting units, we rely solely on the income approach. We use the income approach exclusively as many of our products are sold in multiple reporting units and as one reporting unit is geographic-based while the others are product and/or customer-based. Further, the projected cash flows from a single product may reside in up to three reporting units at different points in future years and the discounted cash flow method would reflect the movement of products among reporting units. As such, the use of the comparable guideline company method was not practical or reliable. However, on a limited basis and as deemed reasonable, we attempt to corroborate our outcomes with the market approach. For the income approach, we use the discounted cash flow method.
|
•
|
When we estimate the fair value of our Consumer Healthcare reporting unit, we use a combination of approaches and methods. We use the income approach and the market approach, which we weight equally in our analysis. We weight them equally as we have equal confidence in the appropriateness of the approaches for this reporting unit. For the income approach, we use the discounted cash flow method and for the market approach, we use both the guideline public company method and the guideline transaction method, which we weight equally to arrive at our market approach value.
|
•
|
When we estimate the fair value of our Animal Health reporting unit, we use the income approach, relying exclusively on the discounted cash flow method. We rely exclusively on the income approach as the discounted cash flow method provides a more reliable outlook of the business. However, on a limited basis and as deemed reasonable, we attempt to corroborate our outcomes with the market approach. (See also Notes to Consolidated Financial Statements––
Note 19A. Subsequent Events: Zoetis Debt Offering and Initial Public Offering.
)
|
2012 Financial Report
|
|
13
|
|
|
|
|
14
|
|
2012 Financial Report
|
|
|
|
|
|
|
Year Ended December 31,
|
|
% Change
|
||||||||||||||
(MILLIONS OF DOLLARS)
|
|
2012
|
|
|
2011
|
|
|
2010
|
|
|
12/11
|
|
|
11/10
|
|
|||
Revenues
|
|
$
|
58,986
|
|
|
$
|
65,259
|
|
|
$
|
65,165
|
|
|
(10
|
)%
|
|
—
|
%
|
Cost of sales
|
|
11,334
|
|
|
14,076
|
|
|
14,788
|
|
|
(19
|
)%
|
|
(5
|
)%
|
|||
% of revenues
|
|
19.2
|
%
|
|
21.6
|
%
|
|
22.7
|
%
|
|
|
|
|
|||||
Selling, informational and administrative expenses
|
|
16,616
|
|
|
18,832
|
|
|
18,973
|
|
|
(12
|
)%
|
|
(1
|
)%
|
|||
% of revenues
|
|
28.2
|
%
|
|
28.9
|
%
|
|
29.1
|
%
|
|
|
|
|
|||||
Research and development expenses
|
|
7,870
|
|
|
9,074
|
|
|
9,483
|
|
|
(13
|
)%
|
|
(4
|
)%
|
|||
% of revenues
|
|
13.3
|
%
|
|
13.9
|
%
|
|
14.6
|
%
|
|
|
|
|
|||||
Amortization of intangible assets
|
|
5,175
|
|
|
5,544
|
|
|
5,364
|
|
|
(7
|
)%
|
|
3
|
%
|
|||
% of revenues
|
|
8.8
|
%
|
|
8.5
|
%
|
|
8.2
|
%
|
|
|
|
|
|||||
Restructuring charges and certain acquisition-related costs
|
|
1,880
|
|
|
2,930
|
|
|
3,145
|
|
|
(36
|
)%
|
|
(7
|
)%
|
|||
% of revenues
|
|
3.2
|
%
|
|
4.5
|
%
|
|
4.8
|
%
|
|
|
|
|
|||||
Other deductions—net
|
|
4,031
|
|
|
2,499
|
|
|
3,941
|
|
|
61
|
%
|
|
(37
|
)%
|
|||
Income from continuing operations before provision for taxes on income
|
|
12,080
|
|
|
12,304
|
|
|
9,471
|
|
|
(2
|
)%
|
|
30
|
%
|
|||
% of revenues
|
|
20.5
|
%
|
|
18.9
|
%
|
|
14.5
|
%
|
|
|
|
|
|||||
Provision for taxes on income
|
|
2,562
|
|
|
3,909
|
|
|
1,153
|
|
|
(34
|
)%
|
|
239
|
%
|
|||
Effective tax rate
|
|
21.2
|
%
|
|
31.8
|
%
|
|
12.2
|
%
|
|
|
|
|
|||||
Plus: Discontinued operations—net of tax
|
|
5,080
|
|
|
1,654
|
|
|
(30
|
)
|
|
207
|
%
|
|
*
|
|
|||
Less: Net income attributable to noncontrolling interests
|
|
28
|
|
|
40
|
|
|
31
|
|
|
(30
|
)%
|
|
29
|
%
|
|||
Net income attributable to Pfizer Inc.
|
|
$
|
14,570
|
|
|
$
|
10,009
|
|
|
$
|
8,257
|
|
|
46
|
%
|
|
21
|
%
|
% of revenues
|
|
24.7
|
%
|
|
15.3
|
%
|
|
12.7
|
%
|
|
|
|
|
*
|
Calculation not meaningful.
|
•
|
an operational decline of $4.8 billion, or 8%, primarily due to the loss of exclusivity of certain products, including Lipitor, in most major markets; and
|
•
|
the unfavorable impact of foreign exchange, which decreased revenues by approximately $1.5 billion, or 2%.
|
•
|
the favorable impact of foreign exchange, which increased revenues by approximately $1.9 billion, or 3%; and
|
•
|
the inclusion of revenues of $1.3 billion, or 2%, from our acquisition of King,
|
•
|
an operational decline of $2.9 billion, or 4%, primarily due to the loss of exclusivity of certain products.
|
2012 Financial Report
|
|
15
|
|
|
|
|
(a)
|
Rebates are product-specific and, therefore, for any given year are impacted by the mix of products sold.
|
(b)
|
Performance-based contract rebates include contract rebates with managed care customers within the U.S., including health maintenance organizations and pharmacy benefit managers, who receive rebates based on the achievement of contracted performance terms and claims under these contracts.
|
(c)
|
Chargebacks primarily represent reimbursements to wholesalers for honoring contracted prices to third parties.
|
(d)
|
Sales allowances primarily represent pharmaceutical rebates, discounts and price reductions that are contractual or legislatively mandated outside the U.S.
|
•
|
the impact of decreased Medicaid, Medicare and performance-based contract rebates contracted for Lipitor and certain other products that have lost exclusivity;
|
•
|
changes in product mix; and
|
•
|
the impact on chargebacks of decreased sales for certain products that have lost exclusivity,
|
•
|
an increase in chargebacks for our branded products as a result of increasing competitive pressures.
|
16
|
|
2012 Financial Report
|
|
|
|
|
The following table provides Worldwide revenues by operating segment, business unit and geographic area:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
Year Ended December 31,
|
|
% Change
|
||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
Worldwide
|
|
U.S.
|
|
International
|
|
Worldwide
|
|
U.S.
|
|
International
|
||||||||||||||||||||||||||||||||||||||||||
(MILLIONS OF
DOLLARS)
|
|
2012
|
|
|
2011
(a)
|
|
|
2010
|
|
|
2012
|
|
|
2011
(a)
|
|
|
2010
|
|
|
2012
|
|
|
2011
(a)
|
|
|
2010
|
|
|
12/11
|
|
|
11/10
|
|
|
12/11
|
|
|
11/10
|
|
|
12/11
|
|
|
11/10
|
|
|||||||||
Biopharmaceutical revenues:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||||||||||
Primary Care Operating Segment
|
|
$
|
15,558
|
|
|
$
|
22,670
|
|
|
$
|
23,328
|
|
|
$
|
8,191
|
|
|
$
|
12,819
|
|
|
$
|
13,536
|
|
|
$
|
7,367
|
|
|
$
|
9,851
|
|
|
$
|
9,792
|
|
|
(31
|
)
|
|
(3
|
)
|
|
(36
|
)
|
|
(5
|
)
|
|
(25
|
)
|
|
1
|
|
Specialty Care
|
|
14,151
|
|
|
15,245
|
|
|
15,021
|
|
|
6,206
|
|
|
6,870
|
|
|
7,419
|
|
|
7,945
|
|
|
8,375
|
|
|
7,602
|
|
|
(7
|
)
|
|
1
|
|
|
(10
|
)
|
|
(7
|
)
|
|
(5
|
)
|
|
10
|
|
|||||||||
Oncology
|
|
1,310
|
|
|
1,323
|
|
|
1,414
|
|
|
573
|
|
|
391
|
|
|
506
|
|
|
737
|
|
|
932
|
|
|
908
|
|
|
(1
|
)
|
|
(6
|
)
|
|
47
|
|
|
(23
|
)
|
|
(21
|
)
|
|
3
|
|
|||||||||
SC&O Operating Segment
|
|
15,461
|
|
|
16,568
|
|
|
16,435
|
|
|
6,779
|
|
|
7,261
|
|
|
7,925
|
|
|
8,682
|
|
|
9,307
|
|
|
8,510
|
|
|
(7
|
)
|
|
1
|
|
|
(7
|
)
|
|
(8
|
)
|
|
(7
|
)
|
|
9
|
|
|||||||||
Emerging Markets
|
|
9,960
|
|
|
9,295
|
|
|
8,662
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
9,960
|
|
|
9,295
|
|
|
8,662
|
|
|
7
|
|
|
7
|
|
|
—
|
|
|
—
|
|
|
7
|
|
|
7
|
|
|||||||||
Established Products
|
|
10,235
|
|
|
9,214
|
|
|
10,098
|
|
|
4,738
|
|
|
3,627
|
|
|
4,501
|
|
|
5,497
|
|
|
5,587
|
|
|
5,597
|
|
|
11
|
|
|
(9
|
)
|
|
31
|
|
|
(19
|
)
|
|
(2
|
)
|
|
—
|
|
|||||||||
EP&EM Operating Segment
|
|
20,195
|
|
|
18,509
|
|
|
18,760
|
|
|
4,738
|
|
|
3,627
|
|
|
4,501
|
|
|
15,457
|
|
|
14,882
|
|
|
14,259
|
|
|
9
|
|
|
(1
|
)
|
|
31
|
|
|
(19
|
)
|
|
4
|
|
|
4
|
|
|||||||||
|
|
51,214
|
|
|
57,747
|
|
|
58,523
|
|
|
19,708
|
|
|
23,707
|
|
|
25,962
|
|
|
31,506
|
|
|
34,040
|
|
|
32,561
|
|
|
(11
|
)
|
|
(1
|
)
|
|
(17
|
)
|
|
(9
|
)
|
|
(7
|
)
|
|
5
|
|
|||||||||
Other product revenues:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||||||||||
Animal Health
|
|
4,299
|
|
|
4,184
|
|
|
3,575
|
|
|
1,771
|
|
|
1,648
|
|
|
1,382
|
|
|
2,528
|
|
|
2,536
|
|
|
2,193
|
|
|
3
|
|
|
17
|
|
|
7
|
|
|
19
|
|
|
—
|
|
|
16
|
|
|||||||||
Consumer Healthcare
|
|
3,212
|
|
|
3,028
|
|
|
2,748
|
|
|
1,526
|
|
|
1,490
|
|
|
1,408
|
|
|
1,686
|
|
|
1,538
|
|
|
1,340
|
|
|
6
|
|
|
10
|
|
|
2
|
|
|
6
|
|
|
10
|
|
|
15
|
|
|||||||||
Other operating segments
|
|
7,511
|
|
|
7,212
|
|
|
6,323
|
|
|
3,297
|
|
|
3,138
|
|
|
2,790
|
|
|
4,214
|
|
|
4,074
|
|
|
3,533
|
|
|
4
|
|
|
14
|
|
|
5
|
|
|
12
|
|
|
3
|
|
|
15
|
|
|||||||||
Other
(b)
|
|
261
|
|
|
300
|
|
|
319
|
|
|
81
|
|
|
88
|
|
|
103
|
|
|
180
|
|
|
212
|
|
|
216
|
|
|
(13
|
)
|
|
(6
|
)
|
|
(8
|
)
|
|
(15
|
)
|
|
(15
|
)
|
|
(2
|
)
|
|||||||||
Total Revenues
|
|
$
|
58,986
|
|
|
$
|
65,259
|
|
|
$
|
65,165
|
|
|
$
|
23,086
|
|
|
$
|
26,933
|
|
|
$
|
28,855
|
|
|
$
|
35,900
|
|
|
$
|
38,326
|
|
|
$
|
36,310
|
|
|
(10
|
)
|
|
—
|
|
|
(14
|
)
|
|
(7
|
)
|
|
(6
|
)
|
|
6
|
|
(a)
|
For 2011, includes King commencing on the acquisition date of January 31, 2011.
|
(b)
|
Includes revenues generated primarily from Pfizer CentreSource, our contract manufacturing and bulk pharmaceutical chemical sales organization.
|
•
|
the decrease of $7.6 billion in operational revenues from Lipitor, Geodon, Xalatan, Caduet, Aromasin and Detrol, and lower Alliance revenues for Aricept, all due to loss of exclusivity in certain markets, and from lower Alliance revenues for Spiriva due to the final-year terms of our collaboration agreements in certain European countries, Canada and Australia; lower revenues for Effexor and Zosyn/Tazocin; and
|
•
|
the unfavorable impact of foreign exchange of $1.3 billion, or 2%,
|
•
|
an increase in operational revenues in developed markets for certain biopharmaceutical products, particularly Lyrica, Celebrex, and Enbrel, and in revenues from emerging markets.
|
•
|
in the U.S., revenues from biopharmaceutical products decreased 17% in 2012, compared to 2011, primarily reflecting lower revenues from Lipitor, Geodon, Caduet, Xalatan and Aromasin, all due to loss of exclusivity; lower Alliance revenues due to loss of exclusivity of Aricept 5mg and 10mg tablets in November 2010; and lower revenues from Effexor, Zosyn and Detrol/Detrol LA. The impact of these adverse factors was partially offset by the strong performance of certain other biopharmaceutical products, lower reductions related to rebates and the lower reduction in revenues related to the U.S. Healthcare Legislation.
|
2012 Financial Report
|
|
17
|
|
|
|
|
•
|
in our international markets, revenues from biopharmaceutical products decreased 7% in 2012, compared to 2011, primarily due to the loss of exclusivity of Lipitor in most of developed Europe and the unfavorable impact of foreign exchange of 3%. Operationally, revenues decreased 4% in 2012, compared to 2011. In addition to Lipitor, the decrease in operational revenues was driven by Xalatan/Xalacom, Aricept and Aromasin, all due to loss of exclusivity in certain markets, as well as lower Alliance revenues, primarily due to the loss of exclusivity of Aricept in many major European markets, and lower revenues for Spiriva in certain European countries, Canada and Australia (reflecting the final-year terms of our Spiriva collaboration agreements relating to those countries), as well as lower revenues for Norvasc and Effexor. The impact of these adverse factors was partially offset by the strong operational growth of Lyrica, Prevnar 13/Prevenar 13 and Enbrel.
|
•
|
Primary Care unit revenues decreased 31% in 2012 compared to 2011, reflecting lower operational revenues of 30%, primarily due to the losses of exclusivity of Lipitor in most major markets, as well as the resulting shift in the reporting of U.S. and Japan Lipitor revenues to the Established Products unit beginning January 1, 2012. These factors impacted Primary Care operational revenues by approximately $5.6 billion, or 25%, in 2012.
|
•
|
Specialty Care unit revenues decreased 7% compared to 2011, due to lower operational revenues of 5%, as well as the adverse impact of foreign exchange. Operational revenues were negatively impacted by the decline in the Prevnar/Prevenar family in the U.S. and developed Europe, as the pediatric catch-up dose opportunity declined significantly in 2012 compared to 2011, with fewer children eligible to receive the catch-up dose. Additionally, utilization of Prevnar/Prevenar in older adults remains modest at this time.
|
•
|
Oncology unit revenues decreased 1%, compared to 2011, primarily due to the unfavorable impact of foreign exchange of 3%. Operational revenues were positively impacted by the launches of Inlyta and Xalkori in the U.S. and certain other developed markets, partially offset by the unfavorable impact of the loss of exclusivity of Aromasin in the majority of European markets in the second half of 2011 and the resulting shift in the reporting of such revenues to the Established Products unit beginning January 1, 2012. This loss of exclusivity reduced Oncology unit revenues by $229 million, or 17%, in comparison with 2011.
|
•
|
Established Products unit revenues increased 11% compared to 2011, due to higher operational revenues of 13%, partially offset by a 2% unfavorable impact of foreign exchange. The increase in Established Products unit operational revenues in 2012 was mainly due to the shift in the reporting of branded Lipitor revenues in the U.S. and Japan from the Primary Care unit, totaling $1.4 billion, to the Established Products unit beginning January 1, 2012, as well as recent launches of generic versions of certain Pfizer branded primary care and specialty care products, and by contributions from the sales of the authorized generic version of Lipitor in the U.S. by Watson Pharmaceuticals, Inc. (Watson). The agreement with Watson was terminated by mutual consent in January 2013.
|
•
|
Emerging Markets unit revenues increased 7% compared to 2011, due to higher operational revenues of 12%, partially offset by a 5% unfavorable impact of foreign exchange. The increase in Emerging Markets unit operational revenues in 2012 was primarily due to volume growth in China, Brazil and Russia, as a result of more targeted promotional efforts for key innovative and established products, including Lipitor, Norvasc and Lyrica.
|
18
|
|
2012 Financial Report
|
|
|
|
|
•
|
the decrease of $4.7 billion in operational revenues from Lipitor, Effexor, Protonix, Xalatan, Caduet, Vfend, Aromasin and Zosyn/Tazocin, and lower Alliance revenues for Aricept, all due to loss of exclusivity in certain markets; and
|
•
|
a reduction in revenues due to the U.S. Healthcare Legislation that was $359 million larger in 2011 than in 2010,
|
•
|
the solid performance of Lyrica, the Prevnar/Prevenar family and Enbrel;
|
•
|
the inclusion of operational revenues from legacy King products of approximately $950 million, which favorably impacted biopharmaceutical revenues by 2%; and
|
•
|
the favorable impact of foreign exchange of $1.7 billion, or 3%.
|
•
|
in the U.S., revenues from biopharmaceutical products decreased 9% in 2011, compared to 2010, reflecting lower revenues from Lipitor, Protonix, Effexor, Zosyn, Xalatan, Vfend, Caduet and Aromasin, all due to loss of exclusivity, lower Alliance revenues due to loss of exclusivity of Aricept 5mg and 10mg tablets in November 2010 and lower revenues from Detrol/Detrol LA, as well as the reduction in revenues due to the U.S. Healthcare Legislation that was $359 million larger in 2011 than in 2010. The impact of these adverse factors was partially offset by the strong performance of certain other biopharmaceutical products and the addition of U.S. revenues from legacy King products of approximately $904 million in 2011.
|
•
|
in our international markets, revenues from biopharmaceutical products increased 5% in 2011, compared to 2010, reflecting the favorable impact of foreign exchange of 6% in 2011, partially offset by a net operational decrease. Operationally, revenues were favorably impacted by increases in the Prevenar family, Lyrica, Enbrel, Celebrex and Alliance revenues and unfavorably impacted by declines in Lipitor, Effexor, Norvasc and Xalatan/Xalacom. International revenues from legacy King products were not significant to our international revenues in 2011.
|
•
|
Primary Care unit revenues decreased 3% in 2011 compared to 2010, due to lower operational revenues of 6%, partially offset by the favorable impact of foreign exchange of 3%. Primary Care unit revenues were favorably impacted by higher revenues from certain patent-protected products, including Lyrica, Celebrex, Pristiq and Spiriva (in Alliance revenues), among others, as well as the addition of revenues from legacy King products of $404 million, or 2%, in 2011. Operational revenues in 2011 were negatively impacted by the loss of exclusivity of Lipitor and Caduet in the U.S. in November 2011, Lipitor in various other developed markets during 2010, as well as Aricept 5mg and 10mg tablets in the U.S. in November 2010. Taken together, these losses of exclusivity reduced Primary Care unit revenues by approximately $2.1 billion, or 9%, in comparison with 2010.
|
•
|
Specialty Care unit revenues increased 1% compared to 2010, due to the favorable impact of foreign exchange of 3%, partially offset by lower operational revenues of 2%. Operational revenues were favorably impacted by strong growth in the Prevnar/Prevenar family and Enbrel, and unfavorably impacted by the loss of exclusivity of Vfend and Xalatan in the U.S. in February and March 2011, respectively. Collectively, these losses of exclusivity reduced Specialty Care unit revenues by $624 million, or 4%, in comparison with 2010.
|
•
|
Oncology unit revenues decreased 6% compared to 2010, due to lower operational revenues of 10%, partially offset by the favorable impact of foreign exchange of 4%. The decrease in the Oncology unit operational revenues in 2011 was primarily due to the transfer of Aromasin’s U.S. business to the Established Products unit effective January 1, 2011, as a result of its loss of exclusivity in April 2011. This loss of exclusivity reduced Oncology unit revenues by $160 million, or 11%, in comparison with 2010.
|
•
|
Established Products unit revenues decreased 9% in 2011 compared to 2010, due to lower operational revenues of 13%, partially offset by a 4% favorable impact of foreign exchange. The decrease in Established Products unit operational revenues in 2011 was mainly due to the loss of exclusivity of Effexor XR, Protonix and Zosyn in the U.S. Taken together, these losses of exclusivity decreased Established Products unit revenues by $1.7 billion, or 17%, in comparison with 2010. These declines were partially offset by the addition of revenues from legacy King products of $546 million, or 5%, in 2011.
|
•
|
Emerging Markets unit revenues increased 7% compared to 2010, due to higher operational revenues of 5%, as well as a 2% favorable impact of foreign exchange. The increase in Emerging Markets unit operational revenues in 2011 was due to growth in certain key innovative brands, primarily the Prevenar family, Lyrica, Enbrel, Celebrex, Vfend and Zyvox. These increases were partially offset by lower revenues from Lipitor, which lost exclusivity in Brazil in August 2010 and Mexico in December 2010, as well as the impact of price reductions for certain products in certain emerging market countries. These losses of exclusivity reduced Emerging Market unit revenues by $118 million, or 1%, in comparison with 2010.
|
2012 Financial Report
|
|
19
|
|
|
|
|
•
|
Animal Health unit revenues increased 3% in 2012, compared to 2011, reflecting higher operational revenues of 6%, partially offset by the unfavorable impact of foreign exchange of 3%. Operational revenues from Animal Health products were favorably impacted by the solid performance in both the livestock and companion animal portfolios.
|
•
|
Consumer Healthcare unit revenues increased 6% in 2012, compared to 2011, reflecting higher operational revenues of 8%, partially offset by the unfavorable impact of foreign exchange of 2%. The operational revenue increase was primarily due to the addition of products from the acquisitions of the consumer healthcare business of Ferrosan in December 2011 and Alacer Corp. in February 2012.
|
•
|
Animal Health unit revenues increased 17% in 2011, compared to 2010, reflecting higher operational revenues of 14% and the favorable impact of foreign exchange of 3%. Operational revenues from Animal Health products were favorably impacted by approximately $329 million, or 9%, due to the addition of revenues from legacy King animal health products. Legacy Pfizer products grew 7% primarily driven by improving market conditions and resulting increased demand for products across the livestock business, as well as deeper market penetration in emerging markets. This was partially offset by the adverse impact of required product divestitures in 2010 related to the acquisition of Wyeth.
|
•
|
Consumer Healthcare unit revenues increased 10% in 2011, compared to 2010, reflecting higher operational revenues of 8% and the favorable impact of foreign exchange of 2%. The operational revenue increase in 2011 was primarily driven by increased sales of core brands including Advil, Caltrate and Robitussin, as well as the temporary voluntary withdrawal of Centrum in Europe in the third quarter of 2010, which had an adverse impact on 2010 revenues.
|
20
|
|
2012 Financial Report
|
|
|
|
|
Chantix/Champix
|
|
An aid to smoking cessation treatment
|
|
670
|
|
|
720
|
|
|
755
|
|
|
(7
|
)
|
|
(5
|
)
|
|||
Pristiq
|
|
Depression
|
|
630
|
|
|
577
|
|
|
466
|
|
|
9
|
|
|
24
|
|
|||
ReFacto AF/Xyntha
|
|
Hemophilia
|
|
584
|
|
|
506
|
|
|
404
|
|
|
15
|
|
|
25
|
|
|||
Zoloft
|
|
Depression and certain anxiety disorders
|
|
541
|
|
|
573
|
|
|
532
|
|
|
(6
|
)
|
|
8
|
|
|||
Revatio
|
|
Pulmonary arterial hypertension (PAH)
|
|
534
|
|
|
535
|
|
|
481
|
|
|
—
|
|
|
11
|
|
|||
Medrol
|
|
Inflammation
|
|
523
|
|
|
510
|
|
|
455
|
|
|
3
|
|
|
12
|
|
|||
Zosyn/Tazocin
|
|
Antibiotic
|
|
484
|
|
|
636
|
|
|
952
|
|
|
(24
|
)
|
|
(33
|
)
|
|||
Zithromax/Zmax
|
|
Bacterial infections
|
|
435
|
|
|
453
|
|
|
415
|
|
|
(4
|
)
|
|
9
|
|
|||
Effexor
|
|
Depression and certain anxiety disorders
|
|
425
|
|
|
678
|
|
|
1,718
|
|
|
(37
|
)
|
|
(61
|
)
|
|||
Prevnar/Prevenar (7-valent)
|
|
Vaccine for prevention of pneumococcal disease
|
|
399
|
|
|
488
|
|
|
1,253
|
|
|
(18
|
)
|
|
(61
|
)
|
|||
Fragmin
|
|
Anticoagulant
|
|
381
|
|
|
382
|
|
|
341
|
|
|
—
|
|
|
12
|
|
|||
Relpax
|
|
Treat the symptoms of migraine headache
|
|
368
|
|
|
341
|
|
|
323
|
|
|
8
|
|
|
6
|
|
|||
Rapamune
|
|
Immunosuppressant
|
|
346
|
|
|
372
|
|
|
388
|
|
|
(7
|
)
|
|
(4
|
)
|
|||
Cardura
|
|
Hypertension/Benign prostatic hyperplasia
|
|
338
|
|
|
380
|
|
|
413
|
|
|
(11
|
)
|
|
(8
|
)
|
|||
Tygacil
|
|
Antibiotic
|
|
335
|
|
|
298
|
|
|
324
|
|
|
12
|
|
|
(8
|
)
|
|||
Aricept
(a)
|
|
Alzheimer's disease
|
|
326
|
|
|
450
|
|
|
454
|
|
|
(28
|
)
|
|
(1
|
)
|
|||
Xanax XR
|
|
Anxiety disorders
|
|
274
|
|
|
306
|
|
|
307
|
|
|
(10
|
)
|
|
—
|
|
|||
BMP2
|
|
Development of bone and cartilage
|
|
263
|
|
|
340
|
|
|
400
|
|
|
(23
|
)
|
|
(15
|
)
|
|||
Sulperazon
|
|
Antibiotic
|
|
262
|
|
|
218
|
|
|
213
|
|
|
20
|
|
|
2
|
|
|||
Diflucan
|
|
Fungal infections
|
|
259
|
|
|
265
|
|
|
278
|
|
|
(2
|
)
|
|
(5
|
)
|
|||
Caduet
|
|
Reduction of LDL cholesterol and hypertension
|
|
258
|
|
|
538
|
|
|
527
|
|
|
(52
|
)
|
|
2
|
|
|||
Neurontin
|
|
Seizures
|
|
235
|
|
|
289
|
|
|
322
|
|
|
(19
|
)
|
|
(10
|
)
|
|||
Dalacin/Cleocin
|
|
Antibiotic for bacterial infections
|
|
232
|
|
|
192
|
|
|
214
|
|
|
21
|
|
|
(10
|
)
|
|||
Unasyn
|
|
Injectable antibacterial
|
|
228
|
|
|
231
|
|
|
244
|
|
|
(1
|
)
|
|
(5
|
)
|
|||
Metaxalone/Skelaxin
(b)
|
|
Muscle relaxant
|
|
223
|
|
|
203
|
|
|
—
|
|
|
10
|
|
|
*
|
|
|||
Inspra
|
|
High blood pressure
|
|
214
|
|
|
195
|
|
|
157
|
|
|
10
|
|
|
24
|
|
|||
Toviaz
|
|
Overactive bladder
|
|
207
|
|
|
187
|
|
|
137
|
|
|
11
|
|
|
36
|
|
|||
Somavert
|
|
Acromegaly
|
|
197
|
|
|
183
|
|
|
157
|
|
|
8
|
|
|
17
|
|
|||
Alliance revenues
(c)
|
|
Various
|
|
3,492
|
|
|
3,630
|
|
|
4,084
|
|
|
(4
|
)
|
|
(11
|
)
|
|||
All other
(d)
|
|
Various
|
|
8,289
|
|
|
8,584
|
|
|
8,118
|
|
|
(3
|
)
|
|
6
|
|
(a)
|
Represents direct sales under license agreement with Eisai Co., Ltd.
|
(b)
|
Legacy King product. King’s operations are included in our financial statements commencing from the acquisition date of January 31, 2011. Therefore, our results for 2010 do not include King’s results of operations.
|
(c)
|
Enbrel (in the U.S. and Canada), Spiriva, Rebif, Aricept and Exforge.
|
(d)
|
Includes sales of generic atorvastatin.
|
*
|
Calculation not meaningful.
|
•
|
Lyrica
is indicated for the management of post-herpetic neuralgia, neuropathic pain associated with diabetic peripheral neuropathy, the management of fibromyalgia, neuropathic pain due to spinal cord injury, and as adjunctive therapy for adult patients with partial onset seizures in the U.S. For certain countries outside the U.S., Lyrica is indicated for neuropathic pain (peripheral and central), the management of fibromyalgia, adjunctive treatment of epilepsy and general anxiety disorder. Lyrica recorded increases in worldwide revenues of 13% in 2012, compared to 2011. There was strong operational performance in international markets in 2012, including Japan, where Lyrica was launched in 2010 as the first product approved for the peripheral neuropathic pain (NeP) indication. Internationally, Lyrica revenues increased 14% in 2012, compared to 2011, with the growth due to a focus on enhancing the neuropathic pain diagnosis and treatment rates, the successful re-launch of the general anxiety disorder indication in the EU and physician education regarding neuropathic pain in Japan. Foreign exchange had an unfavorable impact on international revenues of 5% in 2012, compared to 2011. In the U.S., revenues increased 10% in 2012, compared to 2011. Notwithstanding these increases, U.S. revenues continue to be affected by increased competition from generic versions of competitive medicines, as well as managed care pricing and formulary pressures.
|
2012 Financial Report
|
|
21
|
|
|
|
|
•
|
Lipitor
, for the treatment of elevated LDL-cholesterol levels in the blood, recorded worldwide revenues of $3.9 billion, a decrease of 59%, in 2012, compared to 2011 due to:
|
◦
|
the impact of loss of exclusivity in Japan in June 2011 (with generic competition occurring in November 2011), the U.S. (with generic competition occurring in November 2011 and multi-source generic competition occurring in May 2012), Australia in April 2012 and most of developed Europe in March 2012 and May 2012;
|
▪
|
the continuing impact of an intensely competitive lipid-lowering market with competition from generics and branded products worldwide; and
|
▪
|
increased payer pressure worldwide, including the need for flexible rebate policies.
|
◦
|
in our international markets, branded Lipitor revenues were $3.0 billion, a decrease of 34% in 2012, compared to 2011. Foreign exchange had an unfavorable impact on international revenues of $70 million in 2012, compared to 2011.
|
•
|
Enbrel
, for the treatment of moderate-to-severe rheumatoid arthritis, polyarticular juvenile rheumatoid arthritis, psoriatic arthritis, plaque psoriasis and ankylosing spondylitis, a type of arthritis affecting the spine, recorded increases in worldwide revenues, excluding the U.S. and Canada, of 2% in 2012, compared to 2011, primarily due to the overall growth in the anti-tumor necrosis factor (TNF) biologic market, partially offset by the unfavorable impact of foreign exchange.
|
•
|
Prevnar 13/Prevenar 13
is our 13-valent pneumococcal conjugate vaccine for the prevention of various syndromes of pneumococcal disease in infants and young children and in adults 50 years of age and older. Prevnar 13/Prevenar 13 for use in infants and young children is marketed in the U.S. for the prevention of invasive pneumococcal disease caused by the 13 serotypes in Prevnar 13 and otitis media caused by the seven serotypes in Prevnar, and in the EU and many other international markets for the prevention of invasive pneumococcal disease, otitis media and pneumococcal pneumonia caused by the vaccine serotypes. In 2011, we received approval of Prevnar 13/Prevenar 13 for use in adults 50 years of age and older in the U.S. for the prevention of pneumococcal pneumonia and invasive pneumococcal disease caused by the 13 serotypes in Prevnar 13, and in the EU for the prevention of invasive pneumococcal disease caused by the vaccine serotypes. To date, Prevenar 13 for use in adults 50 years of age and older has been approved in over 55 countries. On January 25, 2013, the U.S. FDA granted approval for the expansion of Prevnar 13 for use in children ages 6 through 17 years for active immunization for the prevention of invasive disease caused by the 13 vaccine serotypes. EU approval for use in children 6 through 17 years of age was received on January 7, 2013. Worldwide revenues for Prevnar 13/Prevenar 13 increased 2% in 2012, compared to 2011. In the U.S., revenues for Prevnar 13 decreased 2% in 2012, compared to 2011. Developed Europe Prevenar 13 revenues also were lower in 2012, compared to 2011. Revenues in the U.S. and developed Europe declined as the pediatric catch-up dose commercial opportunity declined significantly in 2012 compared to 2011, with fewer children eligible to receive the catch-up dose. In addition, utilization in older adults is modest at this time.
|
•
|
Celebrex
, indicated for the treatment of the signs and symptoms of osteoarthritis and rheumatoid arthritis worldwide and for the management of acute pain in adults in the U.S., Japan and certain markets in the EU, recorded an increase in worldwide revenues of 8% in 2012, compared to 2011. Strong operational performance in the U.S. was primarily driven by price increases, as well as strong market growth, partially offset by continued share erosion due to ongoing generic pressures and higher rebates. However, Celebrex continued to slow the volume erosion due to strong Direct to Customer investment and field force promotion. Strong operational performance in international markets was driven by volume and share growth in Japan and emerging markets in the low back pain indication, partially offset by lower developed Europe revenues in 2012 compared to 2011. Celebrex is supported by continued educational and promotional efforts highlighting its efficacy and safety profile for appropriate patients.
|
22
|
|
2012 Financial Report
|
|
|
|
|
•
|
Viagra
is
indicated for the treatment for erectile dysfunction. Viagra worldwide revenues increased 4% in 2012, compared to 2011, primarily due to the increase in U.S. revenues, partially offset by branded and generic competitive pressure in developed Europe, other developed markets and emerging markets. The increase in the U.S. more than offset the decrease in international markets due to operational factors and the adverse impact of foreign exchange.
|
•
|
Norvasc
, for treating hypertension, lost exclusivity in the U.S. and other major markets in 2007 and in Canada in 2009. Norvasc worldwide revenues decreased 7% in 2012, compared to 2011.
|
•
|
Zyvox
is the world’s best-selling branded agent among those used to treat serious Gram-positive pathogens, including methicillin-resistant staphylococcus-aureus. Zyvox worldwide revenues increased 5% in 2012, compared to 2011, primarily due to growth in both developed and emerging markets.
|
•
|
Sutent
is indicated for the treatment of advanced renal cell carcinoma, including metastatic renal cell carcinoma (mRCC); gastrointestinal stromal tumors after disease progression on, or intolerance to, imatinib mesylate; and advanced pancreatic neuroendocrine tumor. Sutent worldwide revenues increased 4% in 2012, compared to 2011, due to strong operational performance driven in the U.S. by price increases and in other, non-European developed markets by volume growth due to targeted marketing efforts, and in emerging markets, by increased market share, partially offset by the unfavorable impact of foreign exchange. We continue to seek to drive operational revenue and prescription growth, supported by cost-effectiveness, efficacy and therapy management data. As of December 31, 2012, Sutent was the most prescribed oral mRCC therapy in the U.S.
|
•
|
Our
Premarin
family of products helps women address moderate-to-severe menopausal symptoms. It recorded an increase in worldwide revenues of 6% in 2012, compared to 2011. U.S. revenues increased 7% in 2012, compared to 2011, primarily due to favorable wholesaler inventory levels, price increases in January and July 2012, favorable rebates and the launch of multichannel marketing support in 2012. Internationally, revenues decreased 2% compared to 2011. The decline was attributable to the unfavorable impact of foreign exchange of 7% offset by the increase in operational revenues of 5%.
|
•
|
Genotropin
, one of the world’s leading human growth hormones, is used in children for the treatment of short stature with growth hormone deficiency, Prader-Willi Syndrome, Turner Syndrome, Small for Gestational Age Syndrome, Idiopathic Short Stature (in the U.S. only) and Chronic Renal Insufficiency (outside the U.S. only), as well as in adults with growth hormone deficiency. Genotropin is supported by a broad platform of innovative injection-delivery devices and patient-support programs. Genotropin worldwide revenues decreased 6% compared to 2011.
|
•
|
Xalabrands
consists of
Xalatan
, a prostaglandin, which is a branded agent used to reduce elevated eye pressure in patients with open-angle glaucoma or ocular hypertension, and
Xalacom,
a fixed combination prostaglandin (Xalatan) and beta blocker (timolol) available outside the U.S. Xalatan/Xalacom worldwide revenues decreased 36% in 2012, compared to 2011. Lower revenues were due primarily to the loss of exclusivity in the U.S. in March 2011 and in the majority of European markets in January 2012.
|
•
|
BeneFIX and ReFacto AF/Xyntha
are hemophilia products using state-of-the-art manufacturing that assist patients with their lifelong bleeding disorders. BeneFIX is the only available recombinant factor IX product for the treatment of hemophilia B, while ReFacto AF/Xyntha is a recombinant factor VIII product for the treatment of hemophilia A. Both products are indicated for the control and prevention of bleeding in patients with these disorders and in some countries are also indicated for prophylaxis in certain situations, such as surgery. BeneFIX recorded an increase in worldwide revenues of 12% in 2012, compared to 2011, primarily as a result of increases in the U.S. due to a launch of the new 3000 International Unit vial and price increases. ReFacto AF/Xyntha recorded an increase in worldwide revenues of 15% in 2012, compared to 2011, driven by the successful transition of patients to Xyntha as a result of securing a government contract in Australia, continued patient conversion to Xyntha in the U.S., as well as the successful launch of the ReFacto AF dual chamber syringe in several European countries.
|
•
|
Detrol/Detrol LA,
a muscarinic receptor antagonist, is one of the leading branded medicines worldwide for overactive bladder. Detrol LA is an extended-release formulation taken once a day. Detrol/Detrol LA worldwide revenues decreased 14% in 2012, compared to 2011, primarily due to increased branded competition, a shift in promotional focus to our Toviaz product in most major markets and the loss of exclusivity for Detrol IR in the U.S. in June 2012. Generic competition for Detrol LA in the U.S. is expected in the first quarter of 2014.
|
•
|
Vfend
is a broad-spectrum agent for treating yeast and molds. Vfend worldwide revenues increased 1% in 2012, compared to 2011 primarily due to U.S. market growth attributable to a fungal meningitis outbreak and double-digit growth in Latin America and China, largely offset by the unfavorable impact of foreign exchange and supply constraints. International revenues increased 1% in 2012, compared to 2011. Revenues in the U.S. in 2012 increased 3% compared to the same period in 2011, primarily due to the aforementioned meningitis outbreak and lower Medicaid rebates in 2012 compared to 2011, partially offset by the loss of exclusivity of Vfend tablets and the launch of generic voriconazole (generic Vfend) in February 2011.
|
•
|
Chantix/Champix
is an aid to smoking-cessation treatment in adults 18 years of age and older. Chantix/Champix worldwide revenues decreased 7% in 2012, compared to 2011, primarily due to negative media exposure across several key markets and macro-economic decline, which decreased patient willingness to pay out of pocket. We are continuing our educational and promotional efforts, which are focused on addressing the significant health consequences of smoking highlighting the Chantix/Champix benefit-risk proposition, emphasizing the importance of the physician-patient dialogue in helping patients quit smoking and identifying alternative treatment-funding models.
|
•
|
Pristiq
is approved for the treatment of major depressive disorder in the U.S. and in various other countries. Pristiq has also been approved for treatment of moderate-to-severe vasomotor symptoms (VMS) associated with menopause in Thailand, Mexico, the Philippines and Ecuador. Pristiq recorded an increase in worldwide revenues of 9% in 2012, compared to 2011, primarily due to price increases, as well as market growth, partially offset by lower prescription share in the U.S.
|
2012 Financial Report
|
|
23
|
|
|
|
|
•
|
Revatio
is for the treatment of pulmonary arterial hypertension (PAH). Worldwide revenues remained relatively flat in 2012, compared to 2011. 2012 revenues were impacted by the unfavorable impact of foreign exchange, partially offset by an increased PAH awareness driving earlier diagnosis in the U.S. and EU. In the U.S., Revatio tablet lost exclusivity in September 2012, and Revatio intravenous injection will lose exclusivity in May 2013.
|
•
|
Zosyn
/
Tazocin
, our broad-spectrum intravenous antibiotic, faces generic global competition. U.S. exclusivity was lost in September 2009. Zosyn/Tazocin recorded a decrease in worldwide revenues of 24% in 2012, compared to 2011.
|
•
|
Effexor
, an antidepressant for treating adult patients with major depressive disorder, generalized anxiety disorder, social anxiety disorder and panic disorder, faces generic competition in most markets. It recorded a decrease in worldwide revenues of 37% in 2012, compared to 2011.
|
•
|
Prevnar/Prevenar (7-valent),
our 7-valent pneumococcal conjugate vaccine for preventing invasive, and, in certain international markets, non-invasive pneumococcal disease in infants and young children, recorded a decrease in worldwide revenues of 18% in 2012, compared to 2011. Many markets have transitioned from the use of Prevnar/Prevenar (7-valent) to Prevnar 13/Prevenar 13, resulting in lower revenues for Prevnar/Prevenar (7-valent). We expect this trend to continue.
|
•
|
Caduet
is a single-pill therapy combining Lipitor and Norvasc for the prevention of cardiovascular events. Caduet worldwide revenues decreased 52% in 2012, compared to 2011, primarily due to the loss of U.S. exclusivity in November 2011.
|
•
|
Xalkori,
for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test, was approved by the FDA in August 2011. In developed markets, Xalkori has also been approved in Japan, South Korea, Canada and Switzerland, and it received conditional marketing authorization in the EU in October 2012. In addition, it has been filed or approved in more than 25 emerging markets, including China. Xalkori recorded worldwide revenues of $123 million in 2012, with 66% of those revenues generated in the U.S. market.
|
•
|
Inlyta,
for the treatment of patients with advanced renal cell carcinoma after failure of a prior systemic treatment, has been approved in the U.S., Switzerland, Japan, Canada, Australia, South Korea and the EU (exact indications vary by region). Inlyta recorded worldwide revenues of $100 million in 2012.
|
•
|
Xeljanz
(in the U.S.)
was approved by the FDA in November 2012 for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate, to be used as monotherapy or in combination with methotrexate or other nonbiologic disease-modifying antirheumatic drugs.
|
•
|
Alliance revenues
worldwide decreased 4% in 2012, compared to 2011, mainly due to the loss of exclusivity for Aricept 5mg and 10mg tablets in the U.S. in November 2010 and the entry of multi-source generic competition in the U.S. in May 2011, as well as the loss of exclusivity in many major European markets in February 2012, and lower revenues for Spiriva in certain European countries, Canada and Australia due to the expiration of our collaboration with BI in those countries, partially offset by the strong performance of Enbrel and Rebif in the U.S. We expect that the Aricept 23mg tablet will have exclusivity in the U.S. until July 2013. See the “The Loss or Expiration of Intellectual Property Rights” section of this Financial Review for a discussion regarding the expiration of various contract rights relating to Aricept, Spiriva, Enbrel and Rebif. Eliquis (apixaban) has been jointly developed and commercialized by Pfizer and Bristol-Myers Squibb (BMS). In 2012, Eliquis (apixaban) was approved to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation in the 27 countries of the EU, plus Iceland and Norway, Canada, Japan and the U.S., and it was launched for that indication in the U.S. in January 2013. The two companies share commercialization expenses and profit/losses equally on a global basis.
|
•
|
Embeda
—We met with the FDA in May 2012 to discuss our proposal for reintroduction of Embeda to the market. The required stability programs are underway, and we are working toward a submission with the FDA in the first half of 2013.
|
24
|
|
2012 Financial Report
|
|
|
|
|
(a)
|
Our operating segments, in addition to their sales and marketing responsibilities, are responsible for certain development activities. Generally, these responsibilities relate to additional indications for in-line products and IPR&D projects that have achieved proof-of-concept. R&D spending may include upfront and milestone payments for intellectual property rights.
|
(b)
|
Includes the Animal Health operating segment and the Consumer Healthcare operating segment. The increase in 2012 primarily relates to a $250 million payment to AstraZeneca to obtain the exclusive global over-the-counter rights to Nexium.
|
(c)
|
Worldwide Research and Development is generally responsible for human health research projects until proof-of-concept is achieved, and then for transitioning those projects to the appropriate business unit for possible clinical and commercial development. R&D spending may include upfront and milestone payments for intellectual property rights. This organization also has responsibility for certain science-based and other platform-services organizations, which provide technical expertise and other services to the various R&D projects. Worldwide Research and Development is also responsible for all human-health-related regulatory submissions and interactions with regulatory agencies, including all safety event activities. Pfizer Medical is responsible for external affairs relating to all therapeutic areas, providing Pfizer-related medical information to healthcare providers, patients and other parties, and quality assurance and regulatory compliance activities, which include conducting clinical trial audits and readiness reviews. The decreases in 2012 compared to 2011 and in 2011 compared to 2010 result from cost savings associated with the R&D productivity initiative announced on February 1, 2011 (see the “Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives” section of this Financial Review).
|
(d)
|
Corporate and other includes unallocated costs, primarily facility costs, information technology, share-based compensation, and restructuring related costs. The decrease in 2012 primarily results from cost savings associated with the R&D productivity initiative announced on February 1, 2011 and to a lesser extent from lower charges relating to implementing our cost-reduction and productivity initiatives
(see the “Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives” section of this Financial Review).
|
2012 Financial Report
|
|
25
|
|
|
|
|
RECENT FDA APPROVALS
|
||
PRODUCT
|
INDICATION
|
DATE APPROVED
|
Eliquis (Apixaban)
(a)
|
Prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation
|
December 2012
|
Xeljanz (Tofacitinib)
|
Treatment of moderate-to-severe active rheumatoid arthritis
|
November 2012
|
Bosulif (Bosutinib)
|
Treatment of previously treated chronic myelogenous leukemia
|
September 2012
|
Lyrica (Pregabalin) Capsules CV
|
Treatment of neuropathic pain due to spinal cord injury
|
June 2012
|
Elelyso (Taliglucerase Alfa)
(b)
|
Treatment of adults with a confirmed diagnosis of type 1 Gaucher disease
|
May 2012
|
Inlyta (Axitinib)
|
Treatment of advanced renal cell carcinoma after failure of one prior systemic therapy
|
January 2012
|
(a)
|
This indication for Eliquis (apixaban) was developed and is being commercialized in collaboration with BMS.
|
(b)
|
In November 2009, we entered into a license and supply agreement with Protalix BioTherapeutics, which provides us exclusive worldwide rights, except in Israel, to develop and commercialize Elelyso (taliglucerase alpha) for the treatment of Gaucher disease.
|
PENDING U.S. NEW DRUG APPLICATIONS (NDA) AND SUPPLEMENTAL FILINGS
|
||
PRODUCT
|
INDICATION
|
DATE FILED*
|
Bazedoxifene-conjugated estrogens
|
Treatment of symptoms associated with menopause and osteoporosis
|
December 2012
|
Tafamidis meglumine
(a)
|
Treatment of transthyretin familial amyloid polyneuropathy (TTR-FAP)
|
February 2012
|
Genotropin
(b)
|
Replacement of human growth hormone deficiency (Mark VII multidose disposable device)
|
December 2009
|
Celebrex
(c)
|
Chronic pain
|
October 2009
|
Remoxy
(d)
|
Management of moderate-to-severe pain when a continuous, around-the-clock opioid analgesic is needed for an extended period of time
|
August 2008
|
Spiriva
(e)
|
Respimat device for chronic obstructive pulmonary disease
|
January 2008
|
Viviant
(f)
|
Osteoporosis treatment and prevention
|
August 2006
|
(a)
|
In May 2012, the FDA's Peripheral and Central Nervous System Drugs Advisory Committee voted that the tafamidis meglumine data provide substantial evidence of efficacy for a surrogate endpoint that is reasonably likely to predict a clinical benefit. In June 2012, the FDA issued a “complete response” letter with respect to the tafamidis NDA. The FDA has requested the completion of a second efficacy study and also has asked for additional information on the data within the current tafamidis NDA. We are continuing to work with the FDA to define a path forward.
|
(b)
|
In April 2010, we received a “complete response” letter from the FDA for the Genotropin Mark VII multidose disposable device submission. In August 2010, we submitted our response to address the requests and recommendations included in the FDA letter. In April 2011, we received a second “complete response” letter from the FDA, requesting additional information. We are working to address the FDA's requests for additional information.
|
(c)
|
In June 2010, we received a “complete response” letter from the FDA for the Celebrex chronic pain supplemental NDA. The supplemental NDA remains pending while we await the completion of ongoing studies to determine next steps.
|
(d)
|
In 2005, King entered into an agreement with Pain Therapeutics, Inc. (PT) to develop and commercialize Remoxy. In August 2008, the FDA accepted the NDA for Remoxy that had been submitted by King and PT. In December 2008, the FDA issued a “complete response” letter. In March 2009, King exercised its right under the agreement with PT to assume sole control and responsibility for the development of Remoxy. In December 2010, King resubmitted the NDA for Remoxy with the FDA. In June 2011, we and PT announced that a “complete response” letter was received from the FDA with regard to the resubmission of the NDA. We have been working to address the issues raised in the letter, which primarily relate to manufacturing. We have analyzed the results from two, recently completed bioavailability studies, as well as data from other experiments that were conducted to optimize the formulation composition and analytical methods for Remoxy. While we have gained important insights from this work, in the fourth quarter of 2012 we initiated a confirmatory bioavailability study to assess the pharmacokinetic profile of modified Remoxy formulation compositions. Preliminary results from the initial phase of this study are undergoing analysis. We believe the results of this study will provide us with greater clarity as to whether or not we will be able to adequately address the questions raised in the “complete response” letter received from the FDA. We continue to target a late-March 2013 meeting with the FDA to discuss our plan to address the June 2011 “complete response" letter.
|
(e)
|
Boehringer Ingelheim (BI), our alliance partner, holds the NDAs for Spiriva Handihaler and Spiriva Respimat. In September 2008, BI received a “complete response” letter from the FDA for the Spiriva Respimat submission. The FDA is seeking additional data, and we are coordinating with BI, which is working with the FDA to provide the additional information. A full response will be submitted to the FDA upon the completion of planned and ongoing studies.
|
26
|
|
2012 Financial Report
|
|
|
|
|
(f)
|
Two “approvable” letters were received by Wyeth in April and December 2007 from the FDA for Viviant (bazedoxifene), for the prevention of post-menopausal osteoporosis, that set forth the additional requirements for approval. In May 2008, Wyeth received an “approvable” letter from the FDA for the treatment of post-menopausal osteoporosis. The FDA is seeking additional data, and we have been systematically working through these requirements and seeking to address the FDA's concerns. A full response will be provided to the FDA. In February 2008, the FDA advised Wyeth that it expects to convene an advisory committee to review the pending NDAs for both the treatment and prevention indications after we submit our response to the “approvable” letters. In April 2009, Wyeth received approval in the EU for CONBRIZA (the EU trade name for Viviant) for the treatment of post-menopausal osteoporosis in women at increased risk of fracture. Viviant was also approved in Japan in July 2010 for the treatment of post-menopausal osteoporosis and in South Korea in November 2011 for the treatment and prevention of post-menopausal osteoporosis.
|
REGULATORY APPROVALS AND FILINGS IN THE EU AND JAPAN
|
|||
PRODUCT
|
DESCRIPTION OF EVENT
|
DATE APPROVED
|
DATE FILED*
|
Eliquis (Apixaban)
(a)
|
Approval in Japan for prevention of ischemic stroke and systemic embolism in patients with nonvalvular atrial fibrillation
|
December 2012
|
—
|
Toviaz
|
Approval in Japan for treatment of overactive bladder
|
December 2012
|
—
|
Eliquis (Apixaban)
(a)
|
Approval in the EU for prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation
|
November 2012
|
—
|
Xalkori (Crizotinib)
|
Conditional marketing authorization in the EU for treatment of previously treated ALK-positive advanced non-small cell lung cancer
|
October 2012
|
—
|
Inlyta (Axitinib)
|
Approval in the EU for treatment of advanced renal cell carcinoma after failure of prior systemic treatment
|
September 2012
|
—
|
Sutent
|
Approval in Japan for treatment of pancreatic neuroendocrine tumor
|
August 2012
|
—
|
Bazedoxifene-conjugated estrogens
|
Application filed in the EU for treatment of symptoms associated with menopause and osteoporosis
|
—
|
July 2012
|
Prevenar 13 Infant
|
Application filed in Japan for prevention of invasive pneumococcal disease in infants and young children
|
—
|
July 2012
|
Lyrica (Pregabalin)
|
Approval in Japan for treatment of fibromyalgia
|
June 2012
|
—
|
Inlyta (Axitinib)
|
Approval in Japan for treatment of renal cell carcinoma not indicated for curative resection, metastatic renal cell carcinoma
|
June 2012
|
—
|
Xalkori (Crizotinib)
|
Approval in Japan for treatment of ALK-positive advanced non-small cell lung cancer
|
March 2012
|
—
|
Lyrica (Pregabalin)
|
Application filed in Japan for treatment of neuropathic pain: peripheral neuropathic pain, central neuropathic pain
|
—
|
March 2012
|
Tofacitinib
|
Application filed in Japan for treatment of rheumatoid arthritis
|
—
|
December 2011
|
Tofacitinib
|
Application filed in the EU for treatment of moderate-to-severe active rheumatoid arthritis
|
—
|
November 2011
|
Bosutinib
(b)
|
Application filed in the EU for treatment of previously treated chronic myelogenous leukemia
|
—
|
August 2011
|
*
|
For applications in the EU, the dates set forth in this column are the dates on which the European Medicines Agency (EMA) validated our submissions.
|
(a)
|
This indication for Eliquis (apixaban) was developed and is being commercialized in collaboration with BMS.
|
(b)
|
In January 2013, the EMA's Committee for Medicinal Products for Human Use (CHMP) issued an opinion recommending that bosutinib be granted conditional approval for treatment of previously treated chronic myelogenous leukemia. The initial application was for the treatment of newly diagnosed chronic myelogenous leukemia.
|
2012 Financial Report
|
|
27
|
|
|
|
|
NEW DRUG CANDIDATES IN LATE-STAGE DEVELOPMENT
|
|
CANDIDATE
|
INDICATION
|
ALO-02
|
A Mu-type opioid receptor agonist for the management of moderate-to-severe pain when a continuous, around-the-clock opioid analgesic is needed for an extended period of time
|
Dacomitinib
|
A pan-HER tyrosine kinase inhibitor for the treatment of previously treated advanced non-small cell lung cancer
|
Inotuzumab ozogamicin
|
An antibody drug conjugate, consisting of an anti-CD22 monotherapy antibody linked to a cytotoxic agent, calicheamycin, for the treatment of aggressive Non-Hodgkin's Lymphoma and acute lymphoblastic leukemia
|
MnB rLP2086
(PF-05212366)
|
A prophylactic vaccine for prevention of
Neisseria meningitidis
serogroup B invasive disease in adolescents and young adults (ages 11 - 25)
|
Palbociclib (PD-0332991)
|
An oral and selective reversible inhibitor of the CDK 4 and 6 kinases for the treatment of patients with ER positive, HER2 negative advanced breast cancer
|
Tanezumab
(a)
|
An anti-nerve growth factor monoclonal antibody for the treatment of pain (on clinical hold)
|
(a)
|
Following requests by the FDA in 2010, we suspended and subsequently terminated worldwide the osteoarthritis, chronic low back pain and painful diabetic peripheral neuropathy studies of tanezumab. The FDA's requests followed a small number of reports of osteoarthritis patients treated with tanezumab who experienced the worsening of osteoarthritis leading to total joint replacement and also reflected the FDA's concerns regarding the potential for such events in other patient populations. In December 2010, the FDA placed a clinical hold on all other anti-nerve growth factor therapies under clinical investigation in the U.S. Studies of tanezumab in cancer pain were allowed to continue. Extensive analyses were undertaken of all total joint replacements reported in studies of tanezumab. The results of these analyses and the conclusions drawn were provided to the FDA. On March 12, 2012, the FDA's Arthritis Advisory Committee met to discuss the future development of nerve growth factor inhibitors, including tanezumab. The Committee voted that there is a role for the ongoing development of nerve growth factor inhibitors in conditions such as osteoarthritis and for the management of pain associated with conditions other than osteoarthritis for which there are no agents with demonstrated analgesic effect. We submitted a Clinical Hold Complete Response to the FDA on July 31, 2012. On August 28, 2012, the FDA removed the clinical hold completely from the tanezumab program for all indications. On December 14, 2012, the FDA placed a new partial clinical hold on the development of nerve growth factor inhibitors, including tanezumab. The partial clinical hold was based on peripheral nervous system effects observed in animal studies conducted with nerve growth factor inhibitors by other companies. Current and future studies of tanezumab in cancer pain are not affected by this partial clinical hold. We intend to work with the FDA to determine the appropriate path forward.
|
|
|
Year Ended December 31,
|
|
% Change
|
||||||||||||||
(MILLIONS OF DOLLARS)
|
|
2012
|
|
|
2011
|
|
|
2010
|
|
|
12/11
|
|
|
11/10
|
|
|||
Cost of sales
|
|
$
|
11,334
|
|
|
$
|
14,076
|
|
|
$
|
14,788
|
|
|
(19
|
)
|
|
(5
|
)
|
•
|
lower purchase accounting charges, primarily reflecting the fair value adjustments to acquired inventory from Wyeth and King that was subsequently sold;
|
•
|
lower costs related to our cost-reduction and productivity initiatives and acquisition-related costs, as well as the benefits generated from the ongoing productivity initiatives to streamline the manufacturing network;
|
•
|
reduced manufacturing volumes related to products that lost exclusivity in various markets; and
|
•
|
the favorable impact of foreign exchange of 3%,
|
•
|
an unfavorable shift in geographic, product and business mix due to products that lost exclusivity in various markets.
|
•
|
lower purchase accounting charges, primarily reflecting the fair value adjustments to acquired inventory from Wyeth that was subsequently sold; and
|
•
|
savings associated with our cost-reduction and productivity initiatives,
|
•
|
the addition of costs from legacy King’s operations;
|
•
|
the Puerto Rico excise tax (for additional information, see the “Provision for Taxes on Income” section of this Financial Review);
|
28
|
|
2012 Financial Report
|
|
|
|
|
•
|
a shift in geographic and business mix; and
|
•
|
the unfavorable impact of foreign exchange of 2% in 2011.
|
|
|
Year Ended December 31,
|
|
% Change
|
||||||||||||||
(MILLIONS OF DOLLARS)
|
|
2012
|
|
|
2011
|
|
|
2010
|
|
|
12/11
|
|
|
11/10
|
|
|||
Selling, informational and administrative expenses
|
|
$
|
16,616
|
|
|
$
|
18,832
|
|
|
$
|
18,973
|
|
|
(12
|
)
|
|
(1
|
)
|
•
|
savings generated from a reduction in the field force and a decrease in promotional spending, both partly in response to product losses of exclusivity;
|
•
|
more streamlined corporate support functions; and
|
•
|
the favorable impact of foreign exchange of 2%,
|
•
|
costs associated with the separation of Zoetis employees, net assets and operations from Pfizer.
|
•
|
the fee provided for under the U.S. Healthcare Legislation beginning in 2011;
|
•
|
the addition of legacy King operating costs; and
|
•
|
the unfavorable impact of foreign exchange of 2%,
|
•
|
savings associated with our cost-reduction and productivity initiatives.
|
|
|
Year Ended December 31,
|
|
% Change
|
||||||||||||||
(MILLIONS OF DOLLARS)
|
|
2012
|
|
|
2011
|
|
|
2010
|
|
|
12/11
|
|
|
11/10
|
|
|||
Research and development expenses
|
|
$
|
7,870
|
|
|
$
|
9,074
|
|
|
$
|
9,483
|
|
|
(13
|
)
|
|
(4
|
)
|
•
|
savings generated by the discontinuation of certain therapeutic areas and R&D programs in connection with our previously announced cost-reduction and productivity initiatives; and
|
•
|
lower charges related to implementing our cost-reduction and productivity initiatives,
|
•
|
a $250 million payment to AstraZeneca to obtain the exclusive global over-the-counter rights to Nexium.
|
•
|
savings associated with our cost-reduction and productivity initiatives,
|
•
|
higher charges related to implementing our cost-reduction and productivity initiatives;
|
•
|
the addition of legacy King expenses; and
|
•
|
the unfavorable impact of foreign exchange of 1%.
|
2012 Financial Report
|
|
29
|
|
|
|
|
|
|
Year Ended December 31,
|
|
% Change
|
|||||||||||||
(MILLIONS OF DOLLARS)
|
|
2012
|
|
|
2011
|
|
|
2010
|
|
|
12/11
|
|
|
11/10
|
|||
Costs associated with acquisitions and cost-reduction/productivity initiatives
|
|
$
|
2,855
|
|
|
$
|
4,512
|
|
|
$
|
3,926
|
|
|
(37
|
)
|
|
15
|
•
|
In connection with acquisition activity, we typically incur costs associated with executing the transactions, integrating the acquired operations (which may include expenditures for consulting and the integration of systems and processes), and restructuring the combined company (which may include charges related to employees, assets and activities that will not continue in the combined company); and
|
•
|
In connection with our cost-reduction and productivity initiatives, we typically incur costs and charges associated with site closings and other facility rationalization actions, workforce reductions and the expansion of shared services, including the development of global systems.
|
•
|
The closing of duplicative facilities and other site rationalization actions Company-wide, including research and development facilities, manufacturing plants, sales offices and other corporate facilities. Among the more significant actions are the following:
|
◦
|
Manufacturing: After the acquisition of Wyeth, our manufacturing sites totaled 75. Other acquisitions have added 21 manufacturing sites and we have subsequently exited 12 sites, resulting in 84 sites supporting continuing operations as of
December 31, 2012
. Our plant network strategy will result in the exit of a further eight sites over the next several years. These site counts exclude five Nutrition business-related manufacturing sites as the Nutrition business was sold in 2012. See Notes to Consolidated Financial Statements—
Note 2B. Acquisitions, Divestitures, Collaborative Arrangements and Equity-Method Investments: Divestitures
for more information.
|
◦
|
Research and Development: After the acquisition of Wyeth, we operated in 20 R&D sites and announced that we would close a number of sites. We have completed a number of site closures, including our Sandwich, U.K. research and development facility, except for a small presence. In addition, in 2011, we rationalized several other sites to reduce and optimize the overall R&D footprint. We disposed of our toxicology site in Catania, Italy; exited our R&D sites in Aberdeen and Gosport, U.K.; and disposed of a vacant site in
|
30
|
|
2012 Financial Report
|
|
|
|
|
•
|
Workforce reductions across all areas of our business and other organizational changes, primarily in the U.S. field force, manufacturing, R&D and corporate functions. We identified areas for a reduction in workforce across all of our businesses. In January 2009, when Pfizer and Wyeth entered into the merger agreement, the workforce of the two companies totaled approximately 130,000. We have exceeded our original target to reduce the combined Pfizer/Wyeth workforce 15%, or 19,500, within three years. By the end of 2011, we achieved a reduction of 26,300, and by the end of 2012, we achieved a reduction of 38,500. In 2012, the workforce declined by 12,200, from 103,700 to 91,500, primarily in manufacturing, R&D and corporate functions. The aforementioned workforce reductions include the impact of acquisitions and divestitures subsequent to the Wyeth acquisition.
|
•
|
The increased use of shared services and centers of excellence.
|
•
|
Procurement savings.
|
(a)
|
Transaction costs represent external costs directly related to acquired businesses and primarily include expenditures for banking, legal, accounting and other similar services.
|
(b)
|
Integration costs represent external, incremental costs directly related to integrating acquired businesses, and primarily include expenditures for consulting and the integration of systems and processes.
|
(c)
|
From the beginning of our cost-reduction and transformation initiatives in
2005
through
December 31, 2012
,
Employee termination costs
represent the expected reduction of the workforce by approximately
62,200
employees, mainly in manufacturing, sales and research, of which approximately
51,700
employees have been terminated as of
December 31, 2012
. In
2012
, substantially all employee termination costs represent additional costs with respect to approximately
4,800
employees.
|
•
|
Primary Care operating segment (
$295 million
), Specialty Care and Oncology operating segment (
$175 million
), Established Products and Emerging Markets operating segment (
$125 million
), Animal Health operating segment (
$59 million
), Consumer Healthcare operating segment (
$45 million
), research and development operations (
$6 million
income), manufacturing operations (
$265 million
) and Corporate (
$516 million
).
|
•
|
Primary Care operating segment (
$593 million
), Specialty Care and Oncology operating segment (
$220 million
), Established Products and Emerging Markets operating segment (
$110 million
), Animal Health operating segment (
$45 million
), Consumer Healthcare operating segment (
$8 million
), research and development operations (
$490 million
), manufacturing operations (
$287 million
) and Corporate (
$422 million
).
|
•
|
Primary Care operating segment (
$71 million
), Specialty Care and Oncology operating segment (
$197 million
), Established Products and Emerging Markets operating segment (
$43 million
), Animal Health operating segment (
$34 million
), Consumer Healthcare operating segment (
$12 million
), research and development operations (
$297 million
), manufacturing operations (
$1.1 billion
) and Corporate (
$350 million
).
|
2012 Financial Report
|
|
31
|
|
|
|
|
(d)
|
Additional depreciation––asset restructuring represents the impact of changes in the estimated useful lives of assets involved in restructuring actions.
|
(e)
|
Implementation costs represent external, incremental costs directly related to implementing our non-acquisition-related cost-reduction and productivity initiatives.
|
(a)
|
Includes adjustments for foreign currency translation.
|
(b)
|
Included in
Other current liabilities
($
1.6 billion
) and
Other noncurrent liabilities
($
930 million
).
|
(c)
|
Included in
Other current liabilities
(
$1.2 billion
) and
Other noncurrent liabilities
(
$731 million
).
|
|
|
Year Ended December 31,
|
|
% Change
|
|||||||||||||
(MILLIONS OF DOLLARS)
|
|
2012
|
|
|
2011
|
|
|
2010
|
|
|
12/11
|
|
11/10
|
|
|||
Other deductions—net
|
|
$
|
4,031
|
|
|
$
|
2,499
|
|
|
$
|
3,941
|
|
|
61
|
|
(37
|
)
|
•
|
charges for litigation-related matters that were approximately $1.4 billion higher in 2012 than in 2011, primarily due to a $491 million charge resulting from an agreement-in-principle with the U.S. Department of Justice to resolve an investigation into Wyeth's historical promotional practices in connection with Rapamune, a $450 million settlement of a lawsuit by Brigham Young University related to Celebrex, and charges related to Chantix litigation (for additional information, see Notes to Consolidated Financial Statements—
Note 17. Commitments and Contingencies
); and
|
•
|
royalty-related income that was approximately $100 million lower in 2012 than in 2011.
|
•
|
asset impairment charges that were approximately $888 million higher in 2010 than in 2011, (see below); and
|
•
|
charges for litigation-related matters that were $939 million higher in 2010 than in 2011, which reflects charges recorded in 2010 for asbestos litigation related to our wholly owned subsidiary, Quigley Company, Inc. (for additional information, see Notes to Consolidated Financial Statements—
Note 17. Commitments and Contingencies
),
|
•
|
a lower net gain on asset disposals in 2011 than in 2010.
|
32
|
|
2012 Financial Report
|
|
|
|
|
|
|
Year Ended December 31,
|
|
% Change
|
|||||||||||||
(MILLIONS OF DOLLARS)
|
|
2012
|
|
|
2011
|
|
|
2010
|
|
|
12/11
|
|
|
11/10
|
|||
Provision for taxes on income
|
|
$
|
2,562
|
|
|
$
|
3,909
|
|
|
$
|
1,153
|
|
|
(34
|
)
|
|
239
|
Effective tax rate on continuing operations
|
|
21.2
|
%
|
|
31.8
|
%
|
|
12.2
|
%
|
|
|
|
|
•
|
a multi-year settlement with the IRS in 2012 that resulted in a tax benefit of approximately $1.1 billion, representing tax and interest; and
|
•
|
the resolution of certain prior-period tax positions in 2012 with various foreign tax authorities, and from the expiration of certain statutes of limitations that resulted in tax benefits of approximately $310 million, representing tax and interest,
|
•
|
the impact of the expiration of the U.S. research and development tax credit on December 31, 2011; and
|
•
|
the non-deductibility of the 2012 legal charge related to Rapamune (see the "Other Deductions—Net" section of this Financial Review).
|
•
|
the non-recurrence of a multi-year settlement with the IRS that resulted in a tax benefit in 2010 of approximately $2.0 billion, representing tax and interest; and
|
•
|
the non-recurrence of a $460 million tax benefit, representing tax and interest, related to the resolution of certain prior-period tax positions in 2010 with various foreign tax authorities, as well as from the expiration of the statutes of limitations,
|
•
|
the decrease and jurisdictional mix of certain impairment charges related to assets acquired in connection with the Wyeth acquisition; and
|
•
|
the change in the jurisdictional mix of earnings.
|
2012 Financial Report
|
|
33
|
|
|
|
|
The following table provides the components of
Discontinued operations
—
net of tax
:
|
||||||||||||
|
|
Year Ended December 31,
(a)
|
||||||||||
(MILLIONS OF DOLLARS)
|
|
2012
|
|
|
2011
|
|
|
2010
|
|
|||
Revenues
|
|
$
|
2,258
|
|
|
$
|
2,673
|
|
|
$
|
2,643
|
|
Pre-tax income/(loss) from discontinued operations
|
|
414
|
|
|
487
|
|
|
(50
|
)
|
|||
Provision/(benefit) for taxes on income
(b)
|
|
117
|
|
|
137
|
|
|
(31
|
)
|
|||
Income/(loss) from discontinued operations––net of tax
|
|
297
|
|
|
350
|
|
|
(19
|
)
|
|||
Pre-tax gain/(loss) on sale of discontinued operations
|
|
7,123
|
|
|
1,688
|
|
|
(11
|
)
|
|||
Provision for taxes on income
(c)
|
|
2,340
|
|
|
384
|
|
|
—
|
|
|||
Gain/(loss) on sale of discontinued operations––net of tax
|
|
4,783
|
|
|
1,304
|
|
|
(11
|
)
|
|||
Discontinued operations—net of tax
|
|
$
|
5,080
|
|
|
$
|
1,654
|
|
|
$
|
(30
|
)
|
(a)
|
Includes the Nutrition business for all periods presented (through November 30, 2012) and the Capsugel business for
2011
(through August 1, 2011) and
2010
only. The net loss in 2010 includes the impairment of an indefinite-lived Brand intangible asset in the Nutrition business of approximately $385 million.
|
(b)
|
Includes a deferred tax expense of
$24 million
for
2012
, a deferred tax benefit of
$43 million
for
2011
, and a deferred tax benefit of
$156 million
for
2010
. These deferred tax provisions include deferred income taxes related to investments in certain foreign subsidiaries, resulting from our intention not to hold these subsidiaries indefinitely.
|
(c)
|
Includes a deferred tax expense of
$1.4 billion
for
2012
and
$190 million
for
2011
. These deferred tax provisions include deferred tax expense of
$2.2 billion
for
2012
and
$190 million
for
2011
on certain current-year funds earned outside the U.S. that will not be indefinitely reinvested overseas.
|
•
|
senior management receives a monthly analysis of our operating results that is prepared on an Adjusted income basis;
|
•
|
our annual budgets are prepared on an Adjusted income basis; and
|
•
|
senior management’s annual compensation is derived, in part, using this Adjusted income measure. Adjusted income is one of the performance metrics utilized in the determination of bonuses under the Pfizer Inc. Executive Annual Incentive Plan that is designed to limit the bonuses payable to the Executive Leadership Team (ELT) for purposes of Internal Revenue Code Section 162(m). Subject to the Section 162(m) limitation, the bonuses are funded from a pool based on the achievement of three financial metrics, including adjusted diluted earnings per share, which is derived from Adjusted income. Since 2011, this metric accounts for 40% of the bonus pool made available to ELT members and other members of senior management and will constitute a factor in determining each of these individual’s bonus.
|
34
|
|
2012 Financial Report
|
|
|
|
|
2012 Financial Report
|
|
35
|
|
|
|
|
The following table provides a reconciliation of
Net income attributable to Pfizer Inc.
, as reported under U.S. GAAP, and Non-GAAP Adjusted income:
|
||||||||||||||||||
|
|
Year Ended December 31,
|
|
% Change
|
||||||||||||||
(MILLIONS OF DOLLARS)
|
|
2012
|
|
|
2011
|
|
|
2010
|
|
|
12/11
|
|
|
11/10
|
|
|||
GAAP Reported net income attributable to Pfizer Inc.
|
|
$
|
14,570
|
|
|
$
|
10,009
|
|
|
$
|
8,257
|
|
|
46
|
|
|
21
|
|
Purchase accounting adjustments—net of tax
|
|
3,598
|
|
|
5,000
|
|
|
6,011
|
|
|
(28
|
)
|
|
(17
|
)
|
|||
Acquisition-related costs—net of tax
|
|
756
|
|
|
1,457
|
|
|
2,844
|
|
|
(48
|
)
|
|
(49
|
)
|
|||
Discontinued operations—net of tax
|
|
(5,080
|
)
|
|
(1,654
|
)
|
|
30
|
|
|
(207
|
)
|
|
*
|
|
|||
Certain significant items—net of tax
|
|
2,632
|
|
|
3,027
|
|
|
420
|
|
|
(13
|
)
|
|
*
|
|
|||
Non-GAAP Adjusted income
(a)
|
|
$
|
16,476
|
|
|
$
|
17,839
|
|
|
$
|
17,562
|
|
|
(8
|
)
|
|
2
|
|
(a)
|
The effective tax rate on Non-GAAP Adjusted income was 29.3% in
2012
, 29.6% in
2011
and 29.9% in
2010
. The effective tax rate for 2012 compared with the prior-year reflects the impact of the change in the jurisdictional mix of earnings and the expiration of the U.S. research and development tax credit, and the favorable impact of the resolution of certain prior-period tax positions in 2012 with various foreign tax authorities, and from the expiration of certain statutes of limitations.
|
*
|
Calculation not meaningful.
|
(a)
|
EPS amounts may not add due to rounding.
|
(b)
|
Reported and Adjusted diluted earnings per share in 2012 and 2011 were significantly impacted by the decrease in the number of shares outstanding, primarily due to the Company's ongoing share repurchase program.
|
*
|
Calculation not meaningful.
|
36
|
|
2012 Financial Report
|
|
|
|
|
(a)
|
Included primarily in
Amortization of intangible assets
(see Notes to Consolidated Financial Statements—
Note 10. Goodwill and Other Intangible Assets
).
|
(b)
|
Included in
Provision for taxes on income.
Income taxes includes the tax effect of the associated pre-tax amounts, calculated by determining the jurisdictional location of the pre-tax amounts and applying that jurisdiction’s applicable tax rate. In addition, income taxes for Certain significant items in 2012 includes a $1.1 billion tax benefit, representing tax and interest, as a result of a settlement with the IRS related to audits for tax years 2006-2008. Amounts in 2010 include a $2.0 billion tax benefit, representing tax and interest, as a result of a settlement with the IRS of certain audits covering tax years 2002-2005. See Notes to Consolidated Financial Statements—
Note 5A. Tax Matters: Taxes on Income from Continuing Operations
.
|
(c)
|
Included in
Restructuring charges and certain acquisition-related costs
(see Notes to Consolidated Financial Statements—
Note 3. Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives
).
|
(d)
|
Represents the impact of changes in the estimated useful lives of assets involved in restructuring actions related to acquisitions. For 2012, included in
Cost of sales
($267 million),
Selling informational and administrative expenses
($9 million) and
Research and development expenses
($6 million). For 2011, included in
Cost of sales
($555 million),
Selling, informational and administrative expenses
($45 million) and
Research and development expenses
($23 million). For 2010, included in
Cost of sales
($520 million),
Selling, informational and administrative expenses
($227 million) and
Research and development expenses
($34 million).
|
(e)
|
Represents restructuring charges incurred for our cost-reduction and productivity initiatives. Included in
Restructuring charges and certain acquisition-related costs
(see Notes to Consolidated Financial Statements—
Note 3. Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives
).
|
(f)
|
Amounts primarily relate to our cost-reduction and productivity initiatives (see Notes to Consolidated Financial Statements—
Note 3. Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives
). For 2012, included in
Cost of sales
($31 million),
Selling, informational and administrative expenses
($140 million) and
Research and development expenses
($522 million). For 2011, included in
Cost of sales
($250 million),
Selling, informational and administrative expenses
($55 million) and
Research and development expenses
($654 million).
|
(g)
|
Included in
Other deductions—net
(see the “Other Deductions—Net” section of this Financial Review and Notes to Consolidated Financial Statements—
Note 4. Other Deductions—Net
)
.
|
2012 Financial Report
|
|
37
|
|
|
|
|
(h)
|
Substantially all included in
Other deductions—net
(see the “Other Deductions—Net” section of this Financial Review and Notes to Consolidated Financial Statements—
Note 4. Other Deductions—Net
)
.
|
(i)
|
Included in
Cost of sales
(see also the “Costs and Expenses––Cost of Sales” section of this Financial Review)
.
|
(j)
|
Costs incurred in connection with the initial public offering of a 19.8% ownership stake in Zoetis. Includes expenditures for banking, legal, accounting and similar services, as well as costs associated with the separation of Zoetis employees, net assets and operations from Pfizer, such as consulting and systems costs. For 2012, included in
Costs of sales
($6 million),
Selling, informational and administrative expenses
($194 million) and
Other deductions—net
($125 million). For 2011, substantially all included in
Other deductions—net
.
|
38
|
|
2012 Financial Report
|
|
|
|
|
|
|
Year Ended December 31,
|
|
% Change
|
||||||||||||||
(MILLIONS OF DOLLARS)
|
|
2012
|
|
|
2011
|
|
|
2010
|
|
|
12/11
|
|
|
11/10
|
|
|||
Cash provided by/(used in):
|
|
|
|
|
|
|
|
|
|
|
||||||||
Operating activities
|
|
$
|
17,054
|
|
|
$
|
20,240
|
|
|
$
|
11,454
|
|
|
(16
|
)
|
|
77
|
|
Investing activities
|
|
6,154
|
|
|
1,843
|
|
|
(492
|
)
|
|
234
|
|
|
*
|
|
|||
Financing activities
|
|
(15,999
|
)
|
|
(20,607
|
)
|
|
(11,174
|
)
|
|
(22
|
)
|
|
84
|
|
|||
Effect of exchange-rate changes on cash and cash equivalents
|
|
(2
|
)
|
|
(29
|
)
|
|
(31
|
)
|
|
(93
|
)
|
|
(6
|
)
|
|||
Net increase/(decrease) in
Cash and cash equivalents
|
|
7,207
|
|
|
1,447
|
|
|
(243
|
)
|
|
*
|
|
|
*
|
|
*
|
Calculation not meaningful.
|
•
|
the loss of exclusivity of Lipitor, as well as certain other products, resulting in lower revenues and associated expenses (see also “The Loss or Expiration of Intellectual Property Rights” section of this Financial Review), partially offset by spending reductions resulting from our company-wide cost-reduction initiatives;
|
•
|
payments made in connection with certain legal matters; and
|
•
|
the timing of receipts and payments in the ordinary course of business.
|
•
|
income tax payments made in 2010 of approximately $11.8 billion, primarily associated with certain business decisions executed to finance the Wyeth acquisition, including the decision to repatriate certain funds earned outside the U.S., compared with $2.9 billion in 2011; and
|
•
|
the timing of receipts and payments in the ordinary course of business.
|
•
|
net proceeds from the sale of our Nutrition business of $11.85 billion in 2012 compared to net proceeds from the sale of our Capsugel business of $2.4 billion in 2011 (see Notes to Consolidated Financial Statements––
Note 2B. Acquisitions, Divestitures, Collaborative Arrangements and Equity-Method Investments: Divestitures
); and
|
•
|
cash paid of $1.1 billion, net of cash acquired, for our acquisitions of Alacer, Ferrosan and NextWave in 2012 (see Notes to Consolidated Financial Statements––
Note 2A. Acquisitions, Divestitures, Collaborative Arrangements and Equity-Method Investments: Acquisitions
), compared to $3.3 billion cash paid, net of cash acquired, in 2011, for our acquisitions of King, Icagen and Excaliard,
|
•
|
net purchases of investments of $3.4 billion in 2012, compared to net proceeds from redemptions and sales of investments of $4.1 billion in 2011, which were primarily used to finance our acquisition of King.
|
2012 Financial Report
|
|
39
|
|
|
|
|
•
|
net proceeds from redemptions, purchases and sales of investments of $4.1 billion in 2011, which were primarily used to finance our acquisition of King, compared to net proceeds from redemptions, purchases and sales of investments of $1.2 billion in 2010; and
|
•
|
net proceeds of $2.4 billion received from the sale of Capsugel in 2011 (see Notes to Consolidated Financial Statements—
Note 2B. Acquisitions, Divestitures, Collaborative Arrangements and Equity-Method Investments: Divestitures),
|
•
|
cash paid of $3.3 billion, net of cash acquired, for our acquisitions of King, Icagen and Excaliard in 2011, compared to $273 million paid for our acquisitions of FoldRx, Vetnex and Synbiotics in 2010.
|
•
|
net repayments of borrowings of $1.7 billion in 2012, compared to net repayments of borrowings of $5.5 billion in 2011;
|
•
|
purchases of our common stock of $8.2 billion in 2012, compared to $9.0 billion in 2011; and
|
•
|
increased proceeds from the exercise of stock options,
|
•
|
higher cash dividends paid.
|
•
|
net repayments of borrowings of $5.5 billion in 2011, compared to net repayments of borrowings of $4.2 billion in 2010; and
|
•
|
purchases of our common stock of $9.0 billion in 2011, compared to $1.0 billion in 2010.
|
•
|
the working capital requirements of our operations, including our research and development activities;
|
•
|
investments in our business;
|
•
|
dividend payments and potential increases in the dividend rate;
|
•
|
share repurchases;
|
•
|
the cash requirements associated with our cost-reduction/productivity initiatives;
|
•
|
paying down outstanding debt;
|
•
|
contributions to our pension and postretirement plans; and
|
•
|
business-development activities.
|
40
|
|
2012 Financial Report
|
|
|
|
|
(a)
|
See Notes to Consolidated Financial Statements––
Note 7. Financial Instruments
for a description of assets held and for a description of credit risk related to our financial instruments held.
|
(b)
|
Net financial assets increased during 2012 primarily related to the $11.85 billion proceeds received from the sale of the Nutrition business. For additional information, see the “Analysis of the Consolidated Statements of Cash Flows
”
section of this Financial Review.
|
(c)
|
Working capital includes net assets held for sale of $70 million as of
December 31, 2012
and $4.1 billion as of
December 31, 2011
.
|
(d)
|
Represents total Pfizer Inc. shareholders’ equity divided by the actual number of common shares outstanding (which excludes treasury shares and shares held by our employee benefit trust).
|
2012 Financial Report
|
|
41
|
|
|
|
|
42
|
|
2012 Financial Report
|
|
|
|
|
Payments due under contractual obligations as of December 31, 2012, mature as follows:
|
||||||||||||||||||||
|
|
|
|
Years
|
||||||||||||||||
(MILLIONS OF DOLLARS)
|
|
Total
|
|
|
2013
|
|
|
2014-2015
|
|
|
2016-2017
|
|
|
Thereafter
|
|
|||||
Long-term debt, including current portion
(a)
|
|
$
|
33,485
|
|
|
$
|
2,449
|
|
|
$
|
6,987
|
|
|
$
|
6,356
|
|
|
$
|
17,693
|
|
Interest payments on long-term debt obligations
(b)
|
|
17,980
|
|
|
1,494
|
|
|
2,675
|
|
|
2,137
|
|
|
11,674
|
|
|||||
Other long-term liabilities reflected on our consolidated balance sheet under U.S. GAAP
(c)
|
|
5,034
|
|
|
474
|
|
|
899
|
|
|
892
|
|
|
2,769
|
|
|||||
Lease commitments
(d)
|
|
1,288
|
|
|
190
|
|
|
304
|
|
|
164
|
|
|
630
|
|
|||||
Purchase obligations and other
(e)
|
|
3,534
|
|
|
1,500
|
|
|
1,439
|
|
|
277
|
|
|
318
|
|
|||||
Uncertain tax positions
(f)
|
|
80
|
|
|
80
|
|
|
—
|
|
|
—
|
|
|
—
|
|
(a)
|
Long-term debt consists of senior unsecured notes, including fixed and floating rate, foreign currency denominated, and other notes.
|
(b)
|
Our calculations of expected interest payments incorporate only current period assumptions for interest rates, foreign currency translation rates and hedging strategies (see Notes to Consolidated Financial Statements—
Note 7. Financial Instruments
), and assume that interest is accrued through the maturity date or expiration of the related instrument.
|
(c)
|
Includes expected payments relating to our unfunded U.S. supplemental (non-qualified) pension plans, postretirement plans and deferred compensation plans. Excludes amounts relating to our U.S. qualified pension plans and international pension plans, all of which have a substantial amount of plan assets, because the required funding obligations are not expected to be material and/or because such liabilities do not necessarily reflect future cash payments, as the impact of changes in economic conditions on the fair value of the pension plan assets and/or liabilities can be significant; however, we currently anticipate contributing approximately $343 million to these plans in 2013. Also excludes $3.9 billion of liabilities related to the fair value of derivative financial instruments, legal matters, employee terminations, environmental matters and other, most of which do not represent contractual obligations. See also our liquidity discussion above in this "Analysis of Financial Condition, Liquidity and Capital Resources" section, as well as the Notes to Consolidated Financial Statements—
Note 3. Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives, Note 7A. Financial Instruments: Selected Financial Assets and Liabilities, Note 11E. Pension and Postretirement Benefit Plans and Defined Contribution Plans: Cash Flows,
and
Note 17. Commitments and Contingencies.
|
(d)
|
Includes operating and capital lease obligations.
|
(e)
|
Includes agreements to purchase goods and services that are enforceable and legally binding and includes amounts relating to advertising, information technology services, employee benefit administration services, and potential milestone payments deemed reasonably likely to occur.
|
(f)
|
Includes amounts reflected in
Income taxes payable
only. We are unable to predict the timing of tax settlements related to our noncurrent obligations for uncertain tax positions as tax audits can involve complex issues and the resolution of those issues may span multiple years, particularly if subject to negotiation or litigation.
|
2012 Financial Report
|
|
43
|
|
|
|
|
44
|
|
2012 Financial Report
|
|
|
|
|
•
|
the outcome of research and development activities including, without limitation, the ability to meet anticipated
|
•
|
decisions by regulatory authorities regarding whether and when to approve our drug applications, as well as their
|
•
|
the speed with which regulatory authorizations, pricing approvals and product launches may be achieved;
|
•
|
the outcome of post-approval clinical trials, which could result in the loss of marketing approval for a product or
|
•
|
the success of external business-development activities;
|
•
|
competitive developments, including the impact on our competitive position of new product entrants, in-line branded
|
•
|
the implementation by the FDA of an abbreviated legal pathway to approve biosimilar products, which could subject
|
•
|
the ability to meet generic and branded competition after the loss of patent protection for our products or competitor
|
•
|
the ability to successfully market both new and existing products domestically and internationally;
|
•
|
difficulties or delays in manufacturing;
|
•
|
trade buying patterns;
|
•
|
the impact of existing and future legislation and regulatory provisions on product exclusivity;
|
•
|
trends toward managed care and healthcare cost containment;
|
•
|
the impact of the U.S. Budget Control Act of 2011 (the Budget Control Act) and the deficit-reduction actions to be
|
•
|
the possible failure of the U.S. federal government to suspend enforcement of the federal debt ceiling beyond May 18, 2013 or to increase the federal debt ceiling and any resulting inability of the federal government to satisfy its financial obligations, including under Medicare, Medicaid and other publicly funded or subsidized health programs;
|
•
|
the impact of U.S. healthcare legislation enacted in 2010—the Patient Protection and Affordable Care Act, as amended
|
•
|
U.S. legislation or regulatory action affecting, among other things, pharmaceutical product pricing, reimbursement or
|
•
|
legislation or regulatory action in markets outside the U.S. affecting pharmaceutical product pricing, reimbursement or
|
•
|
the exposure of our operations outside the U.S. to possible capital and exchange controls, expropriation and other
|
•
|
contingencies related to actual or alleged environmental contamination;
|
•
|
claims and concerns that may arise regarding the safety or efficacy of in-line products and product candidates;
|
2012 Financial Report
|
|
45
|
|
|
|
|
•
|
any significant breakdown, infiltration or interruption of our information technology systems and infrastructure;
|
•
|
legal defense costs, insurance expenses, settlement costs, the risk of an adverse decision or settlement and the
|
•
|
our ability to protect our patents and other intellectual property, both domestically and internationally;
|
•
|
interest rate and foreign currency exchange rate fluctuations, including the impact of possible currency devaluations in countries experiencing high inflation rates;
|
•
|
governmental laws and regulations affecting domestic and foreign operations, including, without limitation, tax
|
•
|
any significant issues involving our largest wholesaler customers, which account for a substantial portion of our
|
•
|
the possible impact of the increased presence of counterfeit medicines in the pharmaceutical supply chain on our
|
•
|
any significant issues that may arise related to the outsourcing of certain operational and staff functions to third
|
•
|
changes in U.S. generally accepted accounting principles;
|
•
|
uncertainties related to general economic, political, business, industry, regulatory and market conditions including,
|
•
|
any changes in business, political and economic conditions due to actual or threatened terrorist activity in the U.S. and
|
•
|
growth in costs and expenses;
|
•
|
changes in our product, segment and geographic mix;
|
•
|
our ability to successfully implement any strategic alternative that we decide to pursue with regard to our remaining
|
•
|
the impact of acquisitions, divestitures, restructurings, product recalls and withdrawals and other unusual items,
|
46
|
|
2012 Financial Report
|
|
|
|
|
2012 Financial Report
|
|
47
|
|
|
|
|
48
|
|
2012 Financial Report
|
|
|
|
|
|
|
|
Ian Read
|
|
|
Chairman and Chief Executive Officer
|
|
|
|
|
|
Frank D’Amelio
|
|
Loretta Cangialosi
|
Principal Financial Officer
|
|
Principal Accounting Officer
|
|
|
|
February 28, 2013
|
|
|
2012 Financial Report
|
|
49
|
|
|
|
|
|
W. Don Cornwell
|
Chair, Audit Committee
|
|
February 28, 2013
|
50
|
|
2012 Financial Report
|
|
|
|
|
KPMG LLP
|
New York, New York
|
|
February 28, 2013
|
2012 Financial Report
|
|
51
|
|
|
|
|
KPMG LLP
|
New York, New York
|
|
February 28, 2013
|
52
|
|
2012 Financial Report
|
|
|
|
|
|
|
Year Ended December 31,
|
||||||||||
(MILLIONS, EXCEPT PER COMMON SHARE DATA)
|
|
2012
|
|
|
2011
|
|
|
2010
|
|
|||
Revenues
|
|
$
|
58,986
|
|
|
$
|
65,259
|
|
|
$
|
65,165
|
|
Costs and expenses:
|
|
|
|
|
|
|
|
|
||||
Cost of sales
(a)
|
|
11,334
|
|
|
14,076
|
|
|
14,788
|
|
|||
Selling, informational and administrative expenses
(a)
|
|
16,616
|
|
|
18,832
|
|
|
18,973
|
|
|||
Research and development expenses
(a)
|
|
7,870
|
|
|
9,074
|
|
|
9,483
|
|
|||
Amortization of intangible assets
|
|
5,175
|
|
|
5,544
|
|
|
5,364
|
|
|||
Restructuring charges and certain acquisition-related costs
|
|
1,880
|
|
|
2,930
|
|
|
3,145
|
|
|||
Other deductions––net
|
|
4,031
|
|
|
2,499
|
|
|
3,941
|
|
|||
Income from continuing operations before provision for taxes on income
|
|
12,080
|
|
|
12,304
|
|
|
9,471
|
|
|||
Provision for taxes on income
|
|
2,562
|
|
|
3,909
|
|
|
1,153
|
|
|||
Income from continuing operations
|
|
9,518
|
|
|
8,395
|
|
|
8,318
|
|
|||
Discontinued operations:
|
|
|
|
|
|
|
||||||
Income/(loss) from discontinued operations––net of tax
|
|
297
|
|
|
350
|
|
|
(19
|
)
|
|||
Gain/(loss) on sale of discontinued operations––net of tax
|
|
4,783
|
|
|
1,304
|
|
|
(11
|
)
|
|||
Discontinued operations––net of tax
|
|
5,080
|
|
|
1,654
|
|
|
(30
|
)
|
|||
Net income before allocation to noncontrolling interests
|
|
14,598
|
|
|
10,049
|
|
|
8,288
|
|
|||
Less: Net income attributable to noncontrolling interests
|
|
28
|
|
|
40
|
|
|
31
|
|
|||
Net income attributable to Pfizer Inc.
|
|
$
|
14,570
|
|
|
$
|
10,009
|
|
|
$
|
8,257
|
|
|
|
|
|
|
|
|
||||||
Earnings per common share––basic
(
b)
|
|
|
|
|
|
|
|
|
|
|||
Income from continuing operations attributable to Pfizer Inc. common shareholders
|
|
$
|
1.27
|
|
|
$
|
1.07
|
|
|
$
|
1.03
|
|
Discontinued operations––net of tax
|
|
0.68
|
|
|
0.21
|
|
|
—
|
|
|||
Net income attributable to Pfizer Inc. common shareholders
|
|
$
|
1.96
|
|
|
$
|
1.28
|
|
|
$
|
1.03
|
|
Earnings per common share––diluted
(b)
|
|
|
|
|
|
|
|
|
|
|||
Income from continuing operations attributable to Pfizer Inc. common shareholders
|
|
$
|
1.26
|
|
|
$
|
1.06
|
|
|
$
|
1.03
|
|
Discontinued operations––net of tax
|
|
0.68
|
|
|
0.21
|
|
|
—
|
|
|||
Net income attributable to Pfizer Inc. common shareholders
|
|
$
|
1.94
|
|
|
$
|
1.27
|
|
|
$
|
1.02
|
|
|
|
|
|
|
|
|
||||||
Weighted-average shares––basic
|
|
7,442
|
|
|
7,817
|
|
|
8,036
|
|
|||
Weighted-average shares––diluted
|
|
7,508
|
|
|
7,870
|
|
|
8,074
|
|
|||
|
|
|
|
|
|
|
||||||
Cash dividends paid per common share
|
|
$
|
0.88
|
|
|
$
|
0.80
|
|
|
$
|
0.72
|
|
(a)
|
Exclusive of amortization of intangible assets, except as disclosed in
Note 1K. Basis of Presentation and Significant Accounting Policies: Amortization of Intangible Assets, Depreciation and Certain Long-Lived Assets.
|
(b)
|
EPS amounts may not add due to rounding.
|
2012 Financial Report
|
|
53
|
|
|
|
|
|
|
Year Ended December 31,
|
||||||||||
(MILLIONS OF DOLLARS)
|
|
2012
|
|
|
2011
|
|
|
2010
|
|
|||
Net income before allocation to noncontrolling interests
|
|
$
|
14,598
|
|
|
$
|
10,049
|
|
|
$
|
8,288
|
|
|
|
|
|
|
|
|
|
|
|
|||
Foreign currency translation adjustments
|
|
$
|
(811
|
)
|
|
$
|
796
|
|
|
$
|
(3,534
|
)
|
Reclassification adjustments
(a)
|
|
(207
|
)
|
|
(127
|
)
|
|
(7
|
)
|
|||
|
|
(1,018
|
)
|
|
669
|
|
|
(3,541
|
)
|
|||
Unrealized holding gains/(losses) on derivative financial instruments
|
|
684
|
|
|
(502
|
)
|
|
(1,043
|
)
|
|||
Reclassification adjustments for realized (gains)/losses
(b)
|
|
(263
|
)
|
|
239
|
|
|
702
|
|
|||
|
|
421
|
|
|
(263
|
)
|
|
(341
|
)
|
|||
Unrealized holding gains/(losses) on available-for-sale securities
|
|
135
|
|
|
(143
|
)
|
|
7
|
|
|||
Reclassification adjustments for realized (gains)/losses
(b)
|
|
3
|
|
|
15
|
|
|
(141
|
)
|
|||
|
|
138
|
|
|
(128
|
)
|
|
(134
|
)
|
|||
Benefit plans: Actuarial losses, net
|
|
(2,232
|
)
|
|
(2,459
|
)
|
|
(1,426
|
)
|
|||
Reclassification adjustments related to amortization
(c)
|
|
473
|
|
|
284
|
|
|
262
|
|
|||
Reclassification adjustments related to curtailments and settlements, net
(c)
|
|
317
|
|
|
355
|
|
|
266
|
|
|||
Other
|
|
22
|
|
|
(100
|
)
|
|
88
|
|
|||
|
|
(1,420
|
)
|
|
(1,920
|
)
|
|
(810
|
)
|
|||
Benefit plans: Prior service credits and other
|
|
25
|
|
|
106
|
|
|
550
|
|
|||
Reclassification adjustments related to amortization
(c)
|
|
(69
|
)
|
|
(69
|
)
|
|
(42
|
)
|
|||
Reclassification adjustments related to curtailments and settlements, net
(c)
|
|
(130
|
)
|
|
(91
|
)
|
|
(49
|
)
|
|||
Other
|
|
(3
|
)
|
|
3
|
|
|
5
|
|
|||
|
|
(177
|
)
|
|
(51
|
)
|
|
464
|
|
|||
Other comprehensive loss, before tax
|
|
(2,056
|
)
|
|
(1,693
|
)
|
|
(4,362
|
)
|
|||
Tax benefit on other comprehensive loss
(d)
|
|
(225
|
)
|
|
(959
|
)
|
|
(375
|
)
|
|||
Other comprehensive loss before allocation to noncontrolling interests
|
|
$
|
(1,831
|
)
|
|
$
|
(734
|
)
|
|
$
|
(3,987
|
)
|
|
|
|
|
|
|
|
||||||
|
|
|
|
|
|
|
|
|
|
|||
Comprehensive income before allocation to noncontrolling interests
|
|
$
|
12,767
|
|
|
$
|
9,315
|
|
|
$
|
4,301
|
|
Less: Comprehensive income/(loss) attributable to noncontrolling interests
|
|
21
|
|
|
(5
|
)
|
|
36
|
|
|||
Comprehensive income attributable to Pfizer Inc.
|
|
$
|
12,746
|
|
|
$
|
9,320
|
|
|
$
|
4,265
|
|
(a)
|
For 2012 and 2011, reclassified to
Gain/(loss) on sale of discontinued operations—net of tax
.
|
(b)
|
Reclassified into
Other deductions—net
in the consolidated statements of income.
|
(c)
|
Generally reclassified into
Cost of sales, Selling, informational and administrative expenses,
and/or
Research and development expenses
, as appropriate, in the consolidated statements of income.
|
(d)
|
See
Note 5E. Tax Matters: Taxes on Items of Other Comprehensive Income/(Loss).
|
54
|
|
2012 Financial Report
|
|
|
|
|
|
|
As of December 31,
|
||||||
(MILLIONS, EXCEPT PREFERRED STOCK ISSUED AND PER COMMON SHARE DATA)
|
|
2012
|
|
|
2011
|
|
||
|
|
|
|
|
||||
Assets
|
|
|
|
|
||||
Cash and cash equivalents
|
|
$
|
10,389
|
|
|
$
|
3,182
|
|
Short-term investments
|
|
22,319
|
|
|
23,270
|
|
||
Accounts receivable, less allowance for doubtful accounts, 2012—$374; 2011—$226
|
|
12,378
|
|
|
13,058
|
|
||
Inventories
|
|
7,063
|
|
|
6,610
|
|
||
Taxes and other current assets
|
|
9,196
|
|
|
9,380
|
|
||
Assets of discontinued operations and other assets held for sale
|
|
70
|
|
|
5,317
|
|
||
Total current assets
|
|
61,415
|
|
|
60,817
|
|
||
Long-term investments
|
|
14,149
|
|
|
9,814
|
|
||
Property, plant and equipment, less accumulated depreciation
|
|
14,461
|
|
|
15,921
|
|
||
Goodwill
|
|
44,672
|
|
|
44,569
|
|
||
Identifiable intangible assets, less accumulated amortization
|
|
46,013
|
|
|
51,184
|
|
||
Taxes and other noncurrent assets
|
|
5,088
|
|
|
5,697
|
|
||
Total assets
|
|
$
|
185,798
|
|
|
$
|
188,002
|
|
|
|
|
|
|
||||
Liabilities and Equity
|
|
|
|
|
|
|
||
Short-term borrowings, including current portion of long-term debt: 2012—$2,449; 2011—$6
|
|
$
|
6,424
|
|
|
$
|
4,016
|
|
Accounts payable
|
|
4,264
|
|
|
3,678
|
|
||
Dividends payable
|
|
1,734
|
|
|
1,796
|
|
||
Income taxes payable
|
|
1,010
|
|
|
1,009
|
|
||
Accrued compensation and related items
|
|
2,046
|
|
|
2,120
|
|
||
Other current liabilities
|
|
13,141
|
|
|
15,066
|
|
||
Liabilities of discontinued operations
|
|
—
|
|
|
1,224
|
|
||
Total current liabilities
|
|
28,619
|
|
|
28,909
|
|
||
|
|
|
|
|
||||
Long-term debt
|
|
31,036
|
|
|
34,926
|
|
||
Pension benefit obligations
|
|
7,830
|
|
|
6,355
|
|
||
Postretirement benefit obligations
|
|
3,493
|
|
|
3,344
|
|
||
Noncurrent deferred tax liabilities
|
|
21,593
|
|
|
18,861
|
|
||
Other taxes payable
|
|
6,610
|
|
|
6,886
|
|
||
Other noncurrent liabilities
|
|
4,939
|
|
|
6,100
|
|
||
Total liabilities
|
|
104,120
|
|
|
105,381
|
|
||
|
|
|
|
|
||||
Commitments and Contingencies
|
|
|
|
|
|
|
||
|
|
|
|
|
||||
Preferred stock, without par value, at stated value; 27 shares authorized; issued:
2012—967; 2011—1,112 |
|
39
|
|
|
45
|
|
||
Common stock, $0.05 par value; 12,000 shares authorized; issued: 2012—8,956;
2011—8,902 |
|
448
|
|
|
445
|
|
||
Additional paid-in capital
|
|
72,608
|
|
|
71,423
|
|
||
Employee benefit trusts
|
|
(1
|
)
|
|
(3
|
)
|
||
Treasury stock, shares at cost: 2012—1,680; 2011—1,327
|
|
(40,121
|
)
|
|
(31,801
|
)
|
||
Retained earnings
|
|
54,240
|
|
|
46,210
|
|
||
Accumulated other comprehensive loss
|
|
(5,953
|
)
|
|
(4,129
|
)
|
||
Total Pfizer Inc. shareholders’ equity
|
|
81,260
|
|
|
82,190
|
|
||
Equity attributable to noncontrolling interests
|
|
418
|
|
|
431
|
|
||
Total equity
|
|
81,678
|
|
|
82,621
|
|
||
Total liabilities and equity
|
|
$
|
185,798
|
|
|
$
|
188,002
|
|
2012 Financial Report
|
|
55
|
|
|
|
|
|
|
PFIZER INC. SHAREHOLDERS
|
|
|
||||||||||||||||||||||||||||||||||||||||||||||||
Preferred Stock
|
|
Common Stock
|
|
|
|
Employee Benefit Trusts
|
|
Treasury Stock
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||
(MILLIONS,
EXCEPT PREFERRED
SHARES)
|
|
Shares
|
|
|
Stated Value
|
|
|
Shares
|
|
|
Par Value
|
|
|
Add’l
Paid-In
Capital
|
|
|
Shares
|
|
|
Fair Value
|
|
|
Shares
|
|
|
Cost
|
|
|
Retained Earnings
|
|
|
Accum.
Other
Comp. Inc./
(Loss)
|
|
|
Share -
holders’
Equity
|
|
|
Non-controlling Interests
|
|
|
Total
Equity
|
|
||||||||||
Balance, January 1, 2010
|
|
1,511
|
|
|
$
|
61
|
|
|
8,869
|
|
|
$
|
443
|
|
|
$
|
70,497
|
|
|
(19
|
)
|
|
$
|
(333
|
)
|
|
(799
|
)
|
|
$
|
(21,632
|
)
|
|
$
|
40,426
|
|
|
$
|
552
|
|
|
$
|
90,014
|
|
|
$
|
432
|
|
|
$
|
90,446
|
|
Net income
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
8,257
|
|
|
|
|
8,257
|
|
|
31
|
|
|
8,288
|
|
||||||||||||||||||||
Other comprehensive
loss, net of tax
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(3,992
|
)
|
|
(3,992
|
)
|
|
5
|
|
|
(3,987
|
)
|
||||||||||||||||||||
Cash dividends declared:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||||||||||
Common stock
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(5,964
|
)
|
|
|
|
(5,964
|
)
|
|
|
|
(5,964
|
)
|
|||||||||||||||||||||
Preferred stock
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(3
|
)
|
|
|
|
(3
|
)
|
|
|
|
(3
|
)
|
|||||||||||||||||||||
Noncontrolling interests
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(17
|
)
|
|
(17
|
)
|
||||||||||||||||||||||
Share-based payment transactions
|
|
|
|
|
|
2
|
|
|
—
|
|
|
209
|
|
|
1
|
|
|
14
|
|
|
(5
|
)
|
|
(82
|
)
|
|
|
|
|
|
141
|
|
|
|
|
141
|
|
|||||||||||||||
Purchases of common stock
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(61
|
)
|
|
(1,000
|
)
|
|
|
|
|
|
(1,000
|
)
|
|
|
|
(1,000
|
)
|
||||||||||||||||||||
Employee benefit trust transactions—net
|
|
|
|
|
|
|
|
|
|
(19
|
)
|
|
16
|
|
|
292
|
|
|
|
|
|
|
|
|
|
|
273
|
|
|
|
|
273
|
|
|||||||||||||||||||
Preferred stock conversions and redemptions
|
|
(232
|
)
|
|
(9
|
)
|
|
|
|
|
|
(1
|
)
|
|
|
|
|
|
—
|
|
|
2
|
|
|
|
|
|
|
(8
|
)
|
|
|
|
(8
|
)
|
|||||||||||||||||
Other
|
|
|
|
|
|
5
|
|
|
1
|
|
|
74
|
|
|
2
|
|
|
20
|
|
|
1
|
|
|
—
|
|
|
—
|
|
|
|
|
95
|
|
|
1
|
|
|
96
|
|
|||||||||||||
Balance, December 31, 2010
|
|
1,279
|
|
|
52
|
|
|
8,876
|
|
|
444
|
|
|
70,760
|
|
|
—
|
|
|
(7
|
)
|
|
(864
|
)
|
|
(22,712
|
)
|
|
42,716
|
|
|
(3,440
|
)
|
|
87,813
|
|
|
452
|
|
|
88,265
|
|
||||||||||
Net income
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10,009
|
|
|
|
|
10,009
|
|
|
40
|
|
|
10,049
|
|
||||||||||||||||||||
Other comprehensive
loss, net of tax
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(689
|
)
|
|
(689
|
)
|
|
(45
|
)
|
|
(734
|
)
|
||||||||||||||||||||
Cash dividends declared:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||||||||||
Common stock
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(6,512
|
)
|
|
|
|
(6,512
|
)
|
|
|
|
(6,512
|
)
|
|||||||||||||||||||||
Preferred stock
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(3
|
)
|
|
|
|
(3
|
)
|
|
|
|
(3
|
)
|
|||||||||||||||||||||
Noncontrolling interests
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(19
|
)
|
|
(19
|
)
|
||||||||||||||||||||||
Share-based payment transactions
|
|
|
|
|
|
23
|
|
|
1
|
|
|
594
|
|
|
|
|
|
|
(5
|
)
|
|
(90
|
)
|
|
|
|
|
|
505
|
|
|
|
|
505
|
|
|||||||||||||||||
Purchases of common stock
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(459
|
)
|
|
(9,000
|
)
|
|
|
|
|
|
(9,000
|
)
|
|
|
|
(9,000
|
)
|
||||||||||||||||||||
Preferred stock conversions and redemptions
|
|
(167
|
)
|
|
(7
|
)
|
|
|
|
|
|
(2
|
)
|
|
|
|
|
|
—
|
|
|
1
|
|
|
|
|
|
|
(8
|
)
|
|
|
|
(8
|
)
|
|||||||||||||||||
Other
|
|
|
|
|
|
3
|
|
|
—
|
|
|
71
|
|
|
—
|
|
|
4
|
|
|
1
|
|
|
—
|
|
|
—
|
|
|
|
|
75
|
|
|
3
|
|
|
78
|
|
|||||||||||||
Balance, December 31, 2011
|
|
1,112
|
|
|
45
|
|
|
8,902
|
|
|
445
|
|
|
71,423
|
|
|
—
|
|
|
(3
|
)
|
|
(1,327
|
)
|
|
(31,801
|
)
|
|
46,210
|
|
|
(4,129
|
)
|
|
82,190
|
|
|
431
|
|
|
82,621
|
|
||||||||||
Net income
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
14,570
|
|
|
|
|
14,570
|
|
|
28
|
|
|
14,598
|
|
||||||||||||||||||||
Other comprehensive loss, net of tax
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1,824
|
)
|
|
(1,824
|
)
|
|
(7
|
)
|
|
(1,831
|
)
|
||||||||||||||||||||
Cash dividends declared:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||||||||||
Common stock
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(6,537
|
)
|
|
|
|
(6,537
|
)
|
|
|
|
(6,537
|
)
|
|||||||||||||||||||||
Preferred stock
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(3
|
)
|
|
|
|
(3
|
)
|
|
|
|
(3
|
)
|
|||||||||||||||||||||
Noncontrolling interests
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(9
|
)
|
|
(9
|
)
|
||||||||||||||||||||||
Share-based payment transactions
|
|
|
|
|
|
52
|
|
|
3
|
|
|
1,150
|
|
|
|
|
|
|
(4
|
)
|
|
(97
|
)
|
|
|
|
|
|
1,056
|
|
|
|
|
1,056
|
|
|||||||||||||||||
Purchases of common stock
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(349
|
)
|
|
(8,228
|
)
|
|
|
|
|
|
(8,228
|
)
|
|
|
|
(8,228
|
)
|
||||||||||||||||||||
Preferred stock conversions and redemptions
|
|
(145
|
)
|
|
(6
|
)
|
|
|
|
|
|
(3
|
)
|
|
|
|
|
|
—
|
|
|
1
|
|
|
|
|
|
|
(8
|
)
|
|
|
|
(8
|
)
|
|||||||||||||||||
Other
|
|
|
|
|
|
2
|
|
|
—
|
|
|
38
|
|
|
—
|
|
|
2
|
|
|
—
|
|
|
4
|
|
|
—
|
|
|
|
|
44
|
|
|
(25
|
)
|
|
19
|
|
|||||||||||||
Balance, December 31, 2012
|
|
967
|
|
|
$
|
39
|
|
|
8,956
|
|
|
$
|
448
|
|
|
$
|
72,608
|
|
|
—
|
|
|
$
|
(1
|
)
|
|
(1,680
|
)
|
|
$
|
(40,121
|
)
|
|
$
|
54,240
|
|
|
$
|
(5,953
|
)
|
|
$
|
81,260
|
|
|
$
|
418
|
|
|
$
|
81,678
|
|
56
|
|
2012 Financial Report
|
|
|
|
|
|
|
Year Ended December 31,
|
||||||||||
(MILLIONS)
|
|
2012
|
|
|
2011
|
|
|
2010
|
|
|||
|
|
|
|
|
|
|
||||||
Operating Activities
|
|
|
|
|
|
|
||||||
Net income before allocation to noncontrolling interests
|
|
$
|
14,598
|
|
|
$
|
10,049
|
|
|
$
|
8,288
|
|
Adjustments to reconcile net income before allocation to noncontrolling interests to net cash provided by operating activities:
|
|
|
|
|
|
|
|
|
||||
Depreciation and amortization
|
|
7,611
|
|
|
8,907
|
|
|
8,399
|
|
|||
Asset write-offs and impairment charges
|
|
1,299
|
|
|
1,198
|
|
|
3,486
|
|
|||
Share-based compensation expense
|
|
481
|
|
|
419
|
|
|
405
|
|
|||
(Gain)/loss on sale of discontinued operations
|
|
(7,123
|
)
|
|
(1,688
|
)
|
|
11
|
|
|||
Deferred taxes from continuing operations
|
|
739
|
|
|
307
|
|
|
2,109
|
|
|||
Deferred taxes from discontinued operations
|
|
1,459
|
|
|
147
|
|
|
(156
|
)
|
|||
Benefit plan contributions (in excess of)/less than expense
|
|
135
|
|
|
(1,769
|
)
|
|
(677
|
)
|
|||
Other non-cash adjustments, net
|
|
(203
|
)
|
|
(172
|
)
|
|
(49
|
)
|
|||
Other changes in assets and liabilities, net of acquisitions and divestitures:
|
|
|
|
|
|
|
||||||
Accounts receivable
|
|
275
|
|
|
(66
|
)
|
|
(608
|
)
|
|||
Inventories
|
|
(631
|
)
|
|
1,084
|
|
|
2,917
|
|
|||
Other assets
|
|
83
|
|
|
701
|
|
|
(818
|
)
|
|||
Accounts payable
|
|
579
|
|
|
(367
|
)
|
|
(301
|
)
|
|||
Other liabilities
|
|
(3,438
|
)
|
|
1,508
|
|
|
1,114
|
|
|||
Other tax accounts, net
|
|
1,190
|
|
|
(18
|
)
|
|
(12,666
|
)
|
|||
Net cash provided by operating activities
|
|
17,054
|
|
|
20,240
|
|
|
11,454
|
|
|||
|
|
|
|
|
|
|
||||||
Investing Activities
|
|
|
|
|
|
|
|
|
||||
Purchases of property, plant and equipment
|
|
(1,327
|
)
|
|
(1,660
|
)
|
|
(1,513
|
)
|
|||
Purchases of short-term investments
|
|
(24,018
|
)
|
|
(18,447
|
)
|
|
(11,082
|
)
|
|||
Proceeds from redemptions and sales of short-term investments
|
|
25,302
|
|
|
14,176
|
|
|
5,699
|
|
|||
Net proceeds from redemptions and sales of short-term investments with
original maturities of 90 days or less
|
|
1,459
|
|
|
10,874
|
|
|
5,950
|
|
|||
Purchases of long-term investments
|
|
(11,145
|
)
|
|
(4,620
|
)
|
|
(4,128
|
)
|
|||
Proceeds from redemptions and sales of long-term investments
|
|
4,990
|
|
|
2,147
|
|
|
4,737
|
|
|||
Acquisitions, net of cash acquired
|
|
(1,050
|
)
|
|
(3,282
|
)
|
|
(273
|
)
|
|||
Proceeds from sale of businesses
|
|
11,850
|
|
|
2,376
|
|
|
—
|
|
|||
Other investing activities
|
|
93
|
|
|
279
|
|
|
118
|
|
|||
Net cash provided by/(used in) investing activities
|
|
6,154
|
|
|
1,843
|
|
|
(492
|
)
|
|||
|
|
|
|
|
|
|
||||||
Financing Activities
|
|
|
|
|
|
|
|
|
||||
Proceeds from short-term borrowings
|
|
7,995
|
|
|
12,810
|
|
|
6,400
|
|
|||
Principal payments on short-term borrowings
|
|
(3
|
)
|
|
(3,826
|
)
|
|
(9,249
|
)
|
|||
Net payments on short-term borrowings with original maturities of 90 days or less
|
|
(8,204
|
)
|
|
(7,540
|
)
|
|
(1,297
|
)
|
|||
Principal payments on long-term debt
|
|
(1,513
|
)
|
|
(6,986
|
)
|
|
(6
|
)
|
|||
Purchases of common stock
|
|
(8,228
|
)
|
|
(9,000
|
)
|
|
(1,000
|
)
|
|||
Cash dividends paid
|
|
(6,534
|
)
|
|
(6,234
|
)
|
|
(6,088
|
)
|
|||
Other financing activities
|
|
488
|
|
|
169
|
|
|
66
|
|
|||
Net cash used in financing activities
|
|
(15,999
|
)
|
|
(20,607
|
)
|
|
(11,174
|
)
|
|||
Effect of exchange-rate changes on cash and cash equivalents
|
|
(2
|
)
|
|
(29
|
)
|
|
(31
|
)
|
|||
Net increase/(decrease) in cash and cash equivalents
|
|
7,207
|
|
|
1,447
|
|
|
(243
|
)
|
|||
Cash and cash equivalents, beginning
|
|
3,182
|
|
|
1,735
|
|
|
1,978
|
|
|||
|
|
|
|
|
|
|
||||||
Cash and cash equivalents, ending
|
|
$
|
10,389
|
|
|
$
|
3,182
|
|
|
$
|
1,735
|
|
|
|
|
|
|
|
|
||||||
Supplemental Cash Flow Information
|
|
|
|
|
|
|
|
|
||||
Cash paid during the period for:
|
|
|
|
|
|
|
|
|
||||
Income taxes
|
|
$
|
2,430
|
|
|
$
|
2,938
|
|
|
$
|
11,775
|
|
Interest
|
|
1,873
|
|
|
2,085
|
|
|
2,155
|
|
2012 Financial Report
|
|
57
|
|
|
|
|
•
|
Presentation of comprehensive income in financial statements. As a result of adopting this new standard, we have presented separate Consolidated Statements of Comprehensive Income.
|
•
|
An amendment to the guidelines on the measurement and disclosure of fair value that is consistent between U.S. GAAP and International Financial Reporting Standards. The adoption of this new standard did not have a significant impact on our financial statements.
|
58
|
|
2012 Financial Report
|
|
|
|
|
•
|
Market approach, which is based on market prices and other information from market transactions involving identical or comparable assets or liabilities.
|
•
|
Cost approach, which is based on the cost to acquire or construct comparable assets less an allowance for functional and/or economic obsolescence.
|
•
|
Quoted prices for identical assets or liabilities in active markets (Level 1 inputs).
|
•
|
Quoted prices for similar assets or liabilities in active markets or quoted prices for identical or similar assets or liabilities in markets that are not active or are directly or indirectly observable (Level 2 inputs).
|
•
|
Unobservable inputs that reflect estimates and assumptions (Level 3 inputs).
|
2012 Financial Report
|
|
59
|
|
|
|
|
•
|
In the U.S., we record provisions for pharmaceutical Medicaid, Medicare and performance-based contract rebates based upon our experience ratio of rebates paid and actual prescriptions written during prior quarters. We apply the experience ratio to the respective period’s sales to determine the rebate accrual and related expense. This experience ratio is evaluated regularly to ensure that the historical trends are as current as practicable. In addition, to account for the impacts of the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act (together, U.S. Healthcare Legislation), we also consider the increase in minimum rebate and extension of Medicaid prescription drug rebates for drugs dispensed to enrollees. We estimate discounts on branded prescription drug sales to Medicare Part D participants in the Medicare “coverage gap,” also known as the “doughnut hole,” based on historical experience of beneficiary prescriptions and consideration of the utilization that is expected to result from the discount in the coverage gap. We evaluate this estimate regularly to ensure that the historical trends and future expectations are as current as practicable. For performance-based contract rebates, we also consider current contract terms, such as changes in formulary status and discount rates.
|
•
|
Outside the U.S., the majority of our pharmaceutical rebates, discounts and price reductions (collectively, sales allowances) are contractual or legislatively mandated and our estimates are based on actual invoiced sales within each period; both of these elements help to reduce the risk of variations in the estimation process. Some European countries base their rebates on the government’s unbudgeted pharmaceutical spending, and we use an estimated allocation factor (based on historical payments) and total revenues by country against our actual invoiced sales to project the expected level of reimbursement. We obtain third-party information that helps us to monitor the adequacy of these accruals.
|
•
|
Provisions for pharmaceutical chargebacks (primarily reimbursements to wholesalers for honoring contracted prices to third parties) closely approximate actual as we settle these deductions generally within two to five weeks of incurring the liability.
|
•
|
Provisions for pharmaceutical returns are based on a calculation for each market that incorporates the following, as appropriate: local returns policies and practices; returns as a percentage of sales; an understanding of the reasons for past returns; estimated shelf life by product; an estimate of the amount of time between shipment and return or lag time; and any other factors that could impact the estimate of future returns, such as loss of exclusivity, product recalls or a changing competitive environment. Generally, returned products are destroyed, and customers are refunded the sales price in the form of a credit.
|
•
|
We record sales incentives as a reduction of revenues at the time the related revenues are recorded or when the incentive is offered, whichever is later. We estimate the cost of our sales incentives based on our historical experience with similar incentives programs.
|
60
|
|
2012 Financial Report
|
|
|
|
|
•
|
Goodwill
—Goodwill represents the excess of the consideration transferred for an acquired business over the assigned values of its net assets. Goodwill is not amortized.
|
•
|
Identifiable intangible assets, less accumulated amortization
—These acquired assets are recorded at cost. Intangible assets with finite lives are amortized on a straight-line basis over their estimated useful lives. Intangible assets with indefinite lives that are associated with marketed products are not amortized until a useful life can be determined. Intangible assets associated with IPR&D projects are not amortized until approval is obtained in a major market, typically either the U.S. or the European Union (EU), or in a series of other countries, subject to certain specified conditions and management judgment. The useful life of an amortizing asset generally is determined by identifying the period in which substantially all of the cash flows are expected to be generated.
|
•
|
Property, plant and equipment, less accumulated depreciation
—These assets are recorded at cost and are increased by the cost of any significant improvements after purchase. Property, plant and equipment assets, other than land and construction in progress, are depreciated on a straight-line basis over the estimated useful life of the individual assets. Depreciation begins when the asset is ready for its intended use. For tax purposes, accelerated depreciation methods are used as allowed by tax laws.
|
•
|
For finite-lived intangible assets, such as Developed Technology Rights, and for other long-lived assets, such as property, plant and equipment, whenever impairment indicators are present, we calculate the undiscounted value of the projected cash flows associated with the asset, or asset group, and compare this estimated amount to the carrying amount. If the carrying amount is found to be greater, we record an impairment loss for the excess of book value over fair value. In addition, in all cases of an impairment review, we re-evaluate the remaining useful lives of the assets and modify them, as appropriate.
|
•
|
For indefinite-lived intangible assets, such as Brands and IPR&D assets, when necessary, we determine the fair value of the asset and record an impairment loss, if any, for the excess of book value over fair value. In addition, in all cases of an impairment review other than for IPR&D assets, we re-evaluate whether continuing to characterize the asset as indefinite-lived is appropriate.
|
•
|
For goodwill, when necessary, we determine the fair value of each reporting unit and compare that value to its book value. If the carrying amount is found to be greater, we then determine the implied fair value of goodwill by subtracting the fair value of all the identifiable net assets other than goodwill from the fair value of the reporting unit and record an impairment loss, if any, for the excess of the book value of goodwill over the implied fair value.
|
2012 Financial Report
|
|
61
|
|
|
|
|
62
|
|
2012 Financial Report
|
|
|
|
|
2012 Financial Report
|
|
63
|
|
|
|
|
64
|
|
2012 Financial Report
|
|
|
|
|
(a)
|
Goodwill recorded as of the acquisition date totaled
$720 million
for our
three
biopharmaceutical operating segments and
$45 million
for our Animal Health operating segment. (Since the acquisition of King, we have revised our operating segments. See
Note 18A. Segment, Geographic and Other Revenue Information: Segment Information.
)
|
•
|
the expected synergies and other benefits that we believed would result from combining the operations of King with the operations of Pfizer;
|
•
|
any intangible assets that did not qualify for separate recognition, as well as future, yet unidentified projects and products; and
|
•
|
the value of the going-concern element of King’s existing businesses (the higher rate of return on the assembled collection of net assets versus if Pfizer had acquired all of the net assets separately).
|
The following table provides supplemental pro forma information:
|
||||||||
|
|
Unaudited Pro Forma
Consolidated Results
(a)
|
||||||
|
|
Year Ended December 31,
|
||||||
(MILLIONS OF DOLLARS, EXCEPT PER SHARE DATA)
|
|
2011
|
|
|
2010
|
|
||
Revenues
|
|
$
|
65,368
|
|
|
$
|
66,540
|
|
Net income attributable to Pfizer Inc.
|
|
10,228
|
|
|
8,013
|
|
||
Diluted earnings per share attributable to Pfizer Inc. common shareholders
|
|
1.30
|
|
|
0.99
|
|
(a)
|
The pro forma information for December 31, 2011 and 2010 assumes that the acquisition of King occurred on January 1, 2010.
|
2012 Financial Report
|
|
65
|
|
|
|
|
•
|
Elimination of King's historical intangible asset amortization expense (approximately
$6 million
in 2011 and
$116 million
in 2010).
|
•
|
Additional amortization expense (approximately
$15 million
in 2011 and
$190 million
in 2010) related to the fair value of identifiable intangible assets acquired.
|
•
|
Additional depreciation expense (approximately
$3 million
in 2011 and
$35 million
in 2010) related to the fair value adjustment to property, plant and equipment acquired.
|
•
|
Adjustment related to the fair value adjustments to acquisition-date inventory estimated to have been sold (elimination of
$160 million
charge in 2011 and addition of
$160 million
charge in 2010).
|
•
|
Adjustment for acquisition-related costs directly attributable to the acquisition (elimination of
$224 million
of charges in 2011 and addition of
$224 million
of charges in 2010, reflecting charges incurred by both King and Pfizer).
|
•
|
our former Nutrition operating segment and certain prenatal vitamins previously commercialized by the Pfizer Consumer Healthcare operating segment; and
|
•
|
other associated amounts, such as direct manufacturing costs, enabling support functions and other costs not charged to the business, purchase-accounting impacts, acquisition-related costs, impairment charges, restructuring charges and implementation costs associated with our cost reduction/productivity initiatives, all of which are reported outside our operating segment results.
|
66
|
|
2012 Financial Report
|
|
|
|
|
The following table provides the components of
Discontinued operations—net of tax
:
|
||||||||||||
|
|
Year Ended December 31,
(a)
|
||||||||||
(MILLIONS OF DOLLARS)
|
|
2012
|
|
|
2011
|
|
|
2010
|
|
|||
Revenues
|
|
$
|
2,258
|
|
|
$
|
2,673
|
|
|
$
|
2,643
|
|
Pre-tax income/(loss) from discontinued operations
|
|
414
|
|
|
487
|
|
|
(50
|
)
|
|||
Provision/(benefit) for taxes on income
(b)
|
|
117
|
|
|
137
|
|
|
(31
|
)
|
|||
Income/(loss) from discontinued operations––net of tax
|
|
297
|
|
|
350
|
|
|
(19
|
)
|
|||
Pre-tax gain/(loss) on sale of discontinued operations
|
|
7,123
|
|
|
1,688
|
|
|
(11
|
)
|
|||
Provision for taxes on income
(c)
|
|
2,340
|
|
|
384
|
|
|
—
|
|
|||
Gain/(loss) on sale of discontinued operations––net of tax
|
|
4,783
|
|
|
1,304
|
|
|
(11
|
)
|
|||
Discontinued operations––net of tax
|
|
$
|
5,080
|
|
|
$
|
1,654
|
|
|
$
|
(30
|
)
|
(a)
|
Includes the Nutrition business for all periods presented (through November 30, 2012) and the Capsugel business for
2011
(through August 1, 2011) and
2010
only. The net loss in 2010 includes the impairment of an indefinite-lived Brand intangible asset in the Nutrition business of approximately
$385 million
(pre-tax).
|
(b)
|
Includes a deferred tax expense of
$24 million
for
2012
, a deferred tax benefit of
$43 million
for
2011
, and a deferred tax benefit of
$156 million
for
2010
. These deferred tax provisions include deferred taxes related to investments in certain foreign subsidiaries resulting from our intention not to hold these subsidiaries indefinitely.
|
(c)
|
Includes a deferred tax expense of
$1.4 billion
for
2012
and
$190 million
for
2011
. These deferred tax provisions include deferred tax expense of
$2.2 billion
for
2012
and
$190 million
for
2011
on certain current-year funds earned outside the U.S. that will not be indefinitely reinvested overseas.
|
2012 Financial Report
|
|
67
|
|
|
|
|
(a)
|
Represents sales to our partners of products manufactured by us.
|
(b)
|
Substantially all relate to amounts earned from our partners under co-promotion agreements.
|
(c)
|
Primarily relates to royalties earned by our partners and cost of sales associated with inventory purchased from our partners.
|
(d)
|
Represents net reimbursements to our partners for selling, informational and administrative expenses incurred.
|
(e)
|
Primarily related to net reimbursements, as well as upfront payments and pre-approval milestone payments earned by our partners. The upfront and milestone payments were as follows:
$44 million
in 2012,
$210 million
in 2011 and
$147 million
in 2010.
|
68
|
|
2012 Financial Report
|
|
|
|
|
•
|
In connection with acquisition activity, we typically incur costs associated with executing the transactions, integrating the acquired operations (which may include expenditures for consulting and the integration of systems and processes), and restructuring the combined company (which may include charges related to employees, assets and activities that will not continue in the combined company); and
|
•
|
In connection with our cost-reduction and productivity initiatives, we typically incur costs and charges associated with site closings and other facility rationalization actions, workforce reductions and the expansion of shared services, including the development of global systems.
|
(a)
|
Transaction costs represent external costs directly related to acquired businesses and primarily include expenditures for banking, legal, accounting and other similar services.
|
(b)
|
I
ntegration costs represent external, incremental costs directly related to integrating acquired businesses, and primarily include expenditures for consulting and the integration of systems and processes.
|
(c)
|
From the beginning of our cost-reduction and transformation initiatives in
2005
through
December 31, 2012
,
Employee termination costs
represent the expected reduction of the workforce by approximately
62,200
employees, mainly in manufacturing, sales and research, of which approximately
51,700
employees have been terminated as of
December 31, 2012
. In
2012
, substantially all employee termination costs represent additional costs with respect to approximately
4,800
employees.
|
•
|
Primary Care operating segment (
$295 million
), Specialty Care and Oncology operating segment (
$175 million
), Established Products and Emerging Markets operating segment (
$125 million
), Animal Health operating segment (
$59 million
), Consumer Healthcare operating segment (
$45 million
), research and development operations (
$6 million
income), manufacturing operations (
$265 million
) and Corporate (
$516 million
).
|
2012 Financial Report
|
|
69
|
|
|
|
|
•
|
Primary Care operating segment (
$593 million
), Specialty Care and Oncology operating segment (
$220 million
), Established Products and Emerging Markets operating segment (
$110 million
), Animal Health operating segment (
$45 million
), Consumer Healthcare operating segment (
$8 million
), research and development operations (
$490 million
), manufacturing operations (
$287 million
) and Corporate (
$422 million
).
|
•
|
Primary Care operating segment (
$71 million
), Specialty Care and Oncology operating segment (
$197 million
), Established Products and Emerging Markets operating segment (
$43 million
), Animal Health operating segment (
$34 million
), Consumer Healthcare operating segment (
$12 million
), research and development operations (
$297 million
), manufacturing operations (
$1.1 billion
) and Corporate (
$350 million
).
|
(d)
|
Additional depreciation––asset restructuring represents the impact of changes in the estimated useful lives of assets involved in restructuring actions.
|
(e)
|
Implementation costs represent external, incremental costs directly related to implementing our non-acquisition-related cost-reduction/productivity initiatives.
|
(a)
|
Includes adjustments for foreign currency translation.
|
(b)
|
Included in
Other current liabilities
(
$1.6 billion
) and
Other noncurrent liabilities
(
$930 million
).
|
(c)
|
Included in
Other current liabilities
(
$1.2 billion
) and
Other noncurrent liabilities
(
$731 million
).
|
(a)
|
The fair value amount is presented as of the date of impairment, as these assets are not measured at fair value on a recurring basis. See also
Note 1E.
Basis of Presentation and Significant Accounting Policies: Fair Value
.
|
(b)
|
Reflects property, plant and equipment and other long-lived held-for-sale assets written down to their fair value of
$139 million
, less costs to sell of
$3 million
(a net of
$136 million
), in
2012
. The impairment charges of
$210 million
are included in
Restructuring charges and certain acquisition-related costs
. Fair value is determined primarily using a market approach, with various inputs, such as recent sales transactions.
|
70
|
|
2012 Financial Report
|
|
|
|
|
The following table provides components of
Other deductions––net
:
|
||||||||||||
|
|
Year Ended December 31,
|
||||||||||
(MILLIONS OF DOLLARS)
|
|
2012
|
|
|
2011
|
|
|
2010
|
|
|||
Interest income
(a)
|
|
$
|
(383
|
)
|
|
$
|
(456
|
)
|
|
$
|
(400
|
)
|
Interest expense
(a)
|
|
1,524
|
|
|
1,681
|
|
|
1,797
|
|
|||
Net interest expense
|
|
1,141
|
|
|
1,225
|
|
|
1,397
|
|
|||
Royalty-related income
|
|
(469
|
)
|
|
(569
|
)
|
|
(579
|
)
|
|||
Net gain on asset disposals
(b)
|
|
(52
|
)
|
|
(15
|
)
|
|
(243
|
)
|
|||
Certain legal matters, net
(c)
|
|
2,220
|
|
|
784
|
|
|
1,723
|
|
|||
Certain asset impairment charges
(d)
|
|
927
|
|
|
902
|
|
|
1,790
|
|
|||
Costs associated with the separation of Zoetis
(e)
|
|
125
|
|
|
33
|
|
|
—
|
|
|||
Other, net
|
|
139
|
|
|
139
|
|
|
(147
|
)
|
|||
Other deductions––net
|
|
$
|
4,031
|
|
|
$
|
2,499
|
|
|
$
|
3,941
|
|
(a)
|
2012 v. 2011
––
Interest income decreased due to lower average cash balances and lower interest rates earned on investments. Interest expense decreased due to lower debt balances and the effective conversion of some fixed-rate liabilities to floating-rate liabilities. 2011 v. 2010
––
Interest income increased due to higher cash balances and higher interest rates earned on investments. Interest expense decreased due to lower long- and short-term debt balances and the effective conversion of some fixed-rate liabilities to floating rate liabilities. Capitalized interest expense totaled $
41 million
in
2012
, $
50 million
in
2011
and $
36 million
in
2010
.
|
(b)
|
Net gains include realized gains and losses on sales of available-for-sale securities: in
2012
,
2011
and
2010
, gross realized gains were $
39 million
, $
79 million
and $
153 million
, respectively. Gross realized losses were $
6 million
in
2012
, $
73 million
in
2011
and $
12 million
in
2010
. Proceeds, primarily from the sale of available-for-sale securities, were $
19 billion
in
2012
, $
10.2 billion
in
2011
and $
5.3 billion
in
2010
. In 2010, also includes gains on sales of certain investments and businesses.
|
(c)
|
In
2012
, primarily includes a
$491 million
charge resulting from an agreement-in-principle with the U.S. Department of Justice to resolve an investigation into Wyeth's historical promotional practices in connection with Rapamune, a
$450 million
settlement of a lawsuit by Brigham Young University related to Celebrex, and charges related to hormone-replacement therapy litigation and Chantix litigation. In
2011
, primarily includes charges related to hormone-replacement therapy litigation. In
2010
, includes a
$1.3 billion
charge for asbestos litigation related to our wholly owned subsidiary, Quigley Company, Inc. (See
Note 17. Commitments and Contingencies.
)
|
(d)
|
In
2012
, includes intangible asset impairment charges of
$872 million
, reflecting (i)
$393 million
of IPR&D assets, primarily related to compounds that targeted autoimmune and inflammatory diseases (full write-off) and, to a lesser extent, compounds related to pain treatment; (ii)
$175 million
related to our Consumer Healthcare indefinite-lived brand assets, primarily Robitussin, a cough suppressant; (iii)
$279 million
related to Developed Technology Rights, a charge comprised of impairments of various products, none of which individually exceeded
$45 million
; and (iv)
$25 million
of finite-lived brands. The intangible asset impairment charges for
2012
reflect, among other things, the impact of new scientific findings, updated commercial forecasts, changes in pricing, an increased competitive environment, litigation uncertainties regarding intellectual property and declining gross margins. The impairment charges in
2012
are associated with the following: Worldwide Research and Development (
$303 million
); Consumer Healthcare (
$200 million
); Primary Care (
$135 million
); Established Products (
$83 million
); Specialty Care (
$56 million
); Emerging Markets (
$56 million
) and Animal Health (
$39 million
). In addition, in
2012
, also includes charges of approximately
$55 million
for certain investments. These investment impairment charges reflect the difficult global economic environment.
|
(e)
|
Costs incurred in connection with the initial public offering of a
19.8%
ownership stake in Zoetis. Includes expenditures for banking, legal, accounting and similar services. (See
Note 19A. Subsequent Events: Zoetis Debt Offering and Initial Public Offering.)
|
2012 Financial Report
|
|
71
|
|
|
|
|
(a)
|
The fair value amount is presented as of the date of impairment, as these assets are not measured at fair value on a recurring basis. See also
Note 1E.
Basis of Presentation and Significant Accounting Policies: Fair Value
.
|
(b)
|
Reflects intangible assets written down to their estimated fair value of
$1.1 billion
in
2012
. The impairment charges of
$872 million
are included in
Other deductions––net.
Fair value is determined using the income approach, specifically the multi-period excess earnings method, also known as the discounted cash flow method. We start with a forecast of all the expected net cash flows associated with the asset, which includes the application of a terminal value for indefinite-lived assets, and then we apply an asset-specific discount rate to arrive at a net present value amount. Some of the more significant estimates and assumptions inherent in this approach include: the amount and timing of the projected net cash flows, which includes the expected impact of competitive, legal and/or regulatory forces on the projections and the impact of technological risk associated with IPR&D assets, as well as the selection of a long-term growth rate; the discount rate, which seeks to reflect the various risks inherent in the projected cash flows; and the tax rate, which seeks to incorporate the geographic diversity of the projected cash flows.
|
The following table provides the components of
Income from continuing operations before provision for taxes on income
:
|
||||||||||||
|
|
Year Ended December 31,
|
||||||||||
(MILLIONS OF DOLLARS)
|
|
2012
|
|
|
2011
|
|
|
2010
|
|
|||
United States
|
|
$
|
(4,732
|
)
|
|
$
|
(2,210
|
)
|
|
$
|
(2,256
|
)
|
International
|
|
16,812
|
|
|
14,514
|
|
|
11,727
|
|
|||
Income from continuing operations before provision for taxes on income
(
a), (b)
|
|
$
|
12,080
|
|
|
$
|
12,304
|
|
|
$
|
9,471
|
|
(a)
|
2012
v.
2011
––
The increase in the domestic loss was primarily due to the reduction in revenues resulting from the loss of exclusivity of Lipitor, Geodon and certain other biopharmaceutical products; certain legal settlements and related charges, primarily associated with Rapamune, Celebrex, hormone-replacement therapy and Chantix; higher costs associated with the separation of Zoetis; and the payment to AstraZeneca to obtain the exclusive global over-the-counter rights to Nexium, partially offset by lower acquisition-related costs. The increase in international income was due to lower purchase accounting costs, lower acquisition-related costs, and lower charges related to cost-reduction and productivity initiatives, partially offset by the reduction in revenues resulting from the loss of exclusivity of Lipitor, Geodon and certain other biopharmaceutical products.
|
(b)
|
2011
v.
2010
––
The decrease in the domestic loss was primarily due to the non-recurrence of a charge of
$1.3 billion
(pre-tax) in 2010 for asbestos litigation related to our wholly owned subsidiary, Quigley Company, Inc., partially offset by a reduction in revenues due to the loss of exclusivity for several biopharmaceutical products and the impact of the U.S. Healthcare Legislation. The increase in international income was due to the favorable impact of foreign exchange, lower impairment charges, as well as increased revenues from biopharmaceutical products, such as the Prevnar/Prevenar family, Enbrel and Celebrex.
|
72
|
|
2012 Financial Report
|
|
|
|
|
•
|
U.S. tax expense of approximately
$2.2 billion
as a result of providing U.S. deferred income taxes on certain current-year funds earned outside the U.S. that will not be indefinitely reinvested overseas (see
Note 5C. Tax Matters: Deferred Taxes
);
|
•
|
U.S. tax benefits of approximately
$1.1 billion
, representing tax and interest, resulting from a multi-year settlement with the IRS with respect to audits of the Pfizer Inc. tax returns for the years 2006 through 2008, and international tax benefits of approximately
$310 million
, representing tax and interest, resulting from the resolution of certain tax positions pertaining to prior years with various foreign tax authorities, and from the expiration of certain statutes of limitations;
|
•
|
The non-deductibility of a
$336 million
fee payable to the federal government as a result of the U.S. Healthcare Legislation;
|
•
|
The non-deductibility of the
$491 million
legal charge associated with Rapamune litigation (see also
Note 4. Other Deductions
––
Net
); and
|
•
|
The expiration of the U.S. research and development tax credit on December 31, 2011.
|
•
|
U.S. tax expense of approximately $
2.1 billion
as a result of providing U.S. deferred income taxes on certain current-year funds earned outside the U.S. that will not be indefinitely reinvested overseas (see
Note 5C. Tax Matters: Deferred Taxes
);
|
•
|
International tax benefits of approximately
$267 million
, representing tax and interest, resulting from the resolution of certain prior-period tax positions with various foreign tax authorities and from the expiration of certain statutes of limitations, and U.S. tax benefits of approximately
$80 million
, representing tax and interest, resulting from the settlement of certain audits with the IRS; and
|
•
|
The non-deductibility of a
$248 million
fee payable to the federal government as a result of the U.S. Healthcare Legislation.
|
•
|
U.S. tax expense of approximately
$2.5 billion
as a result of providing U.S. deferred income taxes on certain current-year funds earned outside the U.S. that will not be indefinitely reinvested overseas (see
Note 5C. Tax Matters: Deferred Taxes
);
|
•
|
U.S. tax benefits of approximately
$2.0 billion
, representing tax and interest, resulting from a multi-year audit settlement with the IRS, and international tax benefits of approximately
$460 million
, representing tax and interest, resulting from the resolution of certain prior-period tax positions with various foreign tax authorities, and from the expiration of certain statutes of limitations; and
|
•
|
The write-off of approximately
$270 million
of deferred tax assets related to the Medicare Part D subsidy for retiree prescription drug coverage, resulting from the provisions of the U.S. Healthcare Legislation enacted in March 2010 concerning the tax treatment of that subsidy effective for tax years beginning after December 31, 2012.
|
The reconciliation of the U.S. statutory income tax rate to our effective tax rate for
Income from continuing operations
follows:
|
|||||||||
|
|
Year Ended December 31,
|
|||||||
|
|
2012
|
|
|
2011
|
|
|
2010
|
|
U.S. statutory income tax rate
|
|
35.0
|
%
|
|
35.0
|
%
|
|
35.0
|
%
|
Taxation of non-U.S. operations
(a), (b), (c)
|
|
(3.0
|
)
|
|
(3.1
|
)
|
|
2.5
|
|
Tax settlements and resolution of certain tax positions
(d)
|
|
(12.0
|
)
|
|
(2.8
|
)
|
|
(26.3
|
)
|
U.S. Healthcare Legislation
(d)
|
|
1.0
|
|
|
0.7
|
|
|
2.8
|
|
U.S. research and development tax credit and manufacturing deduction
(d)
|
|
(0.3
|
)
|
|
(0.9
|
)
|
|
(2.3
|
)
|
Certain legal settlements and charges
(d)
|
|
1.4
|
|
|
—
|
|
|
0.4
|
|
Acquired IPR&D
|
|
—
|
|
|
—
|
|
|
0.5
|
|
Wyeth acquisition-related costs
|
|
—
|
|
|
—
|
|
|
0.5
|
|
Sales of biopharmaceutical companies
|
|
—
|
|
|
0.2
|
|
|
—
|
|
All other––net
|
|
(0.9
|
)
|
|
2.7
|
|
|
(0.9
|
)
|
Effective tax rate for income from continuing operations
|
|
21.2
|
%
|
|
31.8
|
%
|
|
12.2
|
%
|
(a)
|
For taxation of non-U.S. operations, this rate impact reflects the income tax rates and relative earnings in the locations where we do business outside the United States, together with the cost of repatriation decisions, as well as changes in uncertain tax positions not included in the reconciling item called “Tax settlements and resolution of certain tax positions”. Specifically: (i) the jurisdictional location of earnings is a significant component of our effective tax rate each year as tax rates outside the U.S. are generally lower than the U.S. statutory income tax rate, and the rate impact of this component is influenced by the specific location of non-U.S. earnings and the level of such earnings as compared to our total earnings; (ii) the cost of repatriation decisions, and other U.S. tax implications of our foreign operations, is a significant component of our effective tax rate each year and generally offsets some of the reduction to our effective tax rate each year resulting from the jurisdictional location of earnings; and (iii) the impact of changes in uncertain tax positions not included in the reconciling item called “Tax settlements and resolution of certain tax positions” is a component of our effective tax rate each year that can result in either an increase or decrease to our effective tax rate. The jurisdictional mix of earnings, which includes the impact of the location of earnings as well as repatriation costs, can vary as a result of the repatriation decisions, as a result of operating fluctuations in the normal course of business and as a result of the extent and location of other income and expense items, such as restructuring charges, asset impairments and gains and losses on strategic business decisions. See also
Note 5A. Tax Matters: Taxes on Income from Continuing Operations
for the components of pre-tax income and
Provision for taxes on income,
which is based on the location of the taxing authorities, and for information about settlements and other items impacting
Provision for taxes on income
.
|
2012 Financial Report
|
|
73
|
|
|
|
|
(c)
|
2010
––
The rate impact in 2010 also includes the adjustments to increase our uncertain tax positions based on tax positions taken during a prior period (see also the reconciliation of our gross unrecognized tax benefits for 2010 in
Note 5D. Tax Matters: Tax Contingencies
, where substantially all of the prior period increases relate to non-U.S. jurisdictions). Without this impact, the rate impact in 2010 would have been approximately a
2.1%
reduction of the U.S. statutory income tax rate.
|
(d)
|
For a discussion about tax settlements and resolution of certain tax positions, the impact of U.S. Healthcare Legislation, the U.S. research and development tax credit and the impact of certain legal settlements and charges, see
Note 5A. Tax Matters: Taxes on Income from Continuing Operations
. We received no benefit from the U.S. research and development tax credit in 2012 as the credit expired on December 31, 2011 and was not extended until January 2013.
|
The components of our deferred tax assets and liabilities, shown before jurisdictional netting, follow:
|
||||||||||||||||
|
|
2012 Deferred Tax
|
|
2011 Deferred Tax
|
||||||||||||
(MILLIONS OF DOLLARS)
|
|
Assets
|
|
(Liabilities)
|
|
Assets
|
|
(Liabilities)
|
||||||||
Prepaid/deferred items
|
|
$
|
1,817
|
|
|
$
|
(119
|
)
|
|
$
|
1,659
|
|
|
$
|
(211
|
)
|
Inventories
|
|
330
|
|
|
(198
|
)
|
|
324
|
|
|
(52
|
)
|
||||
Intangible assets
|
|
1,649
|
|
|
(14,187
|
)
|
|
1,713
|
|
|
(15,301
|
)
|
||||
Property, plant and equipment
|
|
508
|
|
|
(1,485
|
)
|
|
226
|
|
|
(1,311
|
)
|
||||
Employee benefits
|
|
5,042
|
|
|
(391
|
)
|
|
4,280
|
|
|
(524
|
)
|
||||
Restructurings and other charges
|
|
784
|
|
|
(334
|
)
|
|
553
|
|
|
(95
|
)
|
||||
Legal and product liability reserves
|
|
1,888
|
|
|
—
|
|
|
1,812
|
|
|
—
|
|
||||
Net operating loss/credit carryforwards
|
|
3,439
|
|
|
—
|
|
|
4,381
|
|
|
—
|
|
||||
Unremitted earnings
(c)
|
|
—
|
|
|
(16,042
|
)
|
|
—
|
|
|
(11,699
|
)
|
||||
State and local tax adjustments
|
|
385
|
|
|
—
|
|
|
476
|
|
|
—
|
|
||||
All other
|
|
1,259
|
|
|
(504
|
)
|
|
1,105
|
|
|
(121
|
)
|
||||
|
|
17,101
|
|
|
(33,260
|
)
|
|
16,529
|
|
|
(29,314
|
)
|
||||
Valuation allowances
|
|
(1,102
|
)
|
|
—
|
|
|
(1,201
|
)
|
|
—
|
|
||||
Total deferred taxes
|
|
$
|
15,999
|
|
|
$
|
(33,260
|
)
|
|
$
|
15,328
|
|
|
$
|
(29,314
|
)
|
Net deferred tax liability
(a), (b)
|
|
|
|
$
|
(17,261
|
)
|
|
|
|
$
|
(13,986
|
)
|
(a)
|
2012 v. 2011
––
The net deferred tax liability position increased, reflecting an increase in noncurrent deferred tax liabilities related to unremitted earnings, as well as a decrease in deferred tax assets related to net operating loss and credit carryforwards, partially offset by the reduction in noncurrent deferred tax liabilities resulting from the amortization of identifiable intangible assets and the increase in deferred tax assets related to employee benefits.
|
(b)
|
In
2012
, included in
Taxes and other current assets
(
$3.6 billion
),
Taxes and other noncurrent assets
(
$700 million
),
Other current liabilities
(
$11 million
) and
Noncurrent deferred tax liabilities
(
$21.6 billion
). In
2011
, included in
Taxes and other current assets
(
$4.0 billion
),
Taxes and other noncurrent assets
(
$1.2 billion
),
Other current liabilities
(
$350 million
) and
Noncurrent deferred tax liabilities
(
$18.9 billion
).
|
(c)
|
See
Note 5A. Tax Matters: Taxes on Income from Continuing Operations
and
Note 2B. Acquisitions, Divestitures, Collaborative Arrangements and Equity-Method Investments: Divestitures.
|
74
|
|
2012 Financial Report
|
|
|
|
|
•
|
Tax assets associated with uncertain tax positions primarily represent our estimate of the potential tax benefits in one tax jurisdiction that could result from the payment of income taxes in another tax jurisdiction. These potential benefits generally result from cooperative efforts among taxing authorities, as required by tax treaties to minimize double taxation, commonly referred to as the competent authority process. The recoverability of these assets, which we believe to be more likely than not, is dependent upon the actual payment of taxes in one tax jurisdiction and, in some cases, the successful petition for recovery in another tax jurisdiction. As of December 31, 2012 and 2011, we had approximately
$1.3 billion
and
$1.2 billion
, respectively, in assets associated with uncertain tax positions. In 2012, these amounts were included in
Taxes and other noncurrent assets
(
$887 million
) and
Noncurrent deferred tax liabilities
(
$446 million
). In 2011, these amounts were included in
Taxes and other noncurrent assets
.
|
•
|
Tax liabilities associated with uncertain tax positions represent unrecognized tax benefits, which arise when the estimated benefit recorded in our financial statements differs from the amounts taken or expected to be taken in a tax return because of the uncertainties described above. These unrecognized tax benefits relate primarily to issues common among multinational corporations. Substantially all of these unrecognized tax benefits, if recognized, would impact our effective income tax rate.
|
(a)
|
The amount in 2011 primarily relates to the acquisition of King. See also
Note 2A. Acquisitions, Divestitures, Collaborative Arrangements and Equity-Method Investments: Acquisitions.
|
(b)
|
Primarily relates to the sale of our Nutrition business. See also
Note 2B. Acquisitions, Divestitures, Collaborative Arrangements and Equity-Method Investments: Divestitures.
|
(c)
|
Primarily included in
Provision for taxes on income.
|
(d)
|
Primarily related to effectively settling certain issues with the U.S. and foreign tax authorities. See also
Note 5A. Tax Matters: Taxes on Income from Continuing Operations.
|
(e)
|
Includes decreases as a result of a lapse of applicable statutes of limitations.
|
(f)
|
In 2012, included in
Income taxes payable
(
$36 million
),
Taxes and other current assets
(
$30 million
),
Taxes and other noncurrent assets
(
$169 million
),
Noncurrent deferred tax liabilities
(
$231 million
) and
Other taxes payable
(
$5.8 billion
). In 2011, included in
Income taxes payable
(
$357 million
),
Taxes and other current assets
(
$11 million
),
Taxes and other noncurrent assets
(
$225 million
),
Noncurrent deferred tax liabilities
(
$677 million
) and
Other taxes payable
(
$6.0 billion
).
|
•
|
Interest related to our unrecognized tax benefits is recorded in accordance with the laws of each jurisdiction and is recorded in
Provision for taxes on income
in our consolidated statements of income. In
2012
, we recorded net interest income of
$120 million
primarily as a result of settling certain issues with the U.S. and various foreign tax authorities; in
2011
, we recorded net interest expense of
$203 million
; and in
2010
, we recorded net interest income of
$545 million
, primarily as a result of settling certain issues with the U.S. and various foreign tax authorities. Gross accrued interest totaled
$766 million
as of
December 31, 2012
(reflecting a decrease of approximately
$63 million
as a result of cash payments) and
$951 million
as of
December 31, 2011
(reflecting a decrease of approximately
$203 million
as a result of cash payments). In
2012
, these amounts were included in
Taxes and other current assets
(
$14 million
) and
Other taxes payable
(
$752 million
). In
|
2012 Financial Report
|
|
75
|
|
|
|
|
•
|
With respect to Pfizer Inc., tax years 2009-2010 are currently under audit. Tax years 2011-2012 are not under audit. All other tax years are closed.
|
•
|
With respect to Wyeth, tax years 2006 through the Wyeth acquisition date (October 15, 2009) are currently under audit. All other tax years are closed.
|
•
|
With respect to King, the audit for tax year 2008 has been effectively settled, and for Alpharma Inc. (a subsidiary of King), tax years 2005-2007 have been effectively settled. For King, tax years 2009 through the date of acquisition (January 31, 2011) are open, but not under audit. All other tax years are closed. The open tax years and audits for King and its subsidiaries are not material to Pfizer Inc.
|
(a)
|
Taxes are not provided for foreign currency translation adjustments relating to investments in international subsidiaries that will be held indefinitely.
|
76
|
|
2012 Financial Report
|
|
|
|
|
The following table provides the changes, net of tax, in
Accumulated other comprehensive income/(loss)
:
|
||||||||||||||||||||||||
|
|
Net Unrealized Gain/(Losses)
|
|
Benefit Plans
|
|
|
||||||||||||||||||
(MILLIONS OF DOLLARS)
|
|
Currency Translation Adjustment And Other
|
|
|
Derivative Financial Instruments
|
|
|
Available-For-Sale Securities
|
|
|
Actuarial Gains/(Losses)
|
|
|
Prior Service (Costs)/ Credits And Other
|
|
|
Accumulated Other Comprehensive Income/(Loss)
|
|
||||||
Balance, January 1, 2010
|
|
$
|
3,550
|
|
|
$
|
6
|
|
|
$
|
269
|
|
|
$
|
(3,367
|
)
|
|
$
|
94
|
|
|
$
|
552
|
|
Other comprehensive income/(loss)
(a)
|
|
(3,381
|
)
|
|
(214
|
)
|
|
(112
|
)
|
|
(580
|
)
|
|
295
|
|
|
(3,992
|
)
|
||||||
Balance, December 31, 2010
|
|
169
|
|
|
(208
|
)
|
|
157
|
|
|
(3,947
|
)
|
|
389
|
|
|
(3,440
|
)
|
||||||
Other comprehensive income/(loss)
(a)
|
|
775
|
|
|
(153
|
)
|
|
(111
|
)
|
|
(1,173
|
)
|
|
(27
|
)
|
|
(689
|
)
|
||||||
Balance, December 31, 2011
|
|
944
|
|
|
(361
|
)
|
|
46
|
|
|
(5,120
|
)
|
|
362
|
|
|
(4,129
|
)
|
||||||
Other comprehensive income/(loss)
(a)
|
|
(1,121
|
)
|
|
273
|
|
|
117
|
|
|
(990
|
)
|
|
(103
|
)
|
|
(1,824
|
)
|
||||||
Balance, December 31, 2012
|
|
$
|
(177
|
)
|
|
$
|
(88
|
)
|
|
$
|
163
|
|
|
$
|
(6,110
|
)
|
|
$
|
259
|
|
|
$
|
(5,953
|
)
|
(a)
|
Amounts do not include foreign currency translation adjustments attributable to noncontrolling interests of
$7 million
loss in
2012
,
$45 million
loss in
2011
and
|
2012 Financial Report
|
|
77
|
|
|
|
|
The following table provides additional information about certain of our financial assets and liabilities:
|
||||||||
|
|
As of December 31,
|
||||||
(MILLIONS OF DOLLARS)
|
|
2012
|
|
|
2011
|
|
||
Selected financial assets measured at fair value on a recurring basis
(a)
|
|
|
|
|
||||
Trading securities
(b)
|
|
$
|
142
|
|
|
$
|
154
|
|
Available-for-sale debt securities
(c)
|
|
32,584
|
|
|
29,179
|
|
||
Available-for-sale money market funds
(d)
|
|
1,727
|
|
|
1,727
|
|
||
Available-for-sale equity securities, excluding money market funds
(c)
|
|
263
|
|
|
317
|
|
||
Derivative financial instruments in receivable positions:
(e)
|
|
|
|
|
|
|
||
Interest rate swaps
|
|
1,036
|
|
|
1,033
|
|
||
Foreign currency forward-exchange contracts
|
|
152
|
|
|
349
|
|
||
Foreign currency swaps
|
|
194
|
|
|
17
|
|
||
|
|
36,098
|
|
|
32,776
|
|
||
Other selected financial assets
|
|
|
|
|
|
|
||
Held-to-maturity debt securities, carried at amortized cost
(c), (f)
|
|
1,513
|
|
|
1,587
|
|
||
Private equity securities, carried at equity method or at cost
(f), (g)
|
|
1,239
|
|
|
1,020
|
|
||
|
|
2,752
|
|
|
2,607
|
|
||
Total selected financial assets
|
|
$
|
38,850
|
|
|
$
|
35,383
|
|
Financial liabilities measured at fair value on a recurring basis
(a)
|
|
|
|
|
|
|
||
Derivative financial instruments in a liability position:
(h)
|
|
|
|
|
|
|
||
Foreign currency swaps
|
|
$
|
428
|
|
|
$
|
1,396
|
|
Foreign currency forward-exchange contracts
|
|
243
|
|
|
355
|
|
||
Interest rate swaps
|
|
33
|
|
|
14
|
|
||
|
|
704
|
|
|
1,765
|
|
||
Other financial liabilities
(i)
|
|
|
|
|
|
|
||
Short-term borrowings, carried at historical proceeds, as adjusted
(f)
|
|
6,424
|
|
|
4,016
|
|
||
Long-term debt, carried at historical proceeds, as adjusted
(j), (k)
|
|
31,036
|
|
|
34,926
|
|
||
|
|
37,460
|
|
|
38,942
|
|
||
Total selected financial liabilities
|
|
$
|
38,164
|
|
|
$
|
40,707
|
|
(a)
|
We use a market approach in valuing financial instruments on a recurring basis. See also
Note 1E.
Basis of Presentation and Significant Accounting Policies: Fair Value
. All of our financial assets and liabilities measured at fair value on a recurring basis use Level 2 inputs in the calculation of fair value, except less than
1%
that use Level 1 or Level 3 inputs.
|
(b)
|
Trading securities are held in trust for legacy business acquisition severance benefits.
|
(c)
|
Gross unrealized gains and losses are not significant.
|
(d)
|
Includes
$408 million
as of
December 31, 2012
and
$357 million
as of
December 31, 2011
of money market funds held in trust in connection with the asbestos litigation involving Quigley Company, Inc., a wholly owned subsidiary. As of
December 31, 2011
, this amount includes approximately
$625 million
of money market funds that were held in escrow to secure certain of Wyeth’s payment obligations under its 1999 Nationwide Class Action Settlement Agreement, which relates to litigation against Wyeth concerning its former weight-loss products, Redux and Pondimin. The amounts held in escrow at
December 31, 2011
were released from restriction during 2012 and classified as part of
Short-term investments.
|
(e)
|
Designated as hedging instruments, except for certain contracts used as offsets; namely, foreign currency forward-exchange contracts with fair values of
$102 million
as of
December 31, 2012
; and foreign currency forward-exchange contracts with fair values of
$169 million
and interest rate swaps with fair values of
$8 million
as of
December 31, 2011
.
|
(f)
|
The differences between the estimated fair values and carrying values of held to maturity debt securities, private equity securities at cost and short-term borrowings not measured at fair value on a recurring basis were not significant as of
December 31, 2012
or
December 31, 2011
. The fair value measurements of our held-to-maturity debt securities and our short-term borrowings are based on Level 2 inputs, using a market approach. The fair value measurements of our
priv
ate equity securities at cost are based on Level 3 inputs, using a market approach.
|
(g)
|
Our private equity securities represent investments in the life sciences sector.
|
(h)
|
Designated as hedging instruments, except for certain contracts used as offsets; namely, foreign currency forward-exchange contracts with fair values of
$141 million
and foreign currency swaps with fair values of
$129 million
as of
December 31, 2012
; and foreign currency forward-exchange contracts with fair values of
$141 million
and foreign currency swaps with fair values of
$123 million
as of
December 31, 2011
.
|
(i)
|
Some carrying amounts may include adjustments for discount or premium amortization or for the effect of interest rate swaps designated as hedges.
|
(j)
|
Includes foreign currency debt with fair values of
$809 million
as of
December 31, 2012
and
$919 million
as of
December 31, 2011
, which are used as hedging instruments.
|
78
|
|
2012 Financial Report
|
|
|
|
|
(k)
|
The fair value of our long-term debt (not including the current portion of long-term debt) is
$37.5 billion
as of
December 31, 2012
and
$40.1 billion
as of
December 31, 2011
. The fair value measurements for our long-term debt are based on Level 2 inputs, using a market approach.
|
•
|
Trading equity securities—quoted market prices.
|
•
|
Trading debt securities—observable market interest rates.
|
•
|
Available-for-sale debt securities—third-party matrix-pricing model that uses significant inputs derived from or corroborated by observable market data and credit-adjusted interest rate yield curves.
|
•
|
Available-for-sale money market funds—observable Net Asset Value prices.
|
•
|
Available-for-sale equity securities, excluding money market funds—third-party pricing services that principally use a composite of observable prices.
|
•
|
Derivative financial instruments (assets and liabilities)—third-party matrix-pricing model that uses significant inputs derived from or corroborated by observable market data. Where applicable, these models discount future cash flow amounts using market-based observable inputs, including interest rate yield curves, and forward and spot prices for currencies. The credit risk impact to our derivative financial instruments was not significant.
|
•
|
Held-to-maturity debt securities—third-party matrix-pricing model that uses significant inputs derived from or corroborated by observable market data and credit-adjusted interest rate yield curves.
|
•
|
Private equity securities, excluding equity-method investments—application of the implied volatility associated with an observable biotech index to the carrying amount of our portfolio.
|
•
|
Short-term borrowings and long-term debt—third-party matrix-pricing model that uses significant inputs derived from or corroborated by observable market data and our own credit rating.
|
(a)
|
As of
December 31, 2012
, derivative instruments at fair value include foreign currency forward-exchange contracts (
$152 million
) and foreign currency swaps (
$144 million
) and, as of
December 31, 2011
, include foreign currency forward-exchange contracts (
$349 million
) and interest rate swaps (
$8 million
).
|
(b)
|
As of
December 31, 2012
, derivative instruments at fair value include interest rate swaps (
$1 billion
) and foreign currency swaps (
$50 million
) and, as of
December 31, 2011
, include interest rate swaps (
$1 billion
) and foreign currency swaps (
$17 million
).
|
(c)
|
At
December 31, 2012
, derivative instruments at fair value include foreign currency forward-exchange contracts (
$243 million
) and foreign currency swaps (
$87 million
) and, as of
December 31, 2011
, include foreign currency forward-exchange contracts (
$355 million
) and foreign currency swaps (
$104 million
).
|
(d)
|
At
December 31, 2012
, derivative instruments at fair value include foreign currency swaps (
$341 million
) and interest rate swaps (
$33 million
) and, as of
December 31, 2011
, include foreign currency swaps (
$1.3 billion
) and interest rate swaps (
$14 million
).
|
2012 Financial Report
|
|
79
|
|
|
|
|
The following table provides the contractual maturities of the available-for-sale and held-to-maturity debt securities:
|
||||||||||||||||
|
|
Years
|
|
|
|
|||||||||||
|
|
|
|
|
Over 1
|
|
|
Over 5
|
|
|
December 31,
2012 |
|
||||
(MILLIONS OF DOLLARS)
|
|
Within 1
|
|
|
to 5
|
|
|
to 10
|
|
|
Total
|
|
||||
Available-for-sale debt securities
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Western European and other government debt
(a)
|
|
$
|
13,671
|
|
|
$
|
2,084
|
|
|
$
|
—
|
|
|
$
|
15,755
|
|
Corporate debt
(b)
|
|
1,085
|
|
|
4,468
|
|
|
1,741
|
|
|
7,294
|
|
||||
Reverse repurchase agreements
(c)
|
|
2,790
|
|
|
—
|
|
|
—
|
|
|
2,790
|
|
||||
Western European, Scandinavian and other government agency debt
(a)
|
|
2,348
|
|
|
415
|
|
|
—
|
|
|
2,763
|
|
||||
Federal Home Loan Mortgage Corporation and Federal National Mortgage Association asset-backed securities
|
|
—
|
|
|
2,492
|
|
|
43
|
|
|
2,535
|
|
||||
U.S. government debt
|
|
688
|
|
|
197
|
|
|
—
|
|
|
885
|
|
||||
Supranational debt
(a)
|
|
168
|
|
|
394
|
|
|
—
|
|
|
562
|
|
||||
Held-to-maturity debt securities
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Certificates of deposit and other
|
|
1,240
|
|
|
273
|
|
|
—
|
|
|
1,513
|
|
||||
Total debt securities
|
|
$
|
21,990
|
|
|
$
|
10,323
|
|
|
$
|
1,784
|
|
|
$
|
34,097
|
|
(a)
|
All issued by above-investment-grade governments, government agencies or supranational entities, as applicable.
|
(b)
|
Largely issued by above-investment-grade institutions in the financial services sector.
|
(c)
|
Involving U.S. government securities.
|
80
|
|
2012 Financial Report
|
|
|
|
|
The following table provides the components of our senior unsecured long-term debt:
|
||||||||||
|
|
|
|
As of December 31,
|
||||||
(MILLIONS OF DOLLARS)
|
|
Maturity Date
|
|
2012
|
|
|
2011
|
|
||
6.20%
(a)
|
|
March 2019
|
|
$
|
3,327
|
|
|
$
|
3,248
|
|
5.35%
(a)
|
|
March 2015
|
|
3,065
|
|
|
3,069
|
|
||
7.20%
(a)
|
|
March 2039
|
|
2,903
|
|
|
2,948
|
|
||
4.75% euro
(b)
|
|
June 2016
|
|
2,638
|
|
|
2,583
|
|
||
5.75% euro
(b)
|
|
June 2021
|
|
2,634
|
|
|
2,581
|
|
||
3.625% euro
(b), (c)
|
|
June 2013
|
|
—
|
|
|
2,392
|
|
||
6.50%
U.K
. pound
(b)
|
|
June 2038
|
|
2,407
|
|
|
2,306
|
|
||
5.95%
|
|
April 2037
|
|
2,086
|
|
|
2,088
|
|
||
5.50%
|
|
February 2014
|
|
1,832
|
|
|
1,893
|
|
||
5.50%
(d)
|
|
March 2013
|
|
—
|
|
|
1,564
|
|
||
4.55% euro
|
|
May 2017
|
|
1,384
|
|
|
1,325
|
|
||
4.75% euro
|
|
December 2014
|
|
1,284
|
|
|
1,266
|
|
||
5.50%
|
|
February 2016
|
|
1,048
|
|
|
1,061
|
|
||
Notes and other debt with a weighted-average interest rate of 6.51%
(e)
|
|
2021–2036
|
|
3,403
|
|
|
3,435
|
|
||
Notes and other debt with a weighted-average interest rate of 5.28%
(f)
|
|
2014–2018
|
|
2,254
|
|
|
2,302
|
|
||
Foreign currency notes and other foreign currency debt with a weighted-
average interest rate of 2.48%
(g)
|
|
2014-2016
|
|
771
|
|
|
865
|
|
||
Long-term debt
|
|
|
|
$
|
31,036
|
|
|
$
|
34,926
|
|
Current portion of long-term debt (not included above)
|
|
|
|
$
|
2,449
|
|
|
$
|
6
|
|
(a)
|
Instrument is callable by us at any time at the greater of
100%
of the principal amount or the sum of the present values of the remaining scheduled payments of principal and interest discounted at the U.S. Treasury rate plus
0.50%
plus, in each case, accrued and unpaid interest.
|
(b)
|
Instrument is callable by us at any time at the greater of
100%
of the principal amount or the sum of the present values of the remaining scheduled payments of principal and interest discounted at a comparable government bond rate plus
0.20%
plus, in each case, accrued and unpaid interest.
|
(c)
|
At December 31, 2012, the note has been reclassified to
Current portion of long-term debt
.
|
(d)
|
At December 31, 2012, the note had been called and is no longer outstanding.
|
(e)
|
Contains debt issuances with a weighted-average maturity of approximately
17 years
.
|
(f)
|
Contains debt issuances with a weighted-average maturity of approximately
4 years
.
|
(g)
|
Contains debt issuances with a weighted-average maturity of approximately
3 years
.
|
The following table provides the maturity schedule of our
Long-term debt
outstanding as of December 31, 2012:
|
||||||||||||||||||||||||
(MILLIONS OF DOLLARS)
|
|
2014
|
|
|
2015
|
|
|
2016
|
|
|
2017
|
|
|
After 2017
|
|
|
Total
|
|
||||||
Maturities
|
|
$
|
3,922
|
|
|
$
|
3,065
|
|
|
$
|
4,449
|
|
|
$
|
1,907
|
|
|
$
|
17,693
|
|
|
$
|
31,036
|
|
2012 Financial Report
|
|
81
|
|
|
|
|
•
|
We record in
Other comprehensive income/(loss)
the effective portion of the gains or losses on foreign currency forward-exchange contracts and foreign currency swaps that are designated as cash flow hedges and reclassify those amounts, as appropriate, into earnings in the same period or periods during which the hedged transaction affects earnings.
|
•
|
We recognize the gains and losses on forward-exchange contracts and foreign currency swaps that are used to offset the same foreign currency assets or liabilities immediately into earnings along with the earnings impact of the items they generally offset. These contracts essentially take the opposite currency position of that reflected in the month-end balance sheet to counterbalance the effect of any currency movement.
|
•
|
We recognize the gain and loss impact on foreign currency swaps designated as hedges of our net investments in earnings in three ways: over time—for the periodic net swap payments; immediately—to the extent of any change in the difference between the foreign exchange spot rate and forward rate; and upon sale or substantial liquidation of our net investments—to the extent of change in the foreign exchange spot rates.
|
•
|
We record in
Other comprehensive income/(loss)
the foreign exchange gains and losses related to foreign exchange-denominated debt designated as a hedge of our net investments in foreign subsidiaries and reclassify those amounts into earnings upon the sale or substantial liquidation of our net investments.
|
•
|
We recognize the gains and losses on interest rate swaps that are designated as fair value hedges in earnings upon the recognition of the change in fair value of the hedged risk. We recognize the offsetting earnings impact of fixed-rate debt attributable to the hedged risk also in earnings.
|
82
|
|
2012 Financial Report
|
|
|
|
|
(a)
|
OID = Other (income)/deductions—net,
included in
Other deductions—net
in the consolidated statements of income
.
OCL = Other comprehensive loss, included in the
consolidated statements of comprehensive income
.
|
(b)
|
Also includes gains and losses attributable to the hedged risk in fair value hedge relationships.
|
(c)
|
There was no significant ineffectiveness for any period presented.
|
(d)
|
Amounts presented represent the effective portion of the gain or loss. For derivative financial instruments in cash flow hedge relationships, the effective portion is included in
Other comprehensive loss––Unrealized holding gains/(losses) on derivative financial instruments
. For derivative financial instruments in net investment hedge relationships and for foreign currency debt designated as hedging instruments, the effective portion is included in
Other comprehensive loss––foreign currency translation adjustments.
|
2012 Financial Report
|
|
83
|
|
|
|
|
The following table provides the components of
Inventories
:
|
||||||||
|
|
As of December 31,
|
||||||
(MILLIONS OF DOLLARS)
|
|
2012
|
|
|
2011
|
|
||
Finished goods
|
|
$
|
2,529
|
|
|
$
|
2,311
|
|
Work-in-process
|
|
3,794
|
|
|
3,514
|
|
||
Raw materials and supplies
|
|
740
|
|
|
785
|
|
||
Inventories
|
|
$
|
7,063
|
|
|
$
|
6,610
|
|
Noncurrent inventories (not included above)
(a)
|
|
$
|
761
|
|
|
$
|
800
|
|
(a)
|
Included in
Taxes and other noncurrent assets
. There are no recoverability issues associated with these amounts.
|
The following table provides the components of
Property, plant and equipment
:
|
|||||||||||
|
|
Useful Lives
|
|
|
As of December 31,
|
||||||
(MILLIONS OF DOLLARS)
|
|
(Years)
|
|
|
2012
|
|
|
2011
|
|
||
Land
|
|
—
|
|
|
$
|
597
|
|
|
$
|
737
|
|
Buildings
|
|
33-50
|
|
|
11,420
|
|
|
12,089
|
|
||
Machinery and equipment
|
|
8-20
|
|
|
10,795
|
|
|
10,882
|
|
||
Furniture, fixtures and other
|
|
3-12 1/2
|
|
|
3,962
|
|
|
4,235
|
|
||
Construction in progress
|
|
—
|
|
|
1,108
|
|
|
1,294
|
|
||
|
|
|
|
27,882
|
|
|
29,237
|
|
|||
Less: Accumulated depreciation
|
|
|
|
13,421
|
|
|
13,316
|
|
|||
Property, plant and equipment
(a)
|
|
|
|
$
|
14,461
|
|
|
$
|
15,921
|
|
(a)
|
The decrease in total property, plant and equipment is primarily due to depreciation, disposals, impairments and the impact of foreign exchange, partially offset by capital additions.
|
The following table provides the components of and changes in the carrying amount of
Goodwill
:
|
|||||||||||||||||||||
(MILLIONS OF DOLLARS)
|
|
Primary
Care
|
|
|
Specialty
Care and
Oncology
|
|
|
Established
Products and
Emerging
Markets
|
|
|
Other Operating Segments
(a)
|
|
|
Total
|
|
||||||
Balance, January 1, 2011
|
|
$
|
6,050
|
|
—
|
|
$
|
16,659
|
|
|
$
|
18,274
|
|
|
$
|
2,449
|
|
|
$
|
43,432
|
|
Additions
(b)
|
|
129
|
|
|
300
|
|
|
321
|
|
|
55
|
|
|
805
|
|
||||||
Other
(c)
|
|
50
|
|
|
138
|
|
|
151
|
|
|
(7
|
)
|
|
332
|
|
||||||
Balance, December 31, 2011
|
|
6,229
|
|
|
17,097
|
|
|
18,746
|
|
|
2,497
|
|
|
44,569
|
|
||||||
Additions
(d)
|
|
—
|
|
|
—
|
|
|
91
|
|
|
514
|
|
|
605
|
|
||||||
Other
(c)
|
|
(77
|
)
|
|
(212
|
)
|
|
(234
|
)
|
|
21
|
|
|
(502
|
)
|
||||||
Balance, December 31, 2012
|
|
$
|
6,152
|
|
|
$
|
16,885
|
|
|
$
|
18,603
|
|
|
$
|
3,032
|
|
|
$
|
44,672
|
|
(a)
|
Reflects amounts associated with Animal Health and Consumer Healthcare.
|
(b)
|
Primarily reflects the acquisition of King (see
Note 2A. Acquisitions, Divestitures, Collaborative Arrangements and Equity-Method Investments: Acquisitions)
.
|
(c)
|
Primarily reflects the impact of foreign exchange.
|
(d)
|
Related to our acquisitions of Ferrosan, Alacer and NextWave (see
Note 2A. Acquisitions, Divestitures, Collaborative Arrangements and Equity-Method Investments: Acquisitions)
.
|
84
|
|
2012 Financial Report
|
|
|
|
|
The following table provides the components of
Identifiable intangible assets
:
|
||||||||||||||||||||||||
|
|
December 31, 2012
|
|
December 31, 2011
|
||||||||||||||||||||
(MILLIONS OF DOLLARS)
|
|
Gross
Carrying
Amount
|
|
|
Accumulated
Amortization
|
|
|
Identifiable
Intangible
Assets, less
Accumulated
Amortization
|
|
|
Gross
Carrying
Amount
|
|
|
Accumulated
Amortization
|
|
|
Identifiable
Intangible
Assets, less
Accumulated
Amortization
|
|
||||||
Finite-lived intangible assets
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Developed technology rights
|
|
$
|
73,112
|
|
|
$
|
(37,069
|
)
|
|
$
|
36,043
|
|
|
$
|
72,678
|
|
|
$
|
(31,922
|
)
|
|
$
|
40,756
|
|
Brands
|
|
1,873
|
|
|
(781
|
)
|
|
1,092
|
|
|
1,678
|
|
|
(687
|
)
|
|
991
|
|
||||||
License agreements and other
|
|
1,085
|
|
|
(793
|
)
|
|
292
|
|
|
1,048
|
|
|
(577
|
)
|
|
471
|
|
||||||
|
|
76,070
|
|
|
(38,643
|
)
|
|
37,427
|
|
|
75,404
|
|
|
(33,186
|
)
|
|
42,218
|
|
||||||
Indefinite-lived intangible assets
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
Brands
|
|
7,828
|
|
|
—
|
|
|
7,828
|
|
|
7,694
|
|
|
—
|
|
|
7,694
|
|
||||||
In-process research and development
|
|
688
|
|
|
—
|
|
|
688
|
|
|
1,200
|
|
|
—
|
|
|
1,200
|
|
||||||
Trademarks/Tradenames
|
|
70
|
|
|
—
|
|
|
70
|
|
|
72
|
|
|
—
|
|
|
72
|
|
||||||
|
|
8,586
|
|
|
—
|
|
|
8,586
|
|
|
8,966
|
|
|
—
|
|
|
8,966
|
|
||||||
Identifiable intangible assets
(a)
|
|
$
|
84,656
|
|
|
$
|
(38,643
|
)
|
|
$
|
46,013
|
|
|
$
|
84,370
|
|
|
$
|
(33,186
|
)
|
|
$
|
51,184
|
|
(a)
|
The decrease is primarily related to amortization, as well as impairment charges (see
Note 4. Other Deductions
—
Net
), partially offset by the assets acquired as part of the acquisitions of NextWave, Ferrosan and Alacer (see
Note 2A. Acquisitions, Divestitures, Collaborative Arrangements and Equity-Method Investments: Acquisitions
).
|
•
|
Developed Technology Rights: Specialty Care (
66%
); Established Products (
19%
); Primary Care (
13%
); Animal Health (
1%
); and Oncology (
1%
);
|
•
|
Brands, finite-lived: Consumer Healthcare (
64%
); Established Products (
24%
); and Animal Health (
12%
);
|
•
|
Brands, indefinite-lived: Consumer Healthcare (
66%
); and Established Products (
34%
); and
|
•
|
IPR&D: Worldwide Research and Development (
55%
); Established Products (
20%
); Primary Care (
12%
); Specialty Care (
10%
); and Animal Health (
3%
).
|
2012 Financial Report
|
|
85
|
|
|
|
|
The following table provides the annual amortization expense expected for the years 2013 through 2017:
|
||||||||||||||||||||
(MILLIONS OF DOLLARS)
|
|
2013
|
|
|
2014
|
|
|
2015
|
|
|
2016
|
|
|
2017
|
|
|||||
Amortization expense
|
|
$
|
4,804
|
|
|
$
|
4,145
|
|
|
$
|
3,735
|
|
|
$
|
3,488
|
|
|
$
|
3,373
|
|
86
|
|
2012 Financial Report
|
|
|
|
|
The following table provides the annual cost and changes in
Other comprehensive loss
for our benefit plans:
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
|
Year Ended December 31,
|
||||||||||||||||||||||||||||||||||||||||||||||
|
|
Pension Plans
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||||||||
|
|
U.S.
Qualified
(a)
|
|
U.S.
Supplemental
(Non-Qualified)
(b)
|
|
International
(c)
|
|
Postretirement
Plans
(d)
|
||||||||||||||||||||||||||||||||||||||||
(MILLIONS OF DOLLARS)
|
|
2012
|
|
|
2011
|
|
|
2010
|
|
|
2012
|
|
|
2011
|
|
|
2010
|
|
|
2012
|
|
|
2011
|
|
|
2010
|
|
|
2012
|
|
|
2011
|
|
|
2010
|
|
||||||||||||
Service cost
(e)
|
|
$
|
357
|
|
|
$
|
351
|
|
|
347
|
|
|
$
|
35
|
|
|
$
|
36
|
|
|
28
|
|
|
$
|
215
|
|
|
$
|
243
|
|
|
224
|
|
|
$
|
68
|
|
|
$
|
68
|
|
|
79
|
|
||||
Interest cost
(e)
|
|
697
|
|
|
734
|
|
|
740
|
|
|
62
|
|
|
72
|
|
|
77
|
|
|
406
|
|
|
443
|
|
|
418
|
|
|
182
|
|
|
195
|
|
|
211
|
|
||||||||||||
Expected return on plan assets
(e)
|
|
(983
|
)
|
|
(871
|
)
|
|
(782
|
)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(424
|
)
|
|
(437
|
)
|
|
(425
|
)
|
|
(46
|
)
|
|
(35
|
)
|
|
(31
|
)
|
||||||||||||
Amortization of:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||
Actuarial losses
(e)
|
|
306
|
|
|
145
|
|
|
151
|
|
|
41
|
|
|
36
|
|
|
29
|
|
|
93
|
|
|
86
|
|
|
67
|
|
|
33
|
|
|
17
|
|
|
15
|
|
||||||||||||
Prior service credits
|
|
(10
|
)
|
|
(8
|
)
|
|
2
|
|
|
(3
|
)
|
|
(3
|
)
|
|
(2
|
)
|
|
(7
|
)
|
|
(5
|
)
|
|
(4
|
)
|
|
(49
|
)
|
|
(53
|
)
|
|
(38
|
)
|
||||||||||||
Curtailments and settlements––net
|
|
83
|
|
|
95
|
|
|
(52
|
)
|
|
24
|
|
|
23
|
|
|
1
|
|
|
(9
|
)
|
|
—
|
|
|
(3
|
)
|
|
(65
|
)
|
|
(68
|
)
|
|
(23
|
)
|
||||||||||||
Special termination benefits
|
|
8
|
|
|
23
|
|
|
73
|
|
|
30
|
|
|
26
|
|
|
180
|
|
|
5
|
|
|
5
|
|
|
6
|
|
|
6
|
|
|
3
|
|
|
19
|
|
||||||||||||
Net periodic benefit costs
|
|
458
|
|
|
469
|
|
|
479
|
|
|
189
|
|
|
190
|
|
|
313
|
|
|
279
|
|
|
335
|
|
|
283
|
|
|
129
|
|
|
127
|
|
|
232
|
|
||||||||||||
Changes in
Other comprehensive loss
(f)
|
|
461
|
|
|
1,879
|
|
|
260
|
|
|
110
|
|
|
36
|
|
|
117
|
|
|
759
|
|
|
(365
|
)
|
|
152
|
|
|
267
|
|
|
421
|
|
|
(183
|
)
|
||||||||||||
Total amount recognized in comprehensive income
|
|
$
|
919
|
|
|
$
|
2,348
|
|
|
$
|
739
|
|
|
$
|
299
|
|
|
$
|
226
|
|
|
$
|
430
|
|
|
$
|
1,038
|
|
|
$
|
(30
|
)
|
|
$
|
435
|
|
|
$
|
396
|
|
|
$
|
548
|
|
|
$
|
49
|
|
(a)
|
2012 v. 2011
––
The decrease in net periodic benefit cost for our U.S. qualified plans was primarily driven by (i) higher expected return on plan assets (resulting from contributions made to the plan in 2011 that increased the plan asset base), (ii) lower interest costs, (iii) a decrease in special termination benefits, and (iv) lower curtailments and settlements
––
net due to the curtailment gain resulting from the decision to freeze the defined benefit plans in the U.S. and Puerto Rico largely offset by an increase in the amounts amortized for actuarial losses (resulting from a decrease in the discount rate and lower than expected actual returns in 2011). 2011 v. 2010
––
The decrease in the U.S. qualified pension plans' net periodic benefit costs was largely driven by lower special termination benefits costs and higher expected returns due to contributions made to the plans, partially offset by lower curtailment gains and an increase in settlement costs associated with on-going restructuring efforts.
|
(b)
|
2012 v. 2011
––
The net periodic benefit cost for our U.S. supplemental (non-qualified) pension plans was largely unchanged as the curtailment gain resulting from the decision to freeze the defined benefit plans in the U.S. and Puerto Rico was more than offset by higher settlement activity. 2011 v. 2010
––
The decrease in the U.S. supplemental (non-qualified) plans’ net periodic benefit costs was primarily driven by lower special termination benefits costs associated with Wyeth-related restructuring initiatives.
|
(c)
|
2012 v. 2011
––
The decrease in net periodic benefit costs for our international pension plans was primarily driven by changes impacting our U.K. plans in 2011 (see (e) below) as well as higher curtailment gains resulting from ongoing restructuring initiatives. 2011 v. 2010
––
The increase in the international plans’ net periodic benefit costs as compared to the prior year was primarily driven by changes in assumptions, including the decrease in discount rates across most plans.
|
(d)
|
2012 v. 2011
––
The net periodic benefit cost for our postretirement plans was largely unchanged, as an increase in amounts amortized for actuarial plan losses was partially offset by higher expected return on plan assets. 2011 v. 2010
––
The decrease in the postretirement plans’ net periodic benefit costs was due to the harmonization of the Wyeth postretirement medical program initiated in mid-2010
.
|
(e)
|
The decrease in service cost in 2012 for our international plans is largely driven by restructuring activities in the U.K. and Ireland. The decrease in interest cost in 2012 and 2011 reflect lower interest rates during the periods. The increase in the expected return on plan assets in 2012 for our U.S. qualified plans is due to a higher plan asset base
.
The higher amortization of actuarial losses is due larger accumulated actuarial losses resulting from lower interest rates.
|
(f)
|
For details, see our Consolidated Statements of Comprehensive Income and
Note 6. Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests.
|
2012 Financial Report
|
|
87
|
|
|
|
|
The following table provides the weighted-average actuarial assumptions of our benefit plans:
|
|||||||||
(PERCENTAGES)
|
|
2012
|
|
2011
|
|
2010
|
|||
Weighted-average assumptions used to determine benefit obligations
|
|
|
|
|
|
|
|||
Discount rate:
|
|
|
|
|
|
|
|||
U.S. qualified pension plans
|
|
4.3
|
%
|
|
5.1
|
%
|
|
5.9
|
%
|
U.S. non-qualified pension plans
|
|
3.9
|
%
|
|
5.0
|
%
|
|
5.8
|
%
|
International pension plans
|
|
3.8
|
%
|
|
4.7
|
%
|
|
4.8
|
%
|
Postretirement plans
|
|
4.1
|
%
|
|
4.8
|
%
|
|
5.6
|
%
|
Rate of compensation increase:
|
|
|
|
|
|
|
|||
U.S. qualified pension plans
|
|
2.7
|
%
|
|
3.5
|
%
|
|
4.0
|
%
|
U.S. non-qualified pension plans
|
|
2.8
|
%
|
|
3.5
|
%
|
|
4.0
|
%
|
International pension plans
|
|
3.1
|
%
|
|
3.3
|
%
|
|
3.5
|
%
|
Weighted-average assumptions used to determine net periodic benefit cost
|
|
|
|
|
|
|
|||
Discount rate:
|
|
|
|
|
|
|
|||
U.S. qualified pension plans
|
|
5.1
|
%
|
|
5.9
|
%
|
|
6.3
|
%
|
U.S. non-qualified pension plans
|
|
5.0
|
%
|
|
5.8
|
%
|
|
6.2
|
%
|
International pension plans
|
|
4.7
|
%
|
|
4.8
|
%
|
|
5.1
|
%
|
Postretirement plans
|
|
4.8
|
%
|
|
5.6
|
%
|
|
6.0
|
%
|
Expected return on plan assets:
|
|
|
|
|
|
|
|||
U.S. qualified pension plans
|
|
8.5
|
%
|
|
8.5
|
%
|
|
8.5
|
%
|
International pension plans
|
|
5.9
|
%
|
|
6.0
|
%
|
|
6.4
|
%
|
Postretirement plans
|
|
8.5
|
%
|
|
8.5
|
%
|
|
8.5
|
%
|
Rate of compensation increase:
|
|
|
|
|
|
|
|||
U.S. qualified pension plans
|
|
3.5
|
%
|
|
4.0
|
%
|
|
4.0
|
%
|
U.S. non-qualified pension plans
|
|
3.5
|
%
|
|
4.0
|
%
|
|
4.0
|
%
|
International pension plans
|
|
3.3
|
%
|
|
3.5
|
%
|
|
3.6
|
%
|
88
|
|
2012 Financial Report
|
|
|
|
|
The following table provides an analysis of the changes in our benefit obligations, plan assets and funded status of our benefit plans:
|
||||||||||||||||||||||||||||||||
|
|
Year Ended December 31,
|
||||||||||||||||||||||||||||||
|
|
Pension Plans
|
|
|
|
|
||||||||||||||||||||||||||
|
|
U.S. Qualified
(a)
|
|
U.S. Supplemental
(Non-Qualified)
(b)
|
|
International
(c)
|
|
Postretirement
Plans
(d)
|
||||||||||||||||||||||||
(MILLIONS OF DOLLARS)
|
|
2012
|
|
|
2011
|
|
|
2012
|
|
|
2011
|
|
|
2012
|
|
|
2011
|
|
|
2012
|
|
|
2011
|
|
||||||||
Change in benefit obligation
(e)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||
Benefit obligation, beginning
|
|
$
|
14,835
|
|
|
$
|
13,035
|
|
|
$
|
1,431
|
|
|
$
|
1,401
|
|
|
$
|
8,891
|
|
|
$
|
8,965
|
|
|
$
|
3,900
|
|
|
$
|
3,582
|
|
Service cost
|
|
357
|
|
|
351
|
|
|
35
|
|
|
36
|
|
|
215
|
|
|
243
|
|
|
68
|
|
|
68
|
|
||||||||
Interest cost
|
|
697
|
|
|
734
|
|
|
62
|
|
|
72
|
|
|
406
|
|
|
443
|
|
|
182
|
|
|
195
|
|
||||||||
Employee contributions
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
9
|
|
|
12
|
|
|
58
|
|
|
45
|
|
||||||||
Plan amendments
|
|
—
|
|
|
(73
|
)
|
|
—
|
|
|
(9
|
)
|
|
(1
|
)
|
|
4
|
|
|
(24
|
)
|
|
(28
|
)
|
||||||||
Changes in actuarial assumptions and other
|
|
1,926
|
|
|
1,808
|
|
|
252
|
|
|
111
|
|
|
1,232
|
|
|
(516
|
)
|
|
259
|
|
|
300
|
|
||||||||
Foreign exchange impact
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(80
|
)
|
|
304
|
|
|
1
|
|
|
—
|
|
||||||||
Acquisitions
|
|
(1
|
)
|
|
56
|
|
|
1
|
|
|
—
|
|
|
71
|
|
|
3
|
|
|
—
|
|
|
14
|
|
||||||||
Curtailments
|
|
(605
|
)
|
|
(97
|
)
|
|
(80
|
)
|
|
(10
|
)
|
|
(101
|
)
|
|
(121
|
)
|
|
(11
|
)
|
|
17
|
|
||||||||
Settlements
|
|
(485
|
)
|
|
(476
|
)
|
|
(121
|
)
|
|
(128
|
)
|
|
(33
|
)
|
|
(56
|
)
|
|
—
|
|
|
—
|
|
||||||||
Special termination benefits
|
|
8
|
|
|
23
|
|
|
30
|
|
|
26
|
|
|
5
|
|
|
5
|
|
|
6
|
|
|
3
|
|
||||||||
Benefits paid
|
|
(464
|
)
|
|
(526
|
)
|
|
(61
|
)
|
|
(68
|
)
|
|
(387
|
)
|
|
(395
|
)
|
|
(274
|
)
|
|
(296
|
)
|
||||||||
Benefit obligation, ending
(e)
|
|
16,268
|
|
|
14,835
|
|
|
1,549
|
|
|
1,431
|
|
|
10,227
|
|
|
8,891
|
|
|
4,165
|
|
|
3,900
|
|
||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||
Change in plan assets
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||
Fair value of plan assets, beginning
|
|
12,005
|
|
|
10,596
|
|
|
—
|
|
|
—
|
|
|
6,953
|
|
|
6,542
|
|
|
422
|
|
|
414
|
|
||||||||
Actual gain on plan assets
|
|
1,464
|
|
|
398
|
|
|
—
|
|
|
—
|
|
|
668
|
|
|
176
|
|
|
85
|
|
|
9
|
|
||||||||
Company contributions
|
|
20
|
|
|
1,969
|
|
|
182
|
|
|
196
|
|
|
383
|
|
|
475
|
|
|
353
|
|
|
250
|
|
||||||||
Employee contributions
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
9
|
|
|
12
|
|
|
58
|
|
|
45
|
|
||||||||
Foreign exchange impact
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(35
|
)
|
|
197
|
|
|
—
|
|
|
—
|
|
||||||||
Acquisitions
|
|
—
|
|
|
44
|
|
|
—
|
|
|
—
|
|
|
31
|
|
|
2
|
|
|
—
|
|
|
—
|
|
||||||||
Settlements
|
|
(485
|
)
|
|
(476
|
)
|
|
(121
|
)
|
|
(128
|
)
|
|
(33
|
)
|
|
(56
|
)
|
|
—
|
|
|
—
|
|
||||||||
Benefits paid
|
|
(464
|
)
|
|
(526
|
)
|
|
(61
|
)
|
|
(68
|
)
|
|
(387
|
)
|
|
(395
|
)
|
|
(274
|
)
|
|
(296
|
)
|
||||||||
Fair value of plan assets, ending
|
|
12,540
|
|
|
12,005
|
|
|
—
|
|
|
—
|
|
|
7,589
|
|
|
6,953
|
|
|
644
|
|
|
422
|
|
||||||||
Funded status—Plan assets less than benefit obligation
|
|
$
|
(3,728
|
)
|
|
$
|
(2,830
|
)
|
|
$
|
(1,549
|
)
|
|
$
|
(1,431
|
)
|
|
$
|
(2,638
|
)
|
|
$
|
(1,938
|
)
|
|
$
|
(3,521
|
)
|
|
$
|
(3,478
|
)
|
(a)
|
The unfavorable change in the funded status of our U.S. qualified plans is primarily due to the decrease in the discount rate, partially offset by the curtailment resulting from the decision to freeze the defined benefit plans in the U.S. and Puerto Rico, and an increase in the actual gain on plan assets.
|
(b)
|
Our U.S. supplemental (non-qualified) plans are generally not funded and these obligations, which are substantially greater than the annual cash outlay for these liabilities, will be paid from cash generated from operations.
|
(c)
|
The unfavorable change in the funded status of our international plans is primarily due to changes in actuarial assumptions, partially offset by an increase in the actual gain on plan assets. Outside the U.S., in general, we fund our defined benefit plans to the extent that tax or other incentives exist.
|
(d)
|
The funded status of our postretirement plans is largely unchanged as changes in actuarial assumptions were offset by the actual return on plan assets and increased contributions.
|
(e)
|
For the U.S. and international pension plans, the benefit obligation is the projected benefit obligation. For the postretirement plans, the benefit obligation is the accumulated postretirement benefit obligation (ABO). The ABO for all of our U.S. qualified pension plans was
$15.9 billion
in
2012
and
$13.8 billion
in
2011
. The ABO for our U.S. supplemental (non-qualified) pension plans was
$1.5 billion
in
2012
and
$1.2 billion
2011
. The ABO for our international pension plans was
$9.4 billion
in
2012
and
$8.3 billion
in
2011
.
|
2012 Financial Report
|
|
89
|
|
|
|
|
(a)
|
Included primarily in
Taxes and other noncurrent assets
.
|
(b)
|
Included in
Accrued compensation and related items
.
|
(c)
|
Included in
Pension benefit obligations
and
Postretirement benefit obligations
, as appropriate.
|
(a)
|
The actuarial losses primarily represent the impact of changes in discount rates and other assumptions that result in cumulative changes in our projected benefit obligations as well as the cumulative difference between the expected return and actual return on plan assets. These actuarial losses are recognized in
Accumulated other comprehensive loss
and are amortized into net periodic benefit costs over an average period of
9.8
years for our U.S. qualified plans, an average period of
9.9
years for our U.S. supplemental (non-qualified) plans, an average period of
14.5
years for our international plans and an average period of
11.0
years for our postretirement plans.
|
90
|
|
2012 Financial Report
|
|
|
|
|
The following table provides the components of plan assets:
|
||||||||||||||||||||||||||||||||
|
|
|
|
Fair Value
(a)
|
|
|
|
Fair Value
(a)
|
||||||||||||||||||||||||
(MILLIONS OF DOLLARS)
|
|
As of December 31, 2012
|
|
|
Level 1
|
|
Level 2
|
|
Level 3
|
|
As of December 31, 2011
|
|
|
Level 1
|
|
Level 2
|
|
Level 3
|
||||||||||||||
U.S. qualified pension plans
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||
Cash and cash equivalents
|
|
$
|
368
|
|
|
$
|
—
|
|
|
$
|
368
|
|
|
$
|
—
|
|
|
$
|
2,111
|
|
|
$
|
—
|
|
|
$
|
2,111
|
|
|
$
|
—
|
|
Equity securities:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||
Global equity securities
|
|
3,536
|
|
|
3,519
|
|
|
17
|
|
|
—
|
|
|
2,522
|
|
|
2,509
|
|
|
12
|
|
|
1
|
|
||||||||
Equity commingled funds
|
|
2,215
|
|
|
—
|
|
|
2,215
|
|
|
—
|
|
|
1,794
|
|
|
—
|
|
|
1,794
|
|
|
—
|
|
||||||||
Debt securities:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||
Fixed income commingled funds
|
|
943
|
|
|
—
|
|
|
943
|
|
|
—
|
|
|
870
|
|
|
—
|
|
|
870
|
|
|
—
|
|
||||||||
Government bonds
|
|
1,093
|
|
|
—
|
|
|
1,093
|
|
|
—
|
|
|
808
|
|
|
—
|
|
|
805
|
|
|
3
|
|
||||||||
Corporate debt securities
|
|
2,414
|
|
|
—
|
|
|
2,411
|
|
|
3
|
|
|
1,971
|
|
|
—
|
|
|
1,966
|
|
|
5
|
|
||||||||
Other investments:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||
Private equity funds
|
|
866
|
|
|
—
|
|
|
—
|
|
|
866
|
|
|
920
|
|
|
—
|
|
|
—
|
|
|
920
|
|
||||||||
Insurance contracts
|
|
348
|
|
|
—
|
|
|
348
|
|
|
—
|
|
|
353
|
|
|
—
|
|
|
353
|
|
|
—
|
|
||||||||
Other
|
|
757
|
|
|
—
|
|
|
—
|
|
|
757
|
|
|
656
|
|
|
—
|
|
|
—
|
|
|
656
|
|
||||||||
Total
|
|
12,540
|
|
|
3,519
|
|
|
7,395
|
|
|
1,626
|
|
|
12,005
|
|
|
2,509
|
|
|
7,911
|
|
|
1,585
|
|
||||||||
International pension plans
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||
Cash and cash equivalents
|
|
299
|
|
|
—
|
|
|
299
|
|
|
—
|
|
|
299
|
|
|
—
|
|
|
299
|
|
|
—
|
|
||||||||
Equity securities:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||
Global equity securities
|
|
1,723
|
|
|
1,638
|
|
|
85
|
|
|
—
|
|
|
1,513
|
|
|
1,432
|
|
|
81
|
|
|
—
|
|
||||||||
Equity commingled funds
|
|
2,194
|
|
|
—
|
|
|
2,194
|
|
|
—
|
|
|
1,966
|
|
|
—
|
|
|
1,966
|
|
|
—
|
|
||||||||
Debt securities:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||
Fixed income commingled funds
|
|
825
|
|
|
—
|
|
|
825
|
|
|
—
|
|
|
785
|
|
|
—
|
|
|
785
|
|
|
—
|
|
||||||||
Government bonds
|
|
914
|
|
|
—
|
|
|
914
|
|
|
—
|
|
|
956
|
|
|
—
|
|
|
956
|
|
|
—
|
|
||||||||
Corporate debt securities
|
|
613
|
|
|
—
|
|
|
613
|
|
|
—
|
|
|
536
|
|
|
—
|
|
|
536
|
|
|
—
|
|
||||||||
Other investments:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||
Private equity funds
|
|
110
|
|
|
—
|
|
|
14
|
|
|
96
|
|
|
55
|
|
|
—
|
|
|
4
|
|
|
51
|
|
||||||||
Insurance contracts
|
|
465
|
|
|
—
|
|
|
117
|
|
|
348
|
|
|
433
|
|
|
—
|
|
|
67
|
|
|
366
|
|
||||||||
Other
|
|
446
|
|
|
—
|
|
|
57
|
|
|
389
|
|
|
410
|
|
|
—
|
|
|
62
|
|
|
348
|
|
||||||||
Total
|
|
7,589
|
|
|
1,638
|
|
|
5,118
|
|
|
833
|
|
|
6,953
|
|
|
1,432
|
|
|
4,756
|
|
|
765
|
|
||||||||
U.S. postretirement plans
(b)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||
Cash and cash equivalents
|
|
28
|
|
|
—
|
|
|
28
|
|
|
—
|
|
|
19
|
|
|
—
|
|
|
19
|
|
|
—
|
|
||||||||
Equity securities:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||
Global equity securities
|
|
79
|
|
|
79
|
|
|
—
|
|
|
—
|
|
|
24
|
|
|
24
|
|
|
—
|
|
|
—
|
|
||||||||
Equity commingled funds
|
|
50
|
|
|
—
|
|
|
50
|
|
|
—
|
|
|
17
|
|
|
—
|
|
|
17
|
|
|
—
|
|
||||||||
Debt securities:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||
Fixed income commingled funds
|
|
20
|
|
|
—
|
|
|
20
|
|
|
—
|
|
|
8
|
|
|
—
|
|
|
8
|
|
|
—
|
|
||||||||
Government bonds
|
|
25
|
|
|
—
|
|
|
25
|
|
|
—
|
|
|
8
|
|
|
—
|
|
|
8
|
|
|
—
|
|
||||||||
Corporate debt securities
|
|
55
|
|
|
—
|
|
|
55
|
|
|
—
|
|
|
19
|
|
|
—
|
|
|
19
|
|
|
—
|
|
||||||||
Other investments:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||
Insurance contracts
|
|
350
|
|
|
—
|
|
|
350
|
|
|
—
|
|
|
312
|
|
|
—
|
|
|
312
|
|
|
—
|
|
||||||||
Other
|
|
37
|
|
|
—
|
|
|
37
|
|
|
—
|
|
|
15
|
|
|
—
|
|
|
15
|
|
|
—
|
|
||||||||
Total
|
|
$
|
644
|
|
|
$
|
79
|
|
|
$
|
565
|
|
|
$
|
—
|
|
|
$
|
422
|
|
|
$
|
24
|
|
|
$
|
398
|
|
|
$
|
—
|
|
(a)
|
Fair values are determined based on valuation inputs categorized as Level 1, 2 or 3 (see
Note 1E. Basis of Presentation and Significant Accounting Policies: Fair Value
).
|
2012 Financial Report
|
|
91
|
|
|
|
|
(b)
|
Reflects postretirement plan assets, which support a portion of our U.S. retiree medical plans.
|
•
|
Cash and cash equivalents, Equity commingled funds, Fixed-income commingled funds––observable prices.
|
•
|
Global equity securities—quoted market prices.
|
•
|
Government bonds, Corporate debt securities—observable market prices.
|
•
|
Other investments—principally unobservable inputs that are significant to the estimation of fair value. These unobservable inputs could include, for example, the investment managers’ assumptions about earnings multiples and future cash flows.
|
92
|
|
2012 Financial Report
|
|
|
|
|
2012 Financial Report
|
|
93
|
|
|
|
|
94
|
|
2012 Financial Report
|
|
|
|
|
2012 Financial Report
|
|
95
|
|
|
|
|
(a)
|
Determined using a constant dividend yield during the expected term of the option.
|
(b)
|
Determined using the interpolated yield on U.S. Treasury zero-coupon issues.
|
(c)
|
Determined using implied volatility, after consideration of historical volatility.
|
(d)
|
Determined using historical exercise and post-vesting termination patterns.
|
96
|
|
2012 Financial Report
|
|
|
|
|
(a)
|
Market price of underlying Pfizer common stock less exercise price.
|
(b)
|
The number of options expected to vest takes into account an estimate of expected forfeitures.
|
(a)
|
Determined using a constant dividend yield during the expected term of the TSRU.
|
(b)
|
Determined using the interpolated yield on U.S. Treasury zero-coupon issues.
|
(c)
|
Determined using implied volatility, after consideration of historical volatility.
|
2012 Financial Report
|
|
97
|
|
|
|
|
98
|
|
2012 Financial Report
|
|
|
|
|
The following table provides the detailed calculation of
Earnings per common share:
|
|||||||||||||
|
|
Year Ended December 31,
|
|||||||||||
(IN MILLIONS)
|
|
2012
|
|
|
2011
|
|
|
2010
|
|
||||
EPS Numerator––Basic
|
|
|
|
|
|
|
|
||||||
Income from continuing operations
|
|
$
|
9,518
|
|
|
$
|
8,395
|
|
|
$
|
8,318
|
|
|
Less: Net income attributable to noncontrolling interests
|
|
28
|
|
|
40
|
|
|
31
|
|
||||
Income from continuing operations attributable to Pfizer Inc.
|
|
9,490
|
|
|
8,355
|
|
|
8,287
|
|
||||
Less: Preferred stock dividends––net of tax
|
|
2
|
|
|
2
|
|
|
2
|
|
||||
Income from continuing operations attributable to Pfizer Inc. common shareholders
|
|
9,488
|
|
|
8,353
|
|
|
8,285
|
|
||||
Discontinued operations––net of tax
|
|
5,080
|
|
|
1,654
|
|
|
(30
|
)
|
||||
Net income attributable to Pfizer Inc. common shareholders
|
|
$
|
14,568
|
|
|
$
|
10,007
|
|
|
$
|
8,255
|
|
|
EPS Numerator––Diluted
|
|
|
|
|
|
|
|
|
|||||
Income from continuing operations attributable to Pfizer Inc. common shareholders and assumed conversions
|
|
$
|
9,490
|
|
|
$
|
8,355
|
|
|
$
|
8,287
|
|
|
Discontinued operations––net of tax
|
|
5,080
|
|
|
1,654
|
|
|
(30
|
)
|
||||
Net income attributable to Pfizer Inc. common shareholders and assumed conversions
|
|
$
|
14,570
|
|
|
$
|
10,009
|
|
|
$
|
8,257
|
|
|
EPS Denominator
|
|
|
|
|
|
|
|
|
|||||
Weighted-average number of common shares outstanding––Basic
|
|
7,442
|
|
|
7,817
|
|
|
8,036
|
|
||||
Common-share equivalents: stock options, stock issuable under employee compensation plans and convertible preferred stock
|
|
66
|
|
|
53
|
|
|
38
|
|
||||
Weighted-average number of common shares outstanding––Diluted
|
|
7,508
|
|
|
7,870
|
|
|
8,074
|
|
||||
Stock options that had exercise prices greater than the average market price of our common stock issuable under employee compensation plans
(a)
|
—
|
|
177
|
|
|
272
|
|
|
413
|
|
(a)
|
These common stock equivalents were outstanding for the years ended
December 31, 2012
,
2011
and
2010
, but were not included in the computation of diluted EPS for those periods because their inclusion would have had an anti-dilutive effect.
|
The future minimum rental commitments under non-cancelable operating leases follow:
|
||||||||||||||||||||||||
(MILLIONS OF DOLLARS)
|
|
2013
|
|
|
2014
|
|
|
2015
|
|
|
2016
|
|
|
2017
|
|
|
After 2017
|
|
||||||
Lease commitments
|
|
$
|
184
|
|
|
$
|
162
|
|
|
$
|
132
|
|
|
$
|
85
|
|
|
$
|
74
|
|
|
$
|
618
|
|
2012 Financial Report
|
|
99
|
|
|
|
|
•
|
Patent litigation, which typically involves challenges to the coverage and/or validity of our patents on various products, processes or dosage forms. We are the plaintiff in the vast majority of these actions. An adverse outcome in actions in which we are the plaintiff could result in a loss of patent protection for the drug at issue, a significant loss of revenues from that drug and impairments of any associated assets.
|
•
|
Product liability and other product-related litigation, which can include personal injury, consumer, off-label promotion, securities-law, antitrust and breach of contract claims, among others, often involves highly complex issues relating to medical causation, label warnings and reliance on those warnings, scientific evidence and findings, actual, provable injury and other matters.
|
•
|
Commercial and other matters, which can include merger-related and product-pricing claims and environmental claims and proceedings, can involve complexities that will vary from matter to matter.
|
•
|
Government investigations, which often are related to the extensive regulation of pharmaceutical companies by national, state and local government agencies in the U.S. and in other countries.
|
100
|
|
2012 Financial Report
|
|
|
|
|
2012 Financial Report
|
|
101
|
|
|
|
|
102
|
|
2012 Financial Report
|
|
|
|
|
•
|
Quigley
|
•
|
the payment to the Ad Hoc Committee, for the benefit of the Ad Hoc Committee claimants, of a first installment of
$500 million
upon receipt by Pfizer of releases of asbestos-related claims against Pfizer Inc. from Ad Hoc Committee claimants holding
$500 million
in the aggregate of claims (Pfizer began paying this first installment in June 2011);
|
•
|
the payment to the Ad Hoc Committee, for the benefit of the Ad Hoc Committee claimants, of a second installment of
$300 million
upon Pfizer’s receipt of releases of asbestos-related claims against Pfizer Inc. from Ad Hoc Committee claimants holding an additional
$300 million
in the aggregate of claims following the earlier of the effective date of a revised plan of reorganization and April 6, 2013;
|
•
|
the payment of the Ad Hoc Committee’s legal fees and expenses incurred in this matter up to a maximum of
$19 million
(Pfizer began paying these legal fees and expenses in May 2011); and
|
•
|
the procurement by Pfizer of insurance for the benefit of certain Ad Hoc Committee claimants to the extent such claimants with non-malignant diseases have a future disease progression to a malignant disease (Pfizer procured this insurance in August 2011).
|
2012 Financial Report
|
|
103
|
|
|
|
|
•
|
Other Matters
|
•
|
Personal Injury and Economic Loss Actions
|
104
|
|
2012 Financial Report
|
|
|
|
|
•
|
Government Inquiries; Action by the State of Nevada
|
•
|
Personal Injury Actions
|
•
|
Antitrust Actions
|
2012 Financial Report
|
|
105
|
|
|
|
|
•
|
Off-Label Promotion Actions in the U.S.
|
•
|
Personal Injury Actions in the U.S. and Certain Other Countries
|
•
|
Antitrust Action in the U.S.
|
106
|
|
2012 Financial Report
|
|
|
|
|
•
|
Whistleblower Action
|
•
|
Antitrust Actions
|
•
|
Actions in the U.S.
|
2012 Financial Report
|
|
107
|
|
|
|
|
•
|
Actions in Canada
|
•
|
In February 2009, special masters of the U.S. Court of Federal Claims rejected the three cases brought on the theory that a combination of MMR and thimerosal-containing vaccines caused petitioners’ conditions. After these rulings were affirmed by the U.S. Court of Federal Claims, two of them were appealed by petitioners to the U.S. Court of Appeals for the Federal Circuit. In 2010, the Federal Circuit affirmed the decisions of the special masters in both of these cases.
|
•
|
In March 2010, special masters of the U.S. Court of Federal Claims rejected the
three
additional test cases brought on the theory that thimerosal-containing vaccines alone caused petitioners’ conditions. Petitioners did not seek review by the U.S. Court of Federal Claims of the decisions of the special masters in these latter three test cases, and judgments were entered dismissing the cases in April 2010.
|
•
|
Petitioners in each of the
six
test cases have filed an election to bring a civil action.
|
108
|
|
2012 Financial Report
|
|
|
|
|
2012 Financial Report
|
|
109
|
|
|
|
|
110
|
|
2012 Financial Report
|
|
|
|
|
•
|
Primary Care operating segment––includes revenues and earnings, as defined by management, from human prescription pharmaceutical products primarily prescribed by primary-care physicians, and may include products in the following therapeutic and disease areas: Alzheimer’s disease, cardiovascular (excluding pulmonary arterial hypertension), erectile dysfunction, genitourinary, major depressive disorder, pain, respiratory and smoking cessation. Examples of products in this unit in 2012 include Celebrex, Chantix/Champix, Eliquis, Lipitor (in certain EU countries and in Australia and New Zealand), Lyrica, Premarin, Pristiq and Viagra. All revenues and earnings for such products are allocated to the Primary Care unit, except those generated in Emerging Markets and those that are managed by the Established Products unit.
|
•
|
Specialty Care and Oncology operating segment––comprises the Specialty Care business unit and the Oncology business unit.
|
◦
|
Specialty Care––includes revenues and earnings, as defined by management, from human prescription pharmaceutical products primarily prescribed by physicians who are specialists, and may include products in the following therapeutic and disease areas: anti-infectives, endocrine disorders, hemophilia, inflammation, ophthalmology, pulmonary arterial hypertension, specialty neuroscience and vaccines. Examples of products in this unit in 2012 include BeneFIX, Enbrel, Genotropin, Geodon (outside the U.S.), the Prevnar/Prevenar family, ReFacto AF, Revatio (outside the U.S.), Tygacil, Vfend (outside the U.S. and South Korea), Vyndaqel (outside the U.S.), Xalatan (outside the U.S., Canada and South Korea), Xeljanz (in the U.S.), Xyntha and Zyvox. All revenues and earnings for such products are allocated to the Specialty Care unit, except those generated in Emerging Markets and those that are managed by the Established Products unit.
|
◦
|
Oncology––includes revenues and earnings, as defined by management, from human prescription pharmaceutical products addressing oncology and oncology-related illnesses. The products in this unit in 2012 include Inlyta, Sutent, Torisel, Xalkori, Mylotarg (in Japan) and Bosulif (in the U.S.). All revenues and earnings for such products are allocated to the Oncology unit, except those generated in Emerging Markets and those that are managed by the Established Products unit.
|
•
|
Established Products and Emerging Markets operating segment––comprises the Established Products business unit and the Emerging Markets business unit.
|
◦
|
Established Products–– includes revenues and earnings, as defined by management, from human prescription pharmaceutical products that have lost patent protection or marketing exclusivity in certain countries and/or regions. Typically, products are transferred to this unit in the beginning of the fiscal year following loss of patent protection or marketing exclusivity. However, in certain situations, products may be transferred to this unit at a different point than the beginning of the fiscal year following loss of patent protection or marketing exclusivity in order to maximize their value. This unit also excludes revenues and earnings generated in Emerging Markets. Examples of products in this unit in 2012 include Arthrotec, Effexor, Lipitor (in the U.S., Canada, South Korea and Japan), Medrol, Norvasc, Protonix, Relpax, Vfend (in the U.S. and South Korea), Xalatan (in the U.S., Canada and South Korea) and Zosyn/Tazocin.
|
◦
|
Emerging Markets––includes revenues and earnings, as defined by management, from all human prescription pharmaceutical products sold in Emerging Markets, including Asia (excluding Japan and South Korea), Latin America, the Middle East, Eastern Europe, Africa, Turkey and Central Europe.
|
2012 Financial Report
|
|
111
|
|
|
|
|
•
|
Animal Health operating segment––includes worldwide revenues and earnings, as defined by management, from products and services to prevent and treat disease in livestock and companion animals, including anti-infectives, vaccines, parasiticides, medicinal feed additives, other pharmaceutical products and other non-pharmaceutical products.
|
•
|
Consumer Healthcare operating segment–– includes worldwide revenues and earnings, as defined by management, from non-prescription products in the following therapeutic categories: dietary supplements, pain management, respiratory and personal care. Products marketed by Consumer Healthcare include Advil, Caltrate, Centrum, ChapStick, Emergen-C, Preparation H and Robitussin.
|
•
|
Worldwide Research and Development (WRD), which is generally responsible for human health research projects until proof-of-concept is achieved and then for transitioning those projects to the appropriate business unit for possible clinical and commercial development. R&D spending may include upfront and milestone payments for intellectual property rights. This organization also has responsibility for certain science-based and other platform-services organizations, which provide technical expertise and other services to the various R&D projects. WRD is also responsible for facilitating all human-health-related regulatory submissions and interactions with regulatory agencies, including all safety-event activities.
|
•
|
Pfizer Medical is responsible for external affairs relating to all therapeutic areas, providing Pfizer-related medical information to healthcare providers, patients and other parties, and quality assurance and regulatory compliance activities, which include conducting clinical trial audits and readiness reviews.
|
•
|
Corporate, which is responsible for platform functions such as finance, global real estate operations, human resources, legal, compliance, science and technology, worldwide procurement, worldwide public affairs and policy and worldwide technology. These costs also include compensation costs and other miscellaneous operating expenses not charged to our operating segments, as well as interest income and expense.
|
•
|
Certain transactions and events such as (i) purchase accounting adjustments, where we incur expenses associated with the amortization of fair value adjustments to inventory, intangible assets and property, plant and equipment; (ii) acquisition-related activities, where we incur costs for restructuring, integration, implementation and executing the transaction; and (iii) certain significant items, which include non-acquisition-related restructuring costs, as well as costs incurred for legal settlements, asset impairments and sales of assets or businesses.
|
112
|
|
2012 Financial Report
|
|
|
|
|
(a)
|
Income from continuing operations before provision for taxes on income.
|
(b)
|
Certain production facilities are shared. Deprecation is allocated based on estimates of physical production.
|
(c)
|
For 2011, includes King commencing on the acquisition date of January 31, 2011.
|
(d)
|
Revenues and Earnings from the Primary Care segment decreased for
2012
as compared to the prior year, and earnings as a percentage of revenues also declined, primarily due to the loss of exclusivity of Lipitor in most major markets, and the subsequent shift in the reporting of Lipitor in those major markets to the Established Products business unit.
|
(e)
|
Revenues and Earnings from the Established Products and Emerging Markets segment increased in
2012
as compared to the prior year, primarily due to additional products losing exclusivity and moving to the Established Products unit and increased operational sales in emerging markets, partially offset by unfavorable foreign exchange. Earnings as a percentage of revenue increased due to the change in the mix of products.
|
(f)
|
Includes the Animal Health operating segment and the Consumer Healthcare operating segment. In 2012, higher R&D expenses and lower Earnings reflect the Consumer Healthcare acquisition of the over-the-counter (OTC) rights for Nexium (see
Note 2A. Acquisitions, Divestitures, Collaborative Arrangements and Equity-Method Investments: Acquisitions
).
|
(g)
|
Other business activities includes the revenues and operating results of Pfizer CentreSource, our contract manufacturing and bulk pharmaceutical chemical sales operation, and the research and development costs managed by our Worldwide Research and Development organization and our Pfizer Medical organization.
|
(h)
|
Corporate for R&D expenses includes, among other things, administration expenses and compensation expenses associated with our research and development activities and for Earnings includes, among other things, administration expenses, interest income/(expense) and certain compensation and other costs not charged to our operating segments.
|
(i)
|
Purchase accounting adjustments include certain charges related to the fair value adjustments to inventory, intangible assets and property, plant and equipment.
|
(j)
|
Acquisition-related costs can include costs associated with acquiring, integrating and restructuring newly acquired businesses, such as transaction costs, integration costs, restructuring charges and additional depreciation associated with asset restructuring (see
Note 3. Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives
for additional information).
|
(k)
|
Certain significant items are substantive, unusual items that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis.
|
(l)
|
Includes overhead expenses associated with our manufacturing and commercial operations not directly attributable to an operating segment.
|
2012 Financial Report
|
|
113
|
|
|
|
|
The following table provides revenues by geographic area:
|
||||||||||||
|
|
Year Ended December 31,
|
||||||||||
(MILLIONS OF DOLLARS)
|
|
2012
|
|
|
2011
(a)
|
|
|
2010
|
|
|||
Revenues
|
|
|
|
|
|
|
||||||
United States
|
|
$
|
23,086
|
|
|
$
|
26,933
|
|
|
$
|
28,855
|
|
Developed Europe
(b)
|
|
13,375
|
|
|
16,099
|
|
|
16,156
|
|
|||
Developed Rest of World
(c)
|
|
10,554
|
|
|
10,975
|
|
|
9,891
|
|
|||
Emerging Markets
(d)
|
|
11,971
|
|
|
11,252
|
|
|
10,263
|
|
|||
Revenues
|
|
$
|
58,986
|
|
|
$
|
65,259
|
|
|
$
|
65,165
|
|
(a)
|
For 2011, includes King commencing on the acquisition date of January 31, 2011.
|
(b)
|
Developed Europe region includes the following markets: Western Europe, Finland and the Scandinavian countries. Revenues denominated in euros were
$10 billion
,
$12 billion
and
$12 billion
for
2012
,
2011
and
2010
, respectively.
|
(c)
|
Developed Rest of World region includes the following markets: Australia, Canada, Japan, New Zealand and South Korea.
|
(d)
|
Emerging Markets region includes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, the Middle East, Eastern Europe, Africa, Turkey and Central Europe.
|
(a)
|
Developed Europe region includes the following markets: Western Europe, Finland and the Scandinavian countries.
|
(b)
|
Developed Rest of World region includes the following markets: Australia, Canada, Japan, New Zealand, and South Korea.
|
(c)
|
Emerging Markets region includes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, Middle East, Africa, Central and Eastern Europe and Turkey.
|
114
|
|
2012 Financial Report
|
|
|
|
|
(a)
|
For
2011
, includes King commencing on the acquisition date of January 31, 2011.
|
2012 Financial Report
|
|
115
|
|
|
|
|
(b)
|
Lipitor lost exclusivity in the U.S. in November 2011 and various other major markets in
2011
and 2012. This loss of exclusivity reduced branded worldwide revenues by
$5.6 billion
in
2012
, in comparison with 2011, and reduced branded worldwide revenues by
$1.2 billion
in
2011
, in comparison with 2010.
|
(c)
|
Represents direct sales under license agreement with Eisai Co., Ltd.
|
(d)
|
Legacy King product.
|
(e)
|
Includes Enbrel (in the U.S. and Canada), Spiriva, Rebif, Aricept and Exforge.
|
(f)
|
Includes sales of generic atorvastatin.
|
(g)
|
Includes revenues generated primarily from Pfizer CentreSource, our contract manufacturing and bulk pharmaceutical chemical sales organization.
|
116
|
|
2012 Financial Report
|
|
|
|
|
|
|
Quarter
|
||||||||||||||
(MILLIONS OF DOLLARS, EXCEPT PER COMMON SHARE DATA)
|
|
First
|
|
Second
|
|
Third
|
|
Fourth
|
||||||||
2012
|
|
|
|
|
|
|
|
|
||||||||
Revenues
|
|
$
|
14,885
|
|
|
$
|
15,057
|
|
|
$
|
13,976
|
|
|
$
|
15,068
|
|
Costs and expenses
(a)
|
|
11,853
|
|
|
10,383
|
|
|
10,683
|
|
|
12,107
|
|
||||
Restructuring charges and certain acquisition-related costs
(b)
|
|
597
|
|
|
190
|
|
|
302
|
|
|
791
|
|
||||
Income from continuing operations before provision/(benefit) for taxes on income
|
|
2,435
|
|
|
4,484
|
|
|
2,991
|
|
|
2,170
|
|
||||
Provision/(benefit) for taxes on income
|
|
711
|
|
|
1,290
|
|
|
(119
|
)
|
|
680
|
|
||||
Income from continuing operations
|
|
1,724
|
|
|
3,194
|
|
|
3,110
|
|
|
1,490
|
|
||||
Discontinued operations—net of tax
(c)
|
|
79
|
|
|
66
|
|
|
104
|
|
|
4,831
|
|
||||
Net income before allocation to noncontrolling interests
|
|
1,803
|
|
|
3,260
|
|
|
3,214
|
|
|
6,321
|
|
||||
Less: Net income attributable to noncontrolling interests
|
|
9
|
|
|
7
|
|
|
6
|
|
|
6
|
|
||||
Net income attributable to Pfizer Inc.
|
|
$
|
1,794
|
|
|
$
|
3,253
|
|
|
$
|
3,208
|
|
|
$
|
6,315
|
|
Earnings per common share—basic:
|
|
|
|
|
|
|
|
|
||||||||
Income from continuing operations attributable to Pfizer Inc. common shareholders
|
|
$
|
0.23
|
|
|
$
|
0.43
|
|
|
$
|
0.42
|
|
|
$
|
0.20
|
|
Discontinued operations—net of tax
|
|
0.01
|
|
|
0.01
|
|
|
0.01
|
|
|
0.66
|
|
||||
Net income attributable to Pfizer Inc. common shareholders
|
|
$
|
0.24
|
|
|
$
|
0.44
|
|
|
$
|
0.43
|
|
|
$
|
0.86
|
|
Earnings per common share—diluted:
|
|
|
|
|
|
|
|
|
||||||||
Income from continuing operations attributable to Pfizer Inc. common shareholders
|
|
$
|
0.23
|
|
|
$
|
0.42
|
|
|
$
|
0.41
|
|
|
$
|
0.20
|
|
Discontinued operations—net of tax
|
|
0.01
|
|
|
0.01
|
|
|
0.01
|
|
|
0.65
|
|
||||
Net income attributable to Pfizer Inc. common shareholders
|
|
$
|
0.24
|
|
|
$
|
0.43
|
|
|
$
|
0.43
|
|
|
$
|
0.85
|
|
|
|
|
|
|
|
|
|
|
||||||||
Cash dividends paid per common share
|
|
$
|
0.22
|
|
|
$
|
0.22
|
|
|
$
|
0.22
|
|
|
$
|
0.22
|
|
Stock prices
|
|
|
|
|
|
|
|
|
||||||||
High
|
|
$
|
22.80
|
|
|
$
|
23.30
|
|
|
$
|
25.15
|
|
|
$
|
26.09
|
|
Low
|
|
$
|
20.75
|
|
|
$
|
21.40
|
|
|
$
|
22.00
|
|
|
$
|
23.55
|
|
(a)
|
The fourth quarter of
2012
reflects historically higher Q4 costs in
Cost of sales, Selling, informational and administrative expenses, Research and development expenses
and
Other deductions—net.
|
(b)
|
The fourth quarter of
2012
reflects higher employee termination costs.
|
(c)
|
The fourth quarter of
2012
reflects the gain on the sale of our Nutrition business.
|
2012 Financial Report
|
|
117
|
|
|
|
|
|
|
Quarter
|
||||||||||||||
(MILLIONS OF DOLLARS, EXCEPT PER COMMON SHARE DATA)
|
|
First
|
|
|
Second
|
|
|
Third
|
|
|
Fourth
|
|
||||
2011
|
|
|
|
|
|
|
|
|
||||||||
Revenues
|
|
$
|
16,024
|
|
|
$
|
16,485
|
|
|
$
|
16,609
|
|
|
$
|
16,141
|
|
Costs and expenses
(a)
|
|
12,124
|
|
|
12,409
|
|
|
11,978
|
|
|
13,514
|
|
||||
Restructuring charges and certain acquisition-related costs
(b)
|
|
890
|
|
|
478
|
|
|
1,090
|
|
|
472
|
|
||||
Income from continuing operations before provision for taxes on income
|
|
3,010
|
|
|
3,598
|
|
|
3,541
|
|
|
2,155
|
|
||||
Provision for taxes on income
(c)
|
|
874
|
|
|
1,077
|
|
|
1,216
|
|
|
742
|
|
||||
Income from continuing operations
|
|
2,136
|
|
|
2,521
|
|
|
2,325
|
|
|
1,413
|
|
||||
Discontinued operations—net of tax
|
|
98
|
|
|
97
|
|
|
1,424
|
|
|
35
|
|
||||
Net income before allocation to noncontrolling interests
|
|
2,234
|
|
|
2,618
|
|
|
3,749
|
|
|
1,448
|
|
||||
Less: Net income attributable to noncontrolling interests
|
|
12
|
|
|
8
|
|
|
11
|
|
|
9
|
|
||||
Net income attributable to Pfizer Inc.
|
|
$
|
2,222
|
|
|
$
|
2,610
|
|
|
$
|
3,738
|
|
|
$
|
1,439
|
|
Earnings per common share—basic:
|
|
|
|
|
|
|
|
|
||||||||
Income from continuing operations attributable to Pfizer Inc. common shareholders
|
|
$
|
0.27
|
|
|
$
|
0.32
|
|
|
$
|
0.30
|
|
|
$
|
0.18
|
|
Discontinued operations—net of tax
|
|
0.01
|
|
|
0.01
|
|
|
0.19
|
|
|
—
|
|
||||
Net income attributable to Pfizer Inc. common shareholders
|
|
$
|
0.28
|
|
|
$
|
0.33
|
|
|
$
|
0.48
|
|
|
$
|
0.19
|
|
Earnings per common share—diluted:
|
|
|
|
|
|
|
|
|
||||||||
Income from continuing operations attributable to Pfizer Inc. common shareholders
|
|
$
|
0.26
|
|
|
$
|
0.32
|
|
|
$
|
0.30
|
|
|
$
|
0.18
|
|
Discontinued operations—net of tax
|
|
0.01
|
|
|
0.01
|
|
|
0.18
|
|
|
—
|
|
||||
Net income attributable to Pfizer Inc. common shareholders
|
|
$
|
0.28
|
|
|
$
|
0.33
|
|
|
$
|
0.48
|
|
|
$
|
0.19
|
|
|
|
|
|
|
|
|
|
|
||||||||
Cash dividends paid per common share
|
|
$
|
0.20
|
|
|
$
|
0.20
|
|
|
$
|
0.20
|
|
|
$
|
0.20
|
|
Stock prices
|
|
|
|
|
|
|
|
|
||||||||
High
|
|
$
|
20.57
|
|
|
$
|
21.45
|
|
|
$
|
20.95
|
|
|
$
|
21.90
|
|
Low
|
|
$
|
17.62
|
|
|
$
|
19.10
|
|
|
$
|
16.63
|
|
|
$
|
17.05
|
|
(a)
|
The fourth quarter of
2011
reflects historically higher Q4 costs in
Cost of sales
and
Selling, informational and administrative expenses
,
Research and development expenses
and
Other deductions—net
.
|
(b)
|
The third quarter of
2011
reflects higher employee termination costs.
|
(c)
|
The third quarter of
2011
reflects the gain on the sale of Capsugel.
|
118
|
|
2012 Financial Report
|
|
|
|
|
|
|
Year Ended/As of December 31,
(a)
|
||||||||||||||||||
(MILLIONS, EXCEPT PER COMMON SHARE DATA)
|
|
2012
|
|
|
2011
|
|
|
2010
|
|
|
2009
|
|
|
2008
|
|
|||||
Revenues
|
|
$
|
58,986
|
|
|
$
|
65,259
|
|
|
$
|
65,165
|
|
|
$
|
49,078
|
|
|
$
|
47,529
|
|
Research and development expenses
(b)
|
|
7,870
|
|
|
9,074
|
|
|
9,483
|
|
|
7,887
|
|
|
8,557
|
|
|||||
Other costs and expenses
|
|
37,156
|
|
|
40,951
|
|
|
43,066
|
|
|
26,138
|
|
|
26,790
|
|
|||||
Restructuring charges and certain acquisition-related costs
(c)
|
|
1,880
|
|
|
2,930
|
|
|
3,145
|
|
|
4,330
|
|
|
2,662
|
|
|||||
Income from continuing operations before provision for taxes on income
|
|
12,080
|
|
|
12,304
|
|
|
9,471
|
|
|
10,723
|
|
|
9,520
|
|
|||||
Provision for taxes on income
|
|
2,562
|
|
|
3,909
|
|
|
1,153
|
|
|
2,150
|
|
|
1,582
|
|
|||||
Income from continuing operations
|
|
9,518
|
|
|
8,395
|
|
|
8,318
|
|
|
8,573
|
|
|
7,938
|
|
|||||
Discontinued operations—net of tax
(d)
|
|
5,080
|
|
|
1,654
|
|
|
(30
|
)
|
|
71
|
|
|
188
|
|
|||||
Less: Net income attributable to noncontrolling interests
|
|
28
|
|
|
40
|
|
|
31
|
|
|
9
|
|
|
22
|
|
|||||
Net income attributable to Pfizer Inc.
|
|
$
|
14,570
|
|
|
$
|
10,009
|
|
|
$
|
8,257
|
|
|
$
|
8,635
|
|
|
$
|
8,104
|
|
Effective tax rate—continuing operations
|
|
21.2
|
%
|
|
31.8
|
%
|
|
12.2
|
%
|
|
20.1
|
%
|
|
16.6
|
%
|
|||||
Depreciation and amortization
(e)
|
|
$
|
7,611
|
|
|
$
|
8,907
|
|
|
$
|
8,399
|
|
|
$
|
4,757
|
|
|
$
|
5,090
|
|
Property, plant and equipment additions
(e)
|
|
1,327
|
|
|
1,660
|
|
|
1,513
|
|
|
1,205
|
|
|
1,701
|
|
|||||
Cash dividends paid
|
|
6,534
|
|
|
6,234
|
|
|
6,088
|
|
|
5,548
|
|
|
8,541
|
|
|||||
Working capital
|
|
32,796
|
|
|
31,908
|
|
|
35,764
|
|
|
28,537
|
|
|
16,748
|
|
|||||
Property, plant and equipment, less accumulated depreciation
|
|
14,461
|
|
|
15,921
|
|
|
17,607
|
|
|
21,316
|
|
|
12,864
|
|
|||||
Total assets
|
|
185,798
|
|
|
188,002
|
|
|
195,014
|
|
|
212,949
|
|
|
111,148
|
|
|||||
Long-term debt
|
|
31,036
|
|
|
34,926
|
|
|
38,410
|
|
|
43,192
|
|
|
7,955
|
|
|||||
Long-term capital
(f)
|
|
134,307
|
|
|
136,408
|
|
|
144,542
|
|
|
150,562
|
|
|
68,637
|
|
|||||
Total Pfizer Inc. shareholders’ equity
|
|
81,260
|
|
|
82,190
|
|
|
87,813
|
|
|
90,014
|
|
|
57,556
|
|
|||||
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Earnings per common share—basic
(g)
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Income from continuing operations attributable to Pfizer Inc. common shareholders
|
|
$
|
1.27
|
|
|
$
|
1.07
|
|
|
$
|
1.03
|
|
|
$
|
1.22
|
|
|
$
|
1.18
|
|
Discontinued operations—net of tax
|
|
0.68
|
|
|
0.21
|
|
|
—
|
|
|
0.01
|
|
|
0.03
|
|
|||||
Net income attributable to Pfizer Inc. common shareholders
|
|
$
|
1.96
|
|
|
$
|
1.28
|
|
|
$
|
1.03
|
|
|
$
|
1.23
|
|
|
$
|
1.20
|
|
Earnings per common share—diluted
(g)
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Income from continuing operations attributable to Pfizer Inc. common shareholders
|
|
$
|
1.26
|
|
|
$
|
1.06
|
|
|
$
|
1.03
|
|
|
$
|
1.22
|
|
|
$
|
1.17
|
|
Discontinued operations—net of tax
|
|
0.68
|
|
|
0.21
|
|
|
—
|
|
|
0.01
|
|
|
0.03
|
|
|||||
Net income attributable to Pfizer Inc. common shareholders
|
|
$
|
1.94
|
|
|
$
|
1.27
|
|
|
$
|
1.02
|
|
|
$
|
1.23
|
|
|
$
|
1.20
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Market value per share (December 31)
|
|
$
|
25.08
|
|
|
$
|
21.64
|
|
|
$
|
17.51
|
|
|
$
|
18.19
|
|
|
$
|
17.71
|
|
Return on Pfizer Inc. shareholders’ equity
|
|
17.83
|
%
|
|
11.78
|
%
|
|
10.39
|
%
|
|
13.42
|
%
|
|
13.22
|
%
|
|||||
Cash dividends paid per common share
|
|
$
|
0.88
|
|
|
$
|
0.80
|
|
|
$
|
0.72
|
|
|
$
|
0.80
|
|
|
$
|
1.28
|
|
Pfizer Inc. shareholders’ equity per common share
(h)
|
|
$
|
11.17
|
|
|
$
|
10.85
|
|
|
$
|
10.96
|
|
|
$
|
11.19
|
|
|
$
|
8.56
|
|
Current ratio
|
|
2.15:1
|
|
|
2.10:1
|
|
|
2.21:1
|
|
|
1.75:1
|
|
|
1.61:1
|
|
|||||
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Weighted-average shares—basic
|
|
7,442
|
|
|
7,817
|
|
|
8,036
|
|
|
7,007
|
|
|
6,727
|
|
|||||
Weighted-average shares—diluted
|
|
7,508
|
|
|
7,870
|
|
|
8,074
|
|
|
7,045
|
|
|
6,750
|
|
(a)
|
For 2011, includes King commencing on the acquisition date of January 31, 2011. For 2009, includes Wyeth commencing on the acquisition date of October 15, 2009.
|
(b)
|
Research and development expenses
includes upfront and milestone payments for intellectual property rights of
$371 million
in
2012
,
$306 million
in
2011
;
$393 million
in
2010
;
$489 million
in
2009
; and
$377 million
in
2008
.
|
(c)
|
Restructuring charges and certain acquisition-related costs
primarily includes the following:
|
(d)
|
The sale of our Nutrition business closed on November 30, 2012. 2012, 2011, 2010 and 2009 reflect the Nutrition business, which was acquired in 2009, as a discontinued operation. All financial information before 2012 reflects Capsugel (the sale of which closed on August 1, 2011) as a discontinued operation.
|
(e)
|
Includes discontinued operations.
|
(f)
|
Defined as long-term debt, noncurrent deferred tax liabilities and total equity. In
2009
, increase reflects the long-term debt and deferred tax liabilities associated with the acquisition of Wyeth.
|
(g)
|
EPS amounts may not add due to rounding.
|
(h)
|
Represents total Pfizer Inc. shareholders’ equity divided by the actual number of common shares outstanding (which excludes treasury shares and those held by our employee benefit trusts). The increase in
2009
was due to the issuance of equity to partially finance the Wyeth acquisition.
|
2012 Financial Report
|
|
119
|
|
|
|
|
|
|
2007
|
|
2008
|
|
2009
|
|
2010
|
|
2011
|
|
2012
|
PFIZER
|
|
100.0
|
|
83.1
|
|
90.0
|
|
90.3
|
|
116.3
|
|
140.0
|
PEER GROUP
|
|
100.0
|
|
84.7
|
|
95.6
|
|
95.2
|
|
111.5
|
|
123.4
|
S&P 500
|
|
100.0
|
|
63.0
|
|
79.7
|
|
91.7
|
|
93.6
|
|
108.6
|
120
|
|
2012 Financial Report
|
Alpharma U.S. Inc.
|
Delaware
|
Alpharma USHP Inc.
|
Delaware
|
Alpharma, LLC
|
Delaware
|
American Food Industries LLC
|
Delaware
|
American Home Products Holdings (U.K.) Limited
|
United Kingdom
|
Andean Services S.A.
|
Colombia
|
Animal Health Holdings C.V.
|
Netherlands
|
Ayerst-Wyeth Pharmaceuticals LLC
|
Delaware
|
Barre Parent Corporation
|
Delaware
|
BINESA 2002, S.L.
|
Spain
|
Biocor Animal Health Inc.
|
Delaware
|
Bioren, Inc.
|
Delaware
|
BioRexis Pharmaceutical Corporation
|
Delaware
|
Blue Point Provider, S. de R.L. de C.V.
|
Mexico
|
Blue Umbrella First Aid, S. de R.L. de C.V.
|
Mexico
|
Blue Umbrella Services, S. de R.L. de C.V.
|
Mexico
|
Blue Whale Re Ltd.
|
Vermont
|
C.E. Commercial Holdings C.V.
|
Netherlands
|
C.E. Commercial Investments C.V.
|
Netherlands
|
C.E. Holdings Europe C.V.
|
Netherlands
|
C.P. Pharma Gyógyszerkereskedelmi Korlátolt Felelõsségû Társaság
|
Hungary
|
C.P. Pharma Services Corporation, S. de R.L. de C.V.
|
Mexico
|
C.P. Pharmaceuticals International C.V.
|
Netherlands
|
Carlerba - Produtos Químicos e Farmacêuticos, Lda.
|
Portugal
|
CICL Corporation
|
Delaware
|
COC I Corporation
|
Delaware
|
Coley Pharmaceutical GmbH
|
Germany
|
Coley Pharmaceutical Group, Inc.
|
Delaware
|
Coley Pharmaceutical Group, Ltd.
|
Canada
|
Compania Farmaceutica Upjohn, S.A.
|
Guatemala
|
Continental Farmaceutica SPRL
|
Belgium
|
Continental Pharma, Inc.
|
Belgium
|
CovX Research LLC
|
Delaware
|
Covx Technologies Ireland Limited
|
Ireland
|
Cyanamid de Argentina S.A.
|
Delaware
|
Cyanamid de Colombia, S.A.
|
Delaware
|
Cyanamid Inter-American Corporation
|
Delaware
|
Cyanamid of Great Britain Limited
|
United Kingdom
|
Design Group Sverige AB
|
Sweden
|
Distribuidora Mercantil Centro Americana, S.A
|
Delaware
|
Durgon Holdings Limited
|
British Virgin Islands
|
Egyptian Company for Animal Health LLC
|
Egypt
|
Embrex Bio-Tech Trade (Shanghai) Co., Ltd.
|
People's Republic of China
|
Embrex Europe Limited
|
United Kingdom
|
Embrex Poultry Health, LLC
|
North Carolina
|
Embrex, Inc.
|
North Carolina
|
Empresa Laboratories de Mexico S.A. de C.V.
|
Mexico
|
Encysive (UK) Limited
|
United Kingdom
|
Encysive Canada Inc.
|
Canada
|
Encysive Pharmaceuticals Inc.
|
Delaware
|
Esperion LUV Development, Inc.
|
Delaware
|
Eurovita Trading Limited
|
Ireland
|
Excaliard Pharmaceuticals, Inc.
|
Delaware
|
Farminova Produtos Farmaceuticos de Inovacao, Lda.
|
Portugal
|
Farmitalia Carlo Erba Limited
|
United Kingdom
|
Farmogene Productos Farmaceuticos Lda
|
Portugal
|
Ferrosan A/S
|
Denmark
|
Ferrosan AB
|
Sweden
|
Ferrosan Finance S.A.
|
Panama
|
Ferrosan Holding A/S
|
Denmark
|
Ferrosan International A/S
|
Denmark
|
Ferrosan Limited
|
United Kingdom
|
Ferrosan Norge AS
|
Norway
|
Ferrosan Poland Sp. z o.o. w likwidacji
|
Poland
|
Ferrosan S.R.L.
|
Romania
|
FoldRx Pharmaceuticals, Inc.
|
Delaware
|
Fort Dodge (Hong Kong) Limited
|
Hong Kong
|
Fort Dodge Animal Health Limited
|
United Kingdom
|
Fort Dodge Animal Health, S. de R.L. de C.V.
|
Mexico
|
Fort Dodge Asia Exports, Inc.
|
Delaware
|
Fort Dodge Australia Pty. Limited
|
Australia
|
Fort Dodge de Venezuela, C.A.
|
Venezuela
|
Fort Dodge Laboratories Inc.
|
Iowa
|
Fort Dodge Manufatura Ltda.
|
Brazil
|
Fort Dodge Saude Animal Ltda.
|
Brazil
|
G. D. Searle & Co. Limited
|
United Kingdom
|
G. D. Searle International Capital LLC
|
Delaware
|
G. D. Searle LLC
|
Delaware
|
Genetics Institute, LLC
|
Delaware
|
GenTrac, Inc.
|
Wisconsin
|
GI Europe, Inc.
|
Delaware
|
GI Japan, Inc.
|
Delaware
|
Grangematic Limited
|
Ireland
|
Greenstone LLC
|
Delaware
|
Hälseprodukter Forserum AB
|
Sweden
|
Haptogen Limited
|
United Kingdom
|
Icagen, Inc.
|
Delaware
|
ImmunoPharmaceutics, Inc.
|
California
|
Industrial Santa Agape, S.A.
|
Guatemala
|
Instituto Pasteur de Lisboa Virginio Leitao Vieira dos Santos & Filhos S.A.
|
Portugal
|
Interfarma - Produtos Quimicos e Farmaceuticos, Lda.
|
Portugal
|
International Affiliated Corporation LLC
|
Delaware
|
Invicta Farma, S.A.
|
Spain
|
JMI-Daniels Pharmaceuticals, Inc.
|
Florida
|
John Wyeth & Brother Limited
|
United Kingdom
|
Kiinteistö oy Espoon Pellavaniementie 14
|
Finland
|
King Pharmaceuticals Holdings LLC
|
Delaware
|
King Pharmaceuticals LLC
|
Delaware
|
PAH Luxembourg 2 SARL
|
Luxembourg
|
PAH Luxembourg 3 SARL
|
Luxembourg
|
PAH Luxembourg 5 SARL
|
Luxembourg
|
PAH Luxmex SARL
|
Luxembourg
|
PAH Mexico Holdco SARL
|
Luxembourg
|
PAH Netherlands 1 Cooperatief U.A.
|
Netherlands
|
PAH Netherlands 2 B.V.
|
Netherlands
|
PAH Netherlands T3 B.V.
|
Netherlands
|
PAH Nominee 2 B.V.
|
Netherlands
|
PAH Nominee 3 B.V.
|
Netherlands
|
PAH Nominee B.V.
|
Netherlands
|
PAH Oceania B.V.
|
Netherlands
|
PAH P&U 2 LLC
|
Delaware
|
PAH P&U LLC
|
Delaware
|
PAH Panama B.V.
|
Netherlands
|
PAH Panama LLC
|
Delaware
|
PAH PD LLC
|
Delaware
|
PAH PH LLC
|
Delaware
|
PAH PI LLC
|
Delaware
|
PAH PM LLC
|
Delaware
|
PAH Portugal Holding B.V.
|
Netherlands
|
PAH PP LLC
|
Delaware
|
PAH Russia Holding B.V.
|
Netherlands
|
PAH SBSS Lux Holding Sarl
|
Luxembourg
|
PAH Singapore Pte. Ltd.
|
Singapore
|
PAH Spain, S.L.
|
Spain
|
PAH Switzerland GmbH
|
Switzerland
|
PAH Tabor LLC
|
Delaware
|
PAH Treasury Center BVBA
|
Belgium
|
PAH Turkey Holding B.V.
|
Netherlands
|
PAH UK 2 Limited
|
United Kingdom
|
PAH USA 15 LLC
|
Delaware
|
PAH USA IN8 LLC
|
Delaware
|
PAH Velvet B.V.
|
Netherlands
|
PAH Venezuela Holding B.V.
|
Netherlands
|
PAH W LLC
|
Delaware
|
PAH WAH LLC
|
Delaware
|
PAH WAI 1 LLC
|
Delaware
|
PAH WAI 2 LLC
|
Delaware
|
PAH Weesp B.V.
|
Netherlands
|
PAH West Europe 2 SARL
|
Luxembourg
|
PAH West Europe SARL
|
Luxembourg
|
PAH WHC 2 LLC
|
Delaware
|
PAH WHC LLC
|
Delaware
|
PAH WHC Splitco LLC
|
Delaware
|
PAH WLC LLC
|
Delaware
|
Parke Davis Limited
|
Hong Kong
|
Parke Davis Productos Farmaceuticos Lda
|
Portugal
|
Parke, Davis & Company LLC
|
Michigan
|
Parkedale Pharmaceuticals, Inc.
|
Michigan
|
Parke-Davis Manufacturing Corp.
|
Delaware
|
P-D Co., LLC
|
Delaware
|
Peak Enterprises LLC
|
Delaware
|
PF Americas Holding C.V.
|
Netherlands
|
PF Asia Manufacturing Coöperatief U.A.
|
Netherlands
|
PF PR Holdings C.V.
|
Netherlands
|
PF PRISM C.V.
|
Netherlands
|
PF PRISM Holdings S.a.r.l.
|
Luxembourg
|
PF Prism S.á.r.l.
|
Luxembourg
|
Pfizer (Far East) Limited
|
Hong Kong
|
Pfizer (H.K.) Holding Limited
|
Hong Kong
|
Pfizer (Malaysia) Sdn Bhd
|
Malaysia
|
Pfizer (People's Republic of China) Research and Development Co. Ltd.
|
People's Republic of China
|
Pfizer (Perth) Pty Limited
|
Australia
|
Pfizer (S.A.S.)
|
France
|
Pfizer (Suzhou) Pharmaceutical Information Consultation Co., Ltd.
|
People's Republic of China
|
Pfizer (Thailand) Limited
|
Thailand
|
Pfizer (Wuhan) Research and Development Co. Ltd.
|
People's Republic of China
|
Pfizer AB
|
Sweden
|
Pfizer Africa & Middle East for Pharmaceuticals, Veterinary Products & Chemicals S.A.E.
|
Egypt
|
Pfizer Afrique de L'Ouest
|
Senegal
|
Pfizer AG
|
Switzerland
|
Pfizer AH LLC
|
Ukraine
|
Pfizer Alpine Holdings Cooperatief U.A.
|
Netherlands
|
Pfizer Animal Health (Ireland) Limited
|
Ireland
|
Pfizer Animal Health (Thailand) Limited
|
Thailand
|
Pfizer Animal Health Australia Manufacturing Pty. Ltd.
|
Australia
|
Pfizer Animal Health Australia Pty Ltd
|
Australia
|
Pfizer Animal Health Austria GmbH
|
Austria
|
Pfizer Animal Health B.V.
|
Netherlands
|
Pfizer Animal Health Canada Inc.
|
Canada
|
Pfizer Animal Health Chile S.A.
|
Chile
|
Pfizer Animal Health Cia. Ltda.
|
Ecuador
|
Pfizer Animal Health Czech Sro
|
Czech Republic
|
Pfizer Animal Health Finland Oy
|
Finland
|
Pfizer Animal Health Germany GmbH
|
Germany
|
Pfizer Animal Health Hungary 1 Kft
|
Hungary
|
Pfizer Animal Health India Limited
|
India
|
Pfizer Animal Health International (S.A.S.)
|
France
|
Pfizer Animal Health Italia S.r.l.
|
Italy
|
Pfizer Animal Health Japan K.K.
|
Japan
|
Pfizer Animal Health Korea Ltd.
|
Republic of Korea
|
Pfizer Animal Health Lithuania UAB
|
Lithuania
|
Pfizer Animal Health MA EEIG
|
United Kingdom
|
Pfizer Animal Health Malaysia Sdn. Bhd.
|
Malaysia
|
Pfizer Animal Health Manufacturing Italia S.r.l.
|
Italy
|
Pfizer Animal Health Mexico, S. de R.L. de C.V.
|
Mexico
|
Pfizer Animal Health New Zealand Limited
|
New Zealand
|
Pfizer Animal Health Panama S. de R.L.
|
Panama
|
Pfizer Animal Health Peru SRL
|
Peru
|
Pfizer Animal Health Philippines, Inc.
|
Philippines
|
Pfizer Animal Health Poland Sp z o.o.
|
Poland
|
Pfizer Animal Health S.A.
|
Belgium
|
Pfizer Animal Health S.R.L.
|
Romania
|
Pfizer Animal Health South Africa (Pty) Ltd.
|
South Africa
|
Pfizer Animal Health Taiwan Limited
|
Taiwan
|
Pfizer Animal Health UK 1 Ltd.
|
United Kingdom
|
Pfizer Animal Health Uruguay SRL
|
Uruguay
|
Pfizer Animal Pharma Private Limited
|
India
|
Pfizer ApS
|
Denmark
|
Pfizer AS
|
Norway
|
Pfizer Asia Limited
|
Taiwan
|
Pfizer Asia Manufacturing Pte. Ltd.
|
Singapore
|
Pfizer Asia Pacific Pte Ltd.
|
Singapore
|
Pfizer AsiaPac Holdings SARL
|
Luxembourg
|
Pfizer Asset Management Luxembourg SARL
|
Luxembourg
|
Pfizer Atlantic Holdings S.a.r.l.
|
Luxembourg
|
Pfizer Australia Holdings B.V.
|
Netherlands
|
Pfizer Australia Holdings Pty Limited
|
Australia
|
Pfizer Australia Investments B.V.
|
Netherlands
|
Pfizer Australia Investments Pty. Ltd.
|
Australia
|
Pfizer Australia Pty Limited
|
Australia
|
Pfizer B.V.
|
Netherlands
|
Pfizer Baltic Holdings B.V.
|
Netherlands
|
Pfizer BH D.o.o.
|
Bosnia and Herzegovina
|
Pfizer Biologics Ireland Holdings Limited
|
Ireland
|
Pfizer Biotech Corporation
|
Taiwan
|
Pfizer Biotechnology Ireland
|
Ireland
|
Pfizer Bolivia S.A.
|
Bolivia
|
Pfizer Business Enterprises C.V.
|
Netherlands
|
Pfizer Canada Inc.
|
Canada
|
Pfizer CentreSource Asia Pacific Pte. Ltd.
|
Singapore
|
Pfizer Chile S.A.
|
Chile
|
Pfizer Cia. Ltda.
|
Ecuador
|
Pfizer Colombia Spinco I LLC
|
Pennsylvania
|
Pfizer Commercial Holdings Coöperatief U.A.
|
Netherlands
|
Pfizer Consumer Healthcare GmbH
|
Germany
|
Pfizer Consumer Healthcare Ltd.
|
United Kingdom
|
Pfizer Continental Holdings SARL
|
Luxembourg
|
Pfizer Continental Services LLC
|
Delaware
|
Pfizer Cork Limited
|
Ireland
|
Pfizer Corporation
|
Panama
|
Pfizer Corporation Austria Gesellschaft m.b.H.
|
Austria
|
Pfizer Corporation Hong Kong Limited
|
Hong Kong
|
Pfizer Croatia d.o.o.
|
Croatia
|
Pfizer Deutschland GmbH
|
Germany
|
Pfizer Development LP
|
United Kingdom
|
Pfizer Development Services (UK) Limited
|
United Kingdom
|
Pfizer Distribution Company
|
Ireland
|
Pfizer Domestic Ventures Limited
|
Isle of Jersey
|
Pfizer Dominicana, S.A.
|
Dominican Republic
|
Pfizer East India B.V.
|
Netherlands
|
Pfizer Eastern Investments B.V.
|
Netherlands
|
Pfizer Egypt S.A.E.
|
Egypt
|
Pfizer Enterprises Inc.
|
Delaware
|
Pfizer Enterprises SARL
|
Luxembourg
|
Pfizer ESP Pty Ltd
|
Australia
|
Pfizer Europe Holdings SARL
|
Luxembourg
|
Pfizer Europe MA EEIG
|
United Kingdom
|
Pfizer Europe Services LLC
|
Delaware
|
Pfizer Export AB
|
Sweden
|
Pfizer Export Company
|
Ireland
|
Pfizer Finance GmbH & Co. KG
|
Germany
|
Pfizer Finance Holding S.r.l.
|
Italy
|
Pfizer Finance Italy S.r.l.
|
Italy
|
Pfizer Finance Share Service (Dalian) Co., Ltd.
|
People's Republic of China
|
Pfizer Finance Verwaltungs GmbH
|
Germany
|
Pfizer Financial Services N.V./S.A.
|
Belgium
|
Pfizer France Coöperatief U.A.
|
Netherlands
|
Pfizer France International Investments SAS
|
France
|
Pfizer France Investment Holdings
|
France
|
Pfizer Free Zone Panama, S. de R.L.
|
Panama
|
Pfizer Global Holdings B.V.
|
Netherlands
|
Pfizer Global Investments SARL
|
Luxembourg
|
Pfizer Global Supply
|
Ireland
|
Pfizer Global Supply Japan Inc.
|
Japan
|
Pfizer Global Trading
|
Ireland
|
Pfizer GmbH
|
Germany
|
Pfizer Gulf FZ-LLC
|
United Arab Emirates
|
Pfizer H.C.P. Corporation
|
New York
|
Pfizer Hayvan Saðliði Limited Þirketi
|
Turkey
|
Pfizer Health AB
|
Sweden
|
Pfizer Health Solutions Inc.
|
Delaware
|
Pfizer Healthcare Consultant (Shanghai) Co., Ltd
|
People's Republic of China
|
Pfizer Healthcare Ireland
|
Ireland
|
Pfizer Hellas Animal Health S.A.
|
Greece
|
Pfizer Hellas, A.E.
|
Greece
|
Pfizer Himalaya Holdings Coöperatief U.A.
|
Netherlands
|
Pfizer HK Service Company Limited
|
Hong Kong
|
Pfizer Holding France (S.C.A.)
|
France
|
Pfizer Holding Italy S.r.l.
|
Italy
|
Pfizer Holding Ventures
|
Ireland
|
Pfizer Holdings Europe
|
Ireland
|
Pfizer Holdings International Luxembourg (PHIL) Sarl
|
Luxembourg
|
Pfizer Holdings K.K.
|
Japan
|
Pfizer Holdings Luxembourg SARL
|
Luxembourg
|
Pfizer Holdings North America SARL
|
Luxembourg
|
Pfizer Holdings Turkey Limited
|
Isle of Jersey
|
Pfizer Holland Holdings B.V.
|
Netherlands
|
Pfizer Ilaclari Limited Sirketi
|
Turkey
|
Pfizer International Business Europe
|
Ireland
|
Pfizer International Investments Ltd.
|
Bermuda
|
Pfizer International LLC
|
New York
|
Pfizer International Luxembourg SA
|
Luxembourg
|
Pfizer International Operations (S.A.S.)
|
France
|
Pfizer International S. de R.L.
|
Panama
|
Pfizer International Sweden
|
Sweden
|
Pfizer International Trading (Shanghai) Limited
|
People's Republic of China
|
Pfizer Investment Capital
|
Ireland
|
Pfizer Investment Co. Ltd.
|
People's Republic of China
|
Pfizer Investment Holdings S.a.r.l.
|
Luxembourg
|
Pfizer Investments Netherlands B.V.
|
Netherlands
|
Pfizer Ireland Investments Limited
|
Ireland
|
Pfizer Ireland Pharmaceuticals
|
Ireland
|
Pfizer Ireland Ventures
|
Ireland
|
Pfizer Italia S.r.l.
|
Italy
|
Pfizer Japan Inc.
|
Japan
|
Pfizer Jersey Capital Limited
|
Isle of Jersey
|
Pfizer Jersey Company Limited
|
Isle of Jersey
|
Pfizer Jersey Finance Limited
|
Isle of Jersey
|
Pfizer Laboratories (Pty) Limited
|
South Africa
|
Pfizer Laboratories Limited
|
Kenya
|
Pfizer Limitada
|
Angola
|
Pfizer Limited
|
India
|
Pfizer Limited
|
Taiwan
|
Pfizer Limited
|
Tanzania
|
Pfizer Limited
|
Uganda
|
Pfizer Limited
|
United Kingdom
|
Pfizer LLC
|
Russia
|
Pfizer Luxco Holdings Sarl
|
Luxembourg
|
Pfizer Luxembourg Global Holdings SARL
|
Luxembourg
|
Pfizer Luxembourg SARL
|
Luxembourg
|
Pfizer Manufacturing Belgium N.V.
|
Belgium
|
Pfizer Manufacturing Deutschland GmbH
|
Germany
|
Pfizer Manufacturing Holdings Coöperatief U.A.
|
Netherlands
|
Pfizer Manufacturing Holdings LLC
|
Delaware
|
Pfizer Manufacturing Ireland
|
Ireland
|
Pfizer Manufacturing LLC
|
Delaware
|
Pfizer Manufacturing Services
|
Ireland
|
Pfizer Medical Technology Group (Belgium) N.V.
|
Belgium
|
Pfizer Medicamentos Genericos e Participacoes Ltda.
|
Brazil
|
Pfizer Mexico Luxco SARL
|
Luxembourg
|
Pfizer Mexico, S.A. de C.V.
|
Mexico
|
Pfizer Middle East for Pharmaceuticals, Animal Health and Chemicals S.A.E.
|
Egypt
|
Pfizer Namibia (Proprietary) Limited
|
Namibia
|
Pfizer New Zealand Limited
|
New Zealand
|
Pfizer North American Holdings Inc.
|
Delaware
|
Pfizer Olot, S.L.
|
Spain
|
Pfizer OTC B.V.
|
Netherlands
|
Pfizer Overseas LLC
|
Delaware
|
Pfizer Overseas Services Inc.
|
Delaware
|
Pfizer Oy
|
Finland
|
Pfizer Pacific Coöperatief U.A.
|
Netherlands
|
Pfizer Pacific Holdings B.V.
|
Netherlands
|
Pfizer Pacific Investments B.V.
|
Netherlands
|
Pfizer Pakistan Limited
|
Pakistan
|
Pfizer Parke Davis
|
Philippines
|
Pfizer Parke Davis (Thailand) Ltd.
|
Thailand
|
Pfizer Parke Davis Pte. Ltd.
|
Singapore
|
Pfizer PGM (S.A.S.)
|
France
|
Pfizer PGRD (S.A.S.)
|
France
|
Pfizer Pharm Algerie
|
Algeria
|
Pfizer Pharma GmbH
|
Germany
|
Pfizer Pharma Trade LLC
|
Egypt
|
Pfizer Pharmaceutical (Wuxi) Co., Ltd.
|
People's Republic of China
|
Pfizer Pharmaceutical India Pvt. Ltd.
|
India
|
Pfizer Pharmaceutical Trading Limited Liability Company (a/k/a Pfizer Kft. or Pfizer LLC)
|
Hungary
|
Pfizer Pharmaceuticals B.V.
|
Netherlands
|
Pfizer Pharmaceuticals Global Coöperatief U.A.
|
Netherlands
|
Pfizer Pharmaceuticals Israel Ltd.
|
Israel
|
Pfizer Pharmaceuticals Korea Limited
|
Republic of Korea
|
Pfizer Pharmaceuticals Limited
|
Cayman Islands
|
Pfizer Pharmaceuticals LLC
|
Delaware
|
Pfizer Pharmaceuticals Ltd.
|
People's Republic of China
|
Pfizer Pharmaceuticals Tunisie Sarl
|
Tunisia
|
Pfizer PHF
|
Ireland
|
Pfizer Philippines Holdings B.V.
|
Netherlands
|
Pfizer Pigments Inc.
|
Delaware
|
Pfizer Polska Sp. z.o.o.
|
Poland
|
Pfizer Precision Holdings SARL
|
Luxembourg
|
Pfizer Prev - Sociedade de Previdencia Privada
|
Brazil
|
Pfizer Private Limited
|
Malaysia
|
Pfizer Private Ltd.
|
Singapore
|
Pfizer Production LLC
|
Delaware
|
Pfizer Products Inc.
|
Connecticut
|
Pfizer Products India Private Limited
|
India
|
Pfizer Romania SRL
|
Romania
|
Pfizer S.A.
|
Peru
|
Pfizer S.A. (Belgium)
|
Belgium
|
Pfizer S.A.S.
|
Colombia
|
Pfizer S.G.P.S. Lda.
|
Portugal
|
Pfizer S.R.L.
|
Argentina
|
Pfizer Saidal Manufacturing
|
Algeria
|
Pfizer Salud Animal, S.L.
|
Spain
|
Pfizer Santé Animale SAS
|
France
|
Pfizer Santé Familiale SAS
|
France
|
Pharmacia Korea Ltd.
|
Republic of Korea
|
Pharmacia Laboratories Limited
|
United Kingdom
|
Pharmacia Limited
|
United Kingdom
|
Pharmacia LLC
|
Delaware
|
Pharmacia Malaysia Sdn Bhd
|
Malaysia
|
Pharmacia Searle Limited
|
United Kingdom
|
Pharmacia South Africa (Pty) Ltd
|
South Africa
|
PHIVCO Corp.
|
Delaware
|
PHIVCO Holdco S.à r.l.
|
Luxembourg
|
PHIVCO Luxembourg SARL
|
Luxembourg
|
PN Mexico LLC
|
Delaware
|
PN North America, S. de R.L. de C.V.
|
Mexico
|
PowderJect Research Limited
|
United Kingdom
|
PowderJect Vaccines, Inc.
|
Delaware
|
PowderMed Limited
|
United Kingdom
|
PowderMed, Inc.
|
Delaware
|
Prosec Forsakrings AB (Prosec Insurance Co. Ltd.)
|
Sweden
|
PT. Fort Dodge Indonesia
|
Indonesia
|
PT. Pfizer Indonesia
|
Indonesia
|
Purepac Pharmaceutical Holdings, Inc.
|
Delaware
|
PZR Ltd.
|
United Kingdom
|
PZR Property Limited
|
United Kingdom
|
Quigley Company, Inc.
|
New York
|
Renrall LLC
|
Wyoming
|
Rinat Neuroscience Corp.
|
Delaware
|
Rivepar (S.A.S.)
|
France
|
RMV Produtos Veterinarios Ltda.
|
Brazil
|
Roerig Produtos Farmaceuticos, Lda.
|
Portugal
|
Roerig S.A.
|
Chile
|
Roerig, S.A.
|
Venezuela
|
Sanidad Animal PAH Bolivia S.A.
|
Bolivia
|
Sao Cristovao Participacoes Ltda.
|
Brazil
|
Searle Laboratorios, Lda.
|
Portugal
|
Searle Ltd.
|
Bermuda
|
Servicios P&U, S. de R.L. de C.V.
|
Mexico
|
Shiley International
|
California
|
Shiley LLC
|
California
|
Sinergis Farma-Produtos Farmaceuticos, Lda.
|
Portugal
|
Site Realty, Inc.
|
Delaware
|
Solinor LLC
|
Delaware
|
STI International Limited
|
United Kingdom
|
Sugen, Inc.
|
Delaware
|
Sutumex, S.A. de C.V.
|
Mexico
|
Synbiotics Corporation
|
California
|
Synbiotics Europe S.A.S.
|
France
|
Tabor LLC
|
Delaware
|
The Pfizer Incubator LLC
|
Delaware
|
Thiakis Limited
|
United Kingdom
|
Trans-Europe Assurance Limited
|
Ireland
|
Upjohn Laboratorios Lda.
|
Portugal
|
US Oral Pharmaceuticals Pty Ltd
|
Australia
|
Vermont Whey Company
|
Vermont
|
Vesterålens Naturprodukter A/S
|
Denmark
|
Vesterålens Naturprodukter AB
|
Sweden
|
Vesterålens Naturprodukter AS
|
Norway
|
Vesterålens Naturprodukter OY
|
Finland
|
Vicuron Holdings LLC
|
Delaware
|
Vicuron Pharmaceuticals Italy S.r.l.
|
Italy
|
Vinci Farma, S.A.
|
Spain
|
Warner Lambert del Uruguay S.A.
|
Uruguay
|
Warner Lambert Ilac Sanayi ve Ticaret Limited Sirketi
|
Turkey
|
Warner Lambert Poland Sp.z.o.o. w likwidacji
|
Poland
|
Warner-Lambert (Tanzania), Limited
|
Tanzania
|
Warner-Lambert (Thailand) Limited
|
Thailand
|
Warner-Lambert Company AG
|
Switzerland
|
Warner-Lambert Company LLC
|
Delaware
|
Warner-Lambert de El Salvador, S.A. de C.V.
|
El Salvador
|
Warner-Lambert de Honduras, Sociedad Anonima
|
Honduras
|
Warner-Lambert de Puerto Rico, Inc.
|
Puerto Rico
|
Warner-Lambert Guatemala, Sociedad Anonima
|
Guatemala
|
Warner-Lambert, S.A.
|
Delaware
|
Whitehall International Inc.
|
New York
|
Whitehall Laboratories Inc.
|
Delaware
|
Whitehall Laboratorios S.A.
|
Uruguay
|
WL de Guatemala, Sociedad Anonima
|
Guatemala
|
W-L LLC
|
Delaware
|
Wyeth (Asia) Limited
|
Delaware
|
Wyeth (Far East) Limited
|
Hong Kong
|
Wyeth (Singapore) Pte. Ltd.
|
Singapore
|
Wyeth (Thailand) Ltd.
|
Thailand
|
Wyeth AB
|
Sweden
|
Wyeth Advertising Inc.
|
New York
|
Wyeth Australia Pty. Limited
|
Australia
|
Wyeth Ayerst Inc.
|
Delaware
|
Wyeth Ayerst SARL
|
Luxembourg
|
Wyeth Canada ULC
|
Canada
|
Wyeth Consumer Healthcare LLC
|
Pennsylvania
|
Wyeth Egypt Ltd.
|
Egypt
|
Wyeth Egypt Trading Ltd.
|
Egypt
|
Wyeth Europa Limited
|
United Kingdom
|
Wyeth Farma, S.A.
|
Spain
|
Wyeth Holdings Corporation
|
Maine
|
Wyeth Ilaclari, S. de R.L. de C.V.
|
Mexico
|
Wyeth Industria Farmaceutica Ltda.
|
Brazil
|
Wyeth KFT.
|
Hungary
|
Wyeth Korea, Inc.
|
Republic of Korea
|
Wyeth Lederle S.r.l.
|
Italy
|
Wyeth Lederle Vaccines S.A.
|
Belgium
|
Wyeth Limited
|
India
|
Wyeth LLC
|
Russia
|
Wyeth LLC
|
Delaware
|
Wyeth Pakistan Limited
|
Pakistan
|
Wyeth Pharmaceutical Co., Ltd.
|
People's Republic of China
|
Wyeth Pharmaceuticals Central America Services, S.A.
|
Panama
|
Wyeth Pharmaceuticals Company
|
Puerto Rico
|
Wyeth Pharmaceuticals FZ-LLC
|
United Arab Emirates
|
Wyeth Pharmaceuticals Inc.
|
Delaware
|
Wyeth Pharmaceuticals India Private Limited
|
India
|
Wyeth Pharmaceuticals Limited
|
Ireland
|
Wyeth Pharmaceuticals S. de R.L. de C.V.
|
Mexico
|
Wyeth Philippines, Co. Ltd.
|
Philippines
|
Wyeth Prev-Sociedade de Previdencia Privada
|
Brazil
|
Wyeth Puerto Rico, Inc.
|
Puerto Rico
|
Wyeth Regional Manufacturing (Singapore) PTE. LTD.
|
Singapore
|
Wyeth Research Ireland Limited
|
Ireland
|
Wyeth Subsidiary Illinois Corporation
|
Illinois
|
Wyeth Whitehall Export GmbH
|
Austria
|
Wyeth Whitehall SARL
|
Luxembourg
|
Wyeth, S. de R.L. de C.V.
|
Mexico
|
Wyeth-Ayerst (Asia) Limited
|
Delaware
|
Wyeth-Ayerst Promotions Limited
|
Delaware
|
Yusafarm D.O.O.
|
Serbia
|
Zoetis Inc.
|
Delaware
|